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  SUMMARY 
Infectious diseases remain a major cause of death worldwide, despite enormous 
control efforts. A major problem in the context of antimicrobial drug resistance, 
which already leads to treatment failures, is the lack of novel antimicrobial drugs. 
Further, current and future control measures are threatened by the inexistence, 
unavailability, and failures of vaccines. In this regard, development of novel tools, 
including new antimicrobial drugs, vaccines, alternative drug/vaccine delivery 
systems, and other strategies, is urgently needed to keep up the fight against 
infectious diseases. Malaria is a typical example of an infectious disease to which 
the above-mentioned problems apply. This disease is caused by Plasmodium spp. 
parasites that are transmitted by Anopheles mosquitoes. The life cycle of malaria 
parasites in humans involves a blood stage cycle that is responsible for disease 
pathogenesis and includes continuous red blood cell (RBC) invasion, asexual 
multiplication, and subsequent egress of parasites back into the bloodstream. 
In this thesis, two alternative nanotechnological strategies aimed at the malaria 
blood stage cycle are presented. Both of these strategies are considered valuable 
alternatives for malaria treatment/prophylaxis compared to conventional drug 
treatment and experimental vaccination schemes. The first ‘nanomimic strategy’ 
aims for a dual drug- and "vaccine-like" action using RBC membrane-mimicking 
nanostructures, termed ‘nanomimics’. The drug action is the inhibition of parasite 
invasion into RBCs by these nanomimics. "Vaccine-like" activity is achieved 
through generation of an immune response by exposed extracellular parasites 
bound to nanomimics as obtained during the drug action. Several amphiphilic 
block copolymers were designed and synthesized that contain a RBC receptor 
molecule that is known to be used by the parasite to attach to RBCs. These 
functional block copolymers were mixed with another type of block copolymer to 
prepare polymer vesicles (polymersomes) by self-assembly, which served as 
nanomimics and giant RBC membrane models. Highly potent invasion-inhibitory 
nanomimics were realized following this procedure as determined by in vitro 
assays using malaria blood stage cultures in suspension. Further analyses revealed 
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binding of multiple nanomimics to one parasite and multivalent, high-affinity 
interaction of receptor molecules on nanomimics with a corresponding parasite 
ligand. Potential adverse effects of nanomimics related to cellular toxicity, 
anticoagulation property, and endotoxin contamination, were found to be 
negligible. Preliminary tests on the second "vaccine-like" activity point in a 
promising direction, but this needs to be further studied in more detail. A potential 
application of nanomimics is treatment and immune boost for children having one 
of their first infections, in order to induce protection from subsequent infections. 
Furthermore, many human pathogens use the same receptor molecule to interact 
with target cells that is currently presented on the nanomimics prepared in the 
scope of this thesis. Therefore, the nanomimic strategy has the potential to be 
directly applied to other infectious diseases, too. 
In the second approach, the delivery of a poorly soluble, metabolically instable 
antimalarial drug candidate to Plasmodium-infected RBCs (iRBCs) using 
functional nanoparticles was examined. For this purpose, a reduction-responsive, 
degradable, polymeric nanoparticle platform was successfully designed and 
applied. The highly reducing cytosol environment of iRBCs acts as the trigger for 
nanoparticle disassembly and subsequent drug release. In contrast, these loaded 
nanoparticles were stable in extracellular environments. This drug delivery 
platform is promising in tackling antimalarial resistance, and to deliver any 
hydrophobic antimicrobial drug candidate at early development stages to 
corresponding diseased cells. 
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  ZUSAMMENFASSUNG 
 
 
Infektionskrankheiten gehören immer noch zu den weltweit häufigsten 
Todesursachen, obwohl enormer Aufwand betrieben wird, sie unter Kontrolle zu 
bringen. Eines der grössten Probleme stellt das Fehlen neuer Antibiotika dar. 
Bereits heute führen Antibiotikaresistenzen zu Behandlungsversagen. Zudem 
bedrohen Inexistenz, mangelnde Verfügbarkeit und ungenügende Wirksamkeit 
von gewissen Impfstoffen Kontrollstrategien für Infektionskrankheiten. In Zukunft 
werden dringendst neue Antibiotika, Impfungen, alternative Antibiotika/ 
Impfstoff-Verteilsysteme und andere Strategien benötigt, um den Kampf gegen 
Infektionskrankheiten nicht zu verlieren. Malaria ist ein typisches Beispiel einer 
Infektionskrankheit, die wegen der obengenannten Probleme schwer zu 
kontrollieren ist. Die Krankheitserreger der Malaria sind Plasmodium spp. 
Parasiten die von Stechmücken der Gattung Anopheles übertragen werden. Der 
Lebenszyklus dieser Parasiten beinhaltet einen Kreislauf im menschlichen Blut, 
welcher schlussendlich für die Pathogenität dieser Krankheit verantwortlich ist. 
Dieser Kreislauf im menschlichen Blut charakterisiert sich durch kontinuierliche 
Invasion von roten Blutkörperchen, asexuelle Vermehrung und anschliessendem 
Austritt von Parasiten zurück in den Blutstrom. 
In dieser Dissertation werden zwei nanotechnologische Strategien vorgestellt, die 
beide auf den Kreislauf von Malariaparasiten im menschlichen Blut abzielen. 
Beide Strategien werden als wertvolle Alternativen zu heutigen konventionellen 
Therapien mit Medikamenten und experimentellen Impfungen zur 
Malariabehandlung und Prophylaxe in Betracht gezogen. Die erste „Nano-Imitat-
Strategie“ zielt auf eine therapeutische und „impfähnliche“ Doppelwirkung ab, 
wobei Nanostrukturen benutzt werden, die rote Blutkörperchenmembrane 
imitieren und deswegen auch „Nano-Imitate“ genannt werden. Die therapeutische 
Wirkung wird erreicht, indem man das Eindringen des Malariaparasiten in seine 
Wirtszelle (rotes Blutkörperchen) durch die Nano-Imitate blockiert. Die dadurch 
exponierten Malariaparasiten sollen eine „impfähnliche“ Wirkung erzeugen, 
indem sie eine Immunantwort auslösen. Dafür wurden zuerst mehrere amphiphile 
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Block-Copolymere synthetisiert, wobei ein Teil davon ein bekannter 
Wirtszellrezeptor ist, der von Malariaparasiten benutzt wird um an rote 
Blutkörperchen anzudocken. Durch das Mischen dieser Block-Copolymere mit 
einem anderen Block-Copolymer konnten Polymer-Vesikel (Polymersome) mittels 
Selbstassemblierung hergestellt werden. Diese Polymer-Vesikel fungierten dann 
als Nano-Imitate und in einer grösseren Version auch als Modelle von roten 
Blutkörperchen. Dank diesem Vorgehen hat man äusserst potente 
invasionsblockierende Nano-Imitate erhalten, was man mittels in vitro-Tests mit 
kultivierten Malariaparasiten in Suspension gezeigt hat. Weitere Analysen haben 
offengelegt, dass mehrere Nano-Imitate an einen Parasiten binden können. Zudem 
wurden multivalente, hochaffine Interaktionen der Rezeptormoleküle auf den 
Nano-Imitaten mit den dazugehörigen Parasitenliganden gemessen. Mögliche 
Nebenwirkungen dieser Nano-Imitate, die durch zelluläre Toxizität, 
Antikoagulationsaktivität und Endotoxinkontaminierung ausgelöst werden 
könnten, wurden als vernachlässigbar tief eingestuft. Erste Tests bezüglich der 
„impfähnlichen“ Aktivität weisen in eine vielversprechende Richtung, dies muss 
aber zuerst im Detail weitergetestet werden. Eine potentielle Anwendung von 
Nano-Imitaten wäre die Behandlung und Verstärkung der Immunantwort bei 
Kindern, die eine ihrer ersten Malariainfektion haben, um sie so vor nächsten 
Infektionen zu schützen. Zudem benützen viele menschliche Krankheitserreger 
denselben Wirtszellrezeptor, der zurzeit auf unseren Nano-Imitaten präsentiert 
wird, um mit Wirtszellen zu interagieren. Aus diesem Grund könnten diese Nano-
Imitate auch direkt auf andere Infektionskrankheiten angewendet werden. 
Die zweite Strategie befasst sich mit einem Medikamenten-Nanoverteilsystem, 
welches ein schlecht wasserlösliches, metabolisch instabiles Anti-Malaria 
Medikament spezifisch zu infizierten roten Blutkörperchen bringt. Dieses 
Nanoverteilsystem besteht aus reduktionssensitiven, abbaubaren Polymer-
basierten Nanopartikeln. Das hochreduzierende Zytosol von intrazellulären 
Malariaparasiten fungiert als Auslöser für den intrazellulären Nanopartikel-Abbau 
und die dazugehörige Medikamentenfreisetzung. Im Gegensatz dazu sind diese 
Nanopartikel in extrazellulären Umgebungen stabil. Dieses Medikamenten-
Nanoverteilsystem ist eine vielversprechende Plattform, um Resistenzen gegen 
Malariamedikamente entgegenzuwirken und um gezielt schwerlöslichen 
Antibiotika, welche sich im Entwicklungsstadium befinden, zu den dazugehörigen 
befallenen Wirtszellen zu bringen. 
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   CHAPTER 1 
1 General Introduction 
This general introduction provides an overview of some major threats to public 
health posed by infectious diseases. Malaria is introduced and few biological 
details relevant to this thesis are given. Specific malaria-related control 
strategies and accompanying problems are discussed in more detail. Thereafter, 
self-assembling amphiphilic copolymers are introduced with a specific focus on 
potential biomedical applications. Finally, nanotechnological approaches, 
mainly polymer-based systems, for infectious diseases, in particular malaria, are 
discussed. Contents of the as-yet unpublished parts of this general introduction 
are being prepared for publication elsewhere. 
1.1 Infectious Diseases: a Contemporary Global Public Health 
Problem 
Infectious diseases are a major and continuous threat to human health. Currently, 
about a quarter of total annual deaths worldwide are attributed to infectious 
diseases.1 The main killers being respiratory infections, diarrheal diseases, human 
immunodeficiency virus (HIV) causing acquired immunodeficiency syndrome 
(AIDS), tuberculosis, and malaria (Figure 1).1  
Throughout human history, infectious diseases have had a tremendous impact on 
civilizations – sometimes even changing the course of history. Some famous, most 
influential examples of disease outbreaks are the 14th century Black Death 
(bubonic plague) pandemic in Europe, the 1918 influenza pandemic, and the 
current HIV/AIDS pandemic.2 Three main names that should not be missed in the 
history of infections are Louis Pasteur and Robert Koch, who consolidated the 
“germ theory” – proposed by Girolamo Fracastoro nearly 350 years earlier – in the 
late 1870s; a turning point in the history of medicine and the start of the hunt for 
microbes and the subsequent development of vaccines and antibiotics.2 Overall, 
public sanitation, personal hygiene (e.g. hand washing), antibiotics, and vaccines 
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can be considered the main factors that dramatically decreased infant/child 
mortality during the 20th century and led to human life expectancy being 
approximately doubled.3 Nevertheless, infectious diseases remain a contemporary 
and ongoing challenge to public health, mainly due to the high evolutionary 
capacity of infectious pathogens that can overcome pressures directed at their 
elimination quite easily.1  
 
 
Figure 1. Main infectious diseases causing in total about 15.0 million (26%) deaths of an estimated 58.8 million total 
global deaths annually. Data does not include secondary infectious causes of death. Reproduced with permission from ref 1. 
Copyright (2012) Massachusetts Medical Society. 
 
Recently, the Zika virus pandemic in South/Central America and the 2014 Ebola 
outbreak in West Africa have received much attention in the mainstream media. 
However, they are only the tip of the iceberg comprising of all the challenges that 
are posed by infectious pathogens. In fact, several arthropod-borne viral diseases 
caused by Dengue, West Nile, Chikungunya, and Zika virus are unexpectedly and 
rapidly spreading all over the globe at the moment, which highlights the fact that 
human-caused influences on ecological balances will cause such rapid outbreaks in 
the future as well.4 Antibiotic resistance is another, and one of the most worrying 
examples, demonstrating the necessity for keeping up efforts in infectious disease 
research and antibiotic development. Systematic misuse and overuse of antibiotics 
in medicine, but also in food production (veterinary medicine) has caused the 
current situation.5 Multiple drug resistant (MDR) pathogens, such as MDR 
Staphylococcus aureus6 and MDR Mycobacterium tuberculosis,7 are two 
frightening examples of bacterial pathogens that have become resistant to various 
antibiotics. MDR tuberculosis affected about 480’000 and killed about 190’000 
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people in 2014.8 The recent occurrence and spread of artemisinin-resistant malaria 
parasites9 combined with the difficulty in formulating an efficacious malaria 
vaccine10 equally represent serious threats to public health (See Chapter 1.2 for 
more details). This demonstrates the urgency for new antimicrobial drugs or 
alternative prophylaxis and treatment strategies.1 To tackle antimicrobial 
resistance – not only resistant bacteria but also resistant viruses, parasites, and 
fungi – WHO has recently drafted and published a global action plan, because it is 
clear that only globally coordinated efforts will have an effect on controlling the 
spread of antimicrobial resistance.5 WHO and various leaders in the field 
strengthen the notion that we might soon enter a post-antibiotic era, if no 
counteraction is undertaken soon.5 In a post-antibiotic era, simple infections or 
injuries might once again lead to death, which is why the overuse of antibiotics e.g. 
in the food sector should be reviewed and changed rapidly.11 Otherwise, we are in 
danger of losing the control tools that helped to double our life expectancy,3 which 
clearly highlights the relevance and urgency of appropriate countermeasures. 
In the context of globalization and climate change, the pattern of infectious disease 
appearance and distribution will further shift and therefore poses considerable 
challenges to global human health management.12 However, the influence of 
climate change on the occurrence, distribution, and severity of infectious diseases 
is not predictable, although a shift in vector habitats can clearly spread vector-born 
diseases to previously disease-free geographic areas.13 Furthermore, these diseases 
particularly affect the most vulnerable individuals of a society: children, pregnant 
women, diseased-, malnourished-, and elderly people. This also highlights an 
ethical responsibility to boost research on infectious diseases for the development 
of future control strategies. 
1.2 Malaria 
Malaria is an infectious disease caused by Plasmodium spp. parasites, which are 
mainly prevalent in developing countries (Figure 2), due to the habitat of their 
arthropod vector: female Anopheles mosquitoes. 
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Figure 2. Worldwide distribution of malaria highlighting countries with on-going transmission of malaria in 2013. Reprinted 
from WHO World Malaria Report 2014.14 
 
Several Plasmodium species are known to infect humans: P. falciparum, P. vivax, 
P. ovale, P. malariae, and P. knowlesi. The most aggressive and life-threatening 
species is P. falciparum, which accounts for most of the malaria-related deaths, 
and is the main form occurring in Sub-Saharan African countries. P. vivax is more 
prevalent in Asia and South America. This parasite species is less life threatening, 
but the liver stage of this parasite can remain latent as hypnozoites, which can 
release pathogens even months or years after infection and cause a relapse of the 
disease. Of an estimated 198 million malaria cases, about 584’000 ended fatally in 
2013.15 About 90% of all the malaria deaths occurred in Sub-Saharan Africa and 
78% were children aged below five years.15 These numbers highlight the large 
burden malaria still puts on public health in less developed countries. 
1.2.1 Life Cycle of Plasmodium falciparum 
Plasmodium spp. parasites – belonging to parasitic protists of the phylum 
Apicomplexa – undergo very complex life cycles, which include arthropod 
(Anopheles mosquito) and human host. Various extracellular (sporozoites, 
merozoites, ookinetes) and intracellular (intra-erythrocytic and intra-hepatocytic 
schizonts) forms of the parasite are involved in the life cycle (Figure 3). 
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Figure 3. Malaria parasite life cycle. During the blood meal, Anopheles mosquitoes can inject sporozoites into the 
bloodstream of humans or take up gametocytes from infected humans. Info on the life cycle in the mosquito vector and 
gametogenesis can be found elsewhere.16 Sporozoites asexually reproduce within hepatocytes in the liver, which release 
thousands of merozoites back into the bloodstream. Merozoites invade red blood cells (RBCs) where they asexually divide to 
form more parasites (schizogeny). After about 48 hours (P. falciparum), all infected RBCs burst and release the freshly 
generated parasites that rapidly invade more RBCs. This erythrocytic cycle is responsible for malaria pathogenesis. Reprinted 
with permission from reference 17. Copyright (2007) Nature Publishing Group. 
 
Only part of the life cycle of P. falciparum that is relevant to this thesis is briefly 
summarized herein. More information on the mosquito-based stages and 
gametogenesis needed for transmission from the human host back to the mosquito 
vector can be found elsewhere.16 Multiplication within the human host exclusively 
occurs by mitosis, whereas meiosis is restricted to the replication within the 
mosquito host.18 First, infected female Anopheles mosquitoes inject from a few 
dozen up to a few hundred sporozoites into the bloodstream of humans, while 
taking their blood meal. This extracellular sporozoite form travels through the 
bloodstream, passes through Kupffer cells in the liver, and finally infects and 
reproduces within hepatocytes. Each infected hepatocyte releases thousands of 
merozoites into the bloodstream, after they were formed through asexual cell 
division. Merozoites are polarized pear-shaped cells with a length of only about 1.5 
µm; merozoites belong to the smallest known eukaryotic cells.19 Merozoites are 
equipped and primed to attach to and invade red blood cells (RBCs). Therein, this 
parasite form undergoes schizogeny for about 48 hours to yield about 16 to 32 
fresh daughter merozoites within each infected RBC (iRBC) in the case of P. 
falciparum.20 Daughter merozoites egress from iRBCs to rapidly infect more RBCs. 
This erythrocytic asexual life cycle of the parasite continues and is finally 
responsible for malaria pathogenesis.18 
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1.2.2 Plasmodium Biology: Red Blood Cell Invasion Mechanism 
RBC invasion by the Plasmodium merozoite form is a very rapid, complex, and 
well-coordinated process (Figure 4). Many different receptor-ligand interactions 
are involved in each step of invasion (Figure 5). Intriguingly, many proteins 
involved in invasion are first located within specific parasite organelles called 
micronemes and rhoptries present at the apical side of merozoites. Along with 
proteolytic enzymes that cleave part of the merozoite surface coat during invasion, 
other microneme and rhoptry proteins are secreted in a time-controlled manor to 
allow well-coordinated receptor-ligand interactions after initial attachment. These 
proteins are mainly members of the erythrocyte binding antigens (EBAs) and 
reticulocyte binding-like homologous (PfRH).21 In total, the whole entry process 
likely happens within only 60 seconds.20 Detailed information on the sequence of 
protein interactions during the invasion of RBCs by malaria parasite can be found 
in recent reviews.19,21-23 Mechanistic aspects of RBC invasion, including host cell 
modifications that facilitate parasite entry, have been discussed in a recent review, 
where the authors suggest that more mechanistic insight into the role of each 
essential invasion-related protein is necessary to finally understand the invasion 
process.24 
A schematic overview of the RBC invasion process by P. falciparum is given in 
Figure 4. Only very few details relating to interactions occurring early in the 
invasion process are highlighted herein, especially related to merozoite/major 
surface protein 1 (MSP1) and heparan sulfate host receptor, because these are most 
relevant for the inhibitory strategy established within this thesis. Involved 
receptor-ligand interactions were traditionally determined by using enzymatic 
receptor cleavage; inhibition of binding via antibodies, peptides and small 
molecules; and genetic deletion of parasite ligands (Figure 5).22 
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Figure 4. Schematic overview of the RBC invasion process by P. falciparum merozoites. After initial attachment 
to the RBC surface, the merozoite re-orientates to face the apical pole towards the RBC surface. Various, well-
coordinated merozoite-RBC interactions occur during the invasion process (highlighted in Figure 5). Finally, the 
parasite enters through the formed tight junction using its actin-myosin motor. Reprinted with permission from ref 
24. Copyright (2016) Creative Commons Licence 4.0. 
 
MSP1 – the main surface protein covering the whole surface of Plasmodium 
merozoites (MW 180 kDa) – is thought to be responsible for early processes of 
merozoite and RBCs interaction.22,25 MSP1 is a glycosylphosphatidylinositol (GPI)-
anchored membrane protein and it forms a non-covalent complex with MSP3, 
MSP6 and MSP7.19 MSP1 is associated with an important role in merozoite egress 
from iRBCs and with subsequent invasion processes, which is coordinated by 
proteases cleaving MSP1 during these processes. A subtilisin-like protease 1 
(SUB1) has been identified to process MSP1 into the fragments MSP183, MSP130, 
MSP138, and the GPI-anchored MSP142 just prior to egress.21 This processing allows 
intracellular merozoites to bind the spectrin network of the erythrocyte 
cytoskeleton via processed MSP1 to finally facilitate parasite egress from iRBCs.26 
The second proteolytic cleavage of MSP1 by SUB2 occurs during parasite invasion. 
After initial contact between merozoite and erythrocyte has been established, the 
microneme content – including SUB2 – is expelled at the apical end of the 
merozoite, and SUB2 subsequently migrates along the merozoite surface.27 SUB2 
is responsible for shedding MSP1 and other proteins from the merozoite surface at 
the tight junction that is formed at merozoite-RBC interaction point.21 Only the 
small MSP119 GPI-anchored fragment is finally carried into the RBC. 
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Figure 5. Schematic representation of known merozoite ligands, their interaction partners on the red blood cells, and 
methods to suppress these interactions. Reprinted with permission from ref 22. Copyright (2015) Creative Commons Licence 
4.0. 
 
MSP1 (more specifically the proteolytic fragment MSP142) was proposed to be 
responsible for the initial attachment of merozoites to RBCs25 or in a slightly later 
stage by mediating weak deformation of the erythrocyte.22 Since this interaction is 
inhibited by soluble heparin, the interaction partner on the RBC side is most 
probably heparan sulfate proteoglycan present on RBCs (Figure 5).25,28 This initial 
attachment has long been thought to be of low affinity,20 but recently it was found 
that adhesion force prior to reorientation is already as strong as thereafter based 
on optical tweezers measurements with whole merozoites and RBCs.29 Besides 
MSP142, many other interaction partners for heparan sulfate were identified and 
found having varying affinities towards this receptor; these include BAEBL (also 
known as EBA-140), PfRH1, PfRH2, PfRH5, apical membrane antigen 1 (AMA1), 
and more.30-32  
After initial attachment of merozoite to RBC, PfRH5 has recently been identified to 
bind basigin on RBCs to anchor the merozoite to the RBC.33 This allows 
subsequent interaction of AMA1 with RON2 to initiate tight junction formation, 
through which the merozoite finally passes, using its actin-myosin motor complex, 
to enter the RBC.21 However, others have suggested that the actin-myosin motor is 
not the sole force governing host cell entry, but rather a combination of parasite 
machinery and host cell forces and dynamics allows efficient and rapid invasion.24 
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1.2.3 Pathogenesis of Malaria and Prophylaxis, Treatment, and Control 
Strategies 
Pathogenesis is solely related to the blood stage cycle of malaria. Symptoms, which 
usually appear about 10 to 15 days after infection, and potential establishment of 
severe malaria, are all attributed to the multiplication and residence of parasites 
within RBCs. Laboratory manifestations of severe malaria include: severe anemia, 
acidosis, hyperlactatemia and hypoglycemia, pulmonary edema, and acute kidney 
injury.18 Severe P. falciparum malaria is responsible for most malaria-related 
deaths and is mainly caused by sequestration of iRBCs and subsequent dysfunction 
of various, vital organs.18 So-called cerebral malaria, which is a syndrome that 
frequently leads to death, is also related to sequestration, in this case within the 
brain microvasculature.34 Sequestration, also called cytoadherence, relates to the 
adhesion of P. falciparum iRBCs (about 12 – 15 h post-invasion) to endothelial cell 
surfaces in veins and capillaries via knob structures on iRBCs. Sequestration leads 
to interference with microcirculatory flow leading to malfunctioning of the affected 
organ and ultimately to death, if not treated.18 
The major adhesion protein in these knob structures of the iRBC surface is P. 
falciparum erythrocyte membrane protein 1 (PfEMP1), which is in fact the main 
responsible molecule for the disease pathogenesis. Intracellular parasites have the 
astonishing ability to dramatically change the RBC physicochemical properties 
during the 48-hour intracellular cycle of e.g. P. falciparum. In fact, the 
intracellular parasite exports about 10% of all its proteins to the host cell cytosol, 
where a parasite-derived membranous sorting machinery, termed Maurer’s clefts, 
further sends certain proteins, including PfEMP1, to the iRBC surface.35 Even more 
astonishing is the fact that the parasite has 60 different var genes, which all 
encode for one specific type of PfEMP1, whereas only one is mutually exclusively 
expressed at each time point.36 This allows the parasite to vary cytoadherence by 
binding to another receptor, which changes pathogenesis and helps the parasite to 
evade the immune system. Important members of host receptors for different 
PfEMP1 are chondroitin sulfate A in the placenta, ICAM1 in the brain, and CD36 in 
many other organs.18,34  
Another important modification of the host cell, relevant to this thesis, is the large 
increase of the membrane permeability towards certain small solutes.37 The 
activity of so-called new permeation pathways (NPPs) on iRBCs, which were 
related to reactivation of endogenous dormant protein channels, has been 
proposed to cause this increase in permeability.37 Nevertheless, access of even 
larger proteins and nanoparticles up to 80 nm diameter to the intracellular 
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parasite, without passing the host cytosol, suggests another yet unclear 
modification of the host cell to increase permeability; one possibility being a duct 
pathway that originates from unsuccessful closure of the merozoite entry site.38-42 
Detailed review of other host cell alterations through exported proteins leading to 
modification of the host’s cytoadherence, permeability, and rigidity can be found 
elsewhere.35,43 
Malaria can be treated using different combination therapies. The first-line 
treatment options include the very effective drugs of the artemisinin class in 
combination with other partner drugs. These drug combinations are also used for 
prophylaxis in travelers. The current drugs act on the intracellular parasites, no 
drug is on the market that can inhibit RBC invasion, for example.44 Similar to 
other antimicrobials, antimalarials constantly lose their efficacy due to the 
development and spread of drug resistance. Recently, drug resistance against the 
artemisinin-based drug combinations emerged in South East Asia,45 is spreading 
westwards,9 and has already led to treatment failures.46 This explains the constant 
need for novel antimalarials. Furthermore, there is an urgent need to develop 
drugs to reduce the high mortality of severe malaria.47 For final elimination of 
malaria it will also be necessary to develop drugs that kill gametocytes, therefore 
blocking transmission, and drugs to eliminate dormant hypnozoites of P. vivax to 
inhibit relapse of the disease months after the infection.47,48 
There is no malaria vaccine on the market yet. Several are in various stages of 
clinical trials. The most advanced being RTS,S/AS01 (MosquirixTM), for which a 
phase 3 clinical trial finished last year,10 and the European Regulators have 
approved the use of the vaccine in July 2015. Nevertheless, the vaccine efficacy for 
this particular vaccine in children and infants was only about 30% after four 
vaccinations,10 which is one of the reasons why WHO has only recommended 
usage in pilot implementation studies; no country-wide implementation has been 
recommended as yet.49 In recent years, the whole pathogen vaccination strategy 
has become more attractive again, especially the attenuated sporozoite vaccine 
approach, which has regained attention due to new, larger-scale production 
possibilities and remarkable protection in small studies.50 However, a very recent 
study with this sporozoite-based vaccine revealed a protection of about 50% for 
homologous challenge in adults for at least one year,51 which is again similar to 
protection achieved in adults using the RTS,S subunit vaccine.52 Larger studies are 
needed to evaluate the sporozoite-based vaccination, especially heterologous 
challenge to demonstrate clone-independent protection. Nevertheless, issues 
regarding affordable large-scale production, dosing, administration, storage, 
distribution, and safety, remain questionable at the moment.53,54 
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Global control measures for malaria, which helped to cut the mortality of malaria 
by half during the last decade, are the extended use of long-lasting insecticide 
impregnated bednets, and indoor residual spraying of insecticides.55 However, 
these efforts are also greatly challenged by insecticide-resistant mosquitoes that 
are already prevalent in many malaria endemic areas.56 
In the following chapters, the focus is shifted to the novel possibilities that are 
provided by polymer chemistry in combination with nanotechnology to tackle 
various medical conditions. Especially, specific malaria-related nanotechnological 
strategies are highlighted. But first, polymers and amphiphilic copolymer-based, 
self-assembled nanostructures, which are the types of nanoparticles used 
throughout this thesis, are introduced.  
1.3 Self-Assembled Amphiphilic Copolymers in the Context of 
Medical Applications 
In general, the two main areas of biomedically applied polymers are (i) “polymer 
therapeutics” – the polymer exhibits a pharmacological activity – and (ii) more 
inert polymeric constructs that function as drug delivery vehicles. In (ii), polymers 
can act to stabilize/protect therapeutics (e.g. small molecular drugs, enzymes, or 
nucleic acids), to increase in vivo circulation times of the drug, to target certain 
diseased cells, and to allow controlled and triggered drug release inside target 
cells. Traditionally, the main focus of polymer-based therapeutic systems was the 
development of novel cancer therapeutics and delivery platforms. Extensive 
reviews on this topic including examples of type (i) and (ii) can be found in many 
recent publications.57-61 Ever since, applications of polymer-based therapeutics are 
expanding (See Chapter 1.3.5). Examples include the treatment of infectious 
diseases (See Chapter 1.4), their use as topical microbiocidals, oral polymeric 
sequestrants, or in tissue regeneration/repair, demonstrating the broadly 
applicable concept of polymer-based approaches.62 
But what is a polymer? Polymers are macromolecules composed of covalently 
connected repeating units. Herein, the design, assembly, and applicability of such 
polymers, mainly in the form of block copolymers that self-assemble into 
supramolecular architectures, are described with an emphasis on intended 
biomedical uses. 
1.3.1 Block Copolymers and Self-Assembly Mechanism 
Polymer-based therapeutics relate to various structures ranging from relatively 
simple linear polymers to more complex copolymer-based macromolecules and 
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supramolecular assemblies thereof, such as dendrimers, micelles, nanoparticles, 
and polymer vesicles (polymersomes) (Figure 7).61,63 These supramolecular 
assemblies can be obtained via self-assembly of amphiphilic block copolymers 
(ABPs). In general, ABPs relate to a class of copolymers, which contain at least two 
domains that allows stabilization of an interface between two materials.64 In most 
cases this refers to at least one hydrophobic and one hydrophilic domain, with 
random, block, graft, star, multiblock, etc. architecture (Figure 6). These 
copolymer architectures, which connect hydrophobic and hydrophilic domains, 
will self-assemble in aqueous solutions to yield supramolecular structures, due to 
the incompatibility of at least one of the blocks and water. 
 
 
Figure 6. Some examples of possible amphiphilic block copolymer architectures: linear AB, ABA, and ABC copolymers, 
and more complex grafted, dendritic, and miktoarm star copolymers. A, B, C represent polymer repeating units of different 
chemical natures. 
 
The concentration limit for amphiphiles to self-assemble into supramolecular 
structures is called the critical micelle concentration (CMC). The driving force for 
aqueous self-assembly of such ABPs is mainly the hydrophobic effect,65 which also 
explains the self-assembly of lipids, surfactants, and biological membranes.66,67 
The hydrophobic effect describes the tendency of nonpolar molecules to self-
assemble in water in order to exclude water molecules, which leads to macrophase 
separation.68 In case of amphiphiles, the molecules assemble in such a way that the 
hydrophobic domains pack together with the hydrophilic domains facing the water 
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interface. The covalent linkage of hydrophobic and hydrophilic part within 
amphiphiles causes microscopic phase separation (e.g. micellation), in contrast to 
macroscopic phase separation for purely hydrophobic molecules in water.68 The 
forces governing the assembly of amphiphiles are similar to the assembly of purely 
hydrophobic molecules in water. However, additional entropic effects, arising from 
the hydrophilic block and the covalent linkage of at least two incompatible blocks, 
have to be included.68 
At room temperature, the change in Gibbs free energy (ΔG), which explains the 
spontaneous self-assembly of ABPs in water, is dominated by entropic forces.69 
This means the self-assemblies described herein are dominated by the fact that 
water tends to maximize its dynamic hydrogen-bonding network and not due to 
affinity between the hydrophobic domains.69 The assembly of hydrophobic 
molecules in water (a decrease in entropy) is overcompensated by the increase in 
entropy for the surrounding water molecules. If all amphiphiles would be 
dissolved, the water molecules, surrounding the amphiphile, would have fewer 
hydrogen bonds and lower degrees of freedom, which would cause an overall 
decrease in entropy. Therefore, it is entropically favorable for ABPs to self-
assemble instead of dissolving at concentrations above the CMC. 
 
 
Figure 7. Schematic representation of the influence of amphiphilic block copolymer geometry, with packing parameter p, 
on the self-assembly architecture: from spherical micelles to inverted structures. Reprinted and modified with permission from 
ref 70. Copyright (2012) Elsevier. This scheme has been prepared based on the theory of ref 67. 
 
The two main forces governing self-assembly of amphiphiles into distinct 
structures are the attractive hydrophobic forces at the water-hydrophobic interface 
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and the hydrophilic head group repulsion, which oppose each other leading to an 
optimal hydrophilic head area (a0).71 Similar to other amphiphiles, such as lipids 
and surfactants,67 the chemical nature of the used blocks in ABPs, the absolute 
length, polydispersity, hydrophilic fraction, and the molecular curvature determine 
the architecture of the self-assembled structures (Figure 7).70,72-74 These inherent 
amphiphile characteristics can be summarized with the so-called packing 
parameter p (Figure 7), which is the ratio of the hydrophobic domain volume (v) to 
the optimal hydrophilic head area (a0) times the length of the hydrophobic block 
(lc).67 The values obtained for p are a key parameter to predict the final structure of 
the self-assembly. Typical values of p to yield micelles, cylindrical micelles, 
vesicles, bilayers, and inverted structures are given in Figure 7.67,70,71  
An even simpler rule for predicting the structure of the self-assemblies is the 
hydrophilic to total mass fraction (fhydrophilic). ABPs with fhydrophilic < 25 % favor 
inverted structures, fhydrophilic ≈ 35 ± 10 % allows vesicle formation, and ABPs with 
fhydrophilic > 45 % typically form micelles.75 The assemblies also depend on pH, 
temperature, ionic strength, types of ions, ABP concentrations, and presence of 
homopolymer and surfactants.71,74 By changing these parameters, the structures 
can be transformed from one to another. Due to the slow dynamics of ABPs in 
solution, a global thermodynamic equilibrium is usually not reached. This allows 
to kinetically trap ABP in a certain self-assembled structure, which is stable due to 
the inability to thermodynamically equilibrate.76 The formation of the specific type 
of ABPs assembly called polymer vesicles is described in a bit more detail, because 
it was the main structure used in this thesis.  
1.3.2 Polymer Vesicles – Polymersomes 
This subsection has been published and was reprinted and modified herein with 
permission from reference 77. Copyright (2015) CRC Press. 
Einfalt, T.; Gunkel, G.; Spulber, M.; Najer, A.; Palivan, C. G. In CRC Concise 
Encyclopedia of Nanotechnology; Kharisov, B. I.; Kharissova, O. V.; Ortiz-
Mendez, U., Eds.; CRC Press, Taylor and Francis Group: Boca Raton, 2016; pp. 
1055–1068. 
Polymer vesicles, or polymersomes,78 are structural analogues to lipid vesicles 
(liposomes) built from ABPs instead of lipids. In an aqueous environment, these 
polymers can form spherical, membranous structure (Figure 8). Either spherical 
mono- (ABA-type polymer) or bilayer membranes (AB-type) enclosing a watery 
core are formed. The hydrophilic to total mass ratio (f-value) and the packing 
parameter (p) are key parameters, which govern the self-assembly process 
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resulting in formation of polymersomes.75,79 f-Ratios in a range of 25 - 45% and p 
parameters between 0.5 and 1 favor formation of polymersomes, when the 
polydispersity index is as close as possible to 1. The polymerization routes to 
obtain well-defined amphiphilic copolymers have been reviewed elsewhere.80-85 
 
 
Figure 8. Schematic representation of AB, ABA, and ABC block copolymers, their assembly into polymersomes, and 
encapsulation of hydrophilic compounds in the vesicle core. Triggered release from polymersomes can be achieved by 
incorporation of stimuli-responsive bonds. Reprinted with permission ref 86. Copyright (2009) Wiley and Sons. 
 
While lipid membranes are typically 3 – 5 nm thick; the membrane thickness of 
polymersomes can be fine-tuned in the range of about 5 to 30 nm by choosing an 
appropriate copolymer. Polymersomes offer a wide variety of advantages 
compared to simple liposomes, especially higher mechanic stability, and greater 
chemical versatility.78,86,87 While the driving force for nanostructure formation is 
mostly the hydrophobic effect as described above (Subchapter 1.3.1), there are 
other interactions, which favor the generation of polymersomes. A special group 
are vesicles with a polyion complex membrane (PICsomes), which are formed by 
ionic interactions of oppositely charged polymers.88 Furthermore, purely 
synthetic,79 biohybrid,88,89 or purely biological90,91 block copolymers have been 
employed to from polymersomes. Specific functions, such as targeting properties, 
can be implemented by including biological entities directly into the block 
copolymer before vesicle formation89 or by functionalizing preformed vesicles with 
targeting ligands.92,93 
Another critical step is to choose the appropriate polymersome formation 
technique for each block copolymer. A technique that works for one polymer 
cannot necessarily be applied to other polymers. Furthermore, the most suitable 
technique might even change depending on the nature of the desired molecules to 
be encapsulated, such as nucleic acids, proteins, or enzymes. Currently used 
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polymersome formation methods are in essence the same as for micelle formation: 
direct dissolution of dry polymer powder, film rehydration, and solvent switch 
method.74,93 In addition, double emulsion technique, and electroformation can be 
used to generate polymer vesicles.74,93 The resulting polymersome size is highly 
dependent on the preparation method. For example, film rehydration yields small 
multilamellar vesicles, whereas electroformation was specifically developed to 
produce micrometer-sized polymersomes.93 Extrusion – separating a 
polymersome solution through a filter with defined pore sizes – can be applied to 
obtain smaller polymersomes with a narrower size distribution. Polymersomes 
made from diblock, but not triblock, copolymers were transformed from 
unilamellar to bilamellar “double” polymersomes under hypertonic shock, 
demonstrating the close relation, and the intrinsic differences of polymersomes 
and liposomes.94  
The hydrophilic interior of polymersomes and the hydrophobic part of the 
membrane allow the simultaneous encapsulation of various hydrophilic and 
hydrophobic compounds, such as drugs, proteins, polysaccharides and nucleic 
acids. This advantage can be used to formulate multifunctional polymersomes. Our 
group e.g. pioneered the combination of polymersomes with membrane proteins 
and enzymes to produce nanoreactors that can even function as artificial 
organelles within cells.59 The polymersomes used in this thesis are mainly based on 
the specific ABA-type triblock ABP poly(2-methyl-2-oxazoline)-block-
poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline) (PMOXA-b-PDMS-b-
PMOXA). Specific fluorescence-based techniques have been extensively used in 
this thesis to characterize such polymersomes and other nanoparticles, which is 
why the next chapter briefly summarizes the concept and applicability of these 
methods. 
1.3.3 Characterization of Nanoassemblies by Fluorescence Correlation 
Spectroscopy 
Fluorescence correlation and cross-correlation spectroscopy (FCS, FCCS) are 
single molecule detection methods to analyze molecular diffusion properties and 
interactions of fluorescent molecules and nanostructures. Since its introduction in 
the early 70s,95 and upgrade by using confocal setups in the 90s,96 FCS and FCCS 
have become powerful tools to investigate a plethora of molecular and 
nanostructure properties in solution, within membranes, inside cells, and even 
within living organisms.97-101 More recently, the introduction of stimulated 
emission depletion (STED) microscopes allows to measure FCS using even smaller 
confocal volumes compared to conventional confocal microscopes.102 FCS/FCCS 
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can also be applied to study nanoassembly architecture, functionality, and 
membrane dynamics in detail. As mainly demonstrated by our group, FCS and 
FCCS can be used to characterize nanostructure hydrodynamic sizes, 
encapsulation efficacies, release behavior, surface functionality, interaction 
parameters for targeting ligands on the surface (e.g. KD), molecular dynamics of 
polymers and membrane proteins within polymersome membranes, and 
more.97,103-106 FCS was also used to characterize more biomedically applied surface 
modification of polymersomes with antibodies.107 
The schematic measurement setup and analysis principle is summarized in Figure 
9. Commercial confocal laser scanning microscopes can be used for these 
measurements. In contrast to confocal imaging – where the confocal volume is 
used to scan an image –conventional FCS and FCCS applications use the confocal 
volume in static condition. The raw signal is the fluorescence intensity fluctuation 
over time, which occurs due to molecular diffusion of the fluorescent analytes 
through the small observation volume in the range of about 1 femtoliter (= 10-15 
L).108 For conventional confocal laser scanning microscopy (CLSM) the x-y 
dimension of the confocal volume (ωxy) is solely given by the numerical aperture 
(NA) of the objective and the laser wavelength (λ): !!" = !2 ∙ !"                                                           Equation 1 
 
 
Figure 9. FCS and FCCS setup and principle. (A) Schematic experimental setup. (B) FCS procedure with a single color. 
Diffusion through the confocal volume induces measurement of fluorescence fluctuation over time, which is auto-correlated to 
yield autocorrelation curves to finally obtain diffusion times and concentrations. (C) Procedure for dual-color FCCS. Both colors 
must be spectrally separable to obtain distinct auto- and cross-correlation curves. The closer the cross-correlation amplitude 
is to the lower auto-correlation the higher is the degree of binding between red and green labeled species. Reprinted with 
permission from ref 98. Copyright (2006) Nature Publishing Group. 
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The measured fluorescence intensity fluctuations are attributed to classical 
Brownian motion of the suspended molecules/nanostructures through the 
confocal volume, which occurs due to thermal collisions at temperatures above 
absolute zero. This irregular and directionless (random) Brownian motion is 
described using a random walk model, which equals the famous Einstein relation 
that relates mean-square displacement in the direction of the x axis !!  to the 
diffusion coefficient D and time t:109,110 !! = 2!"     Equation 2 
Einstein applied van't Hoff's law of osmotic pressure produced by solute molecules 
in a solvent to free Brownian motion by defining a pressure p that is exerted by 
Brownian particles in equilibrium. When combined with the Stokes’ Law that 
describes the force exerted on a fixed sphere that is surrounded by moving fluid 
(velocity v and viscosity η), the Stokes-Einstein equation is obtained:109,110 ! = !"! 16!"!! = !!!6!"!!                                            Equation 3 
T is the absolute temperature, N the Avogadro constant, R the gas constant, kB the 
Boltzmann constant, and RH the hydrodynamic radius of the sphere. This equation 
relates the diffusion coefficient D to the radius RH of a particle that moves by 
Brownian motion within a fluid with viscosity η. This relation is subsequently used 
when analyzing FCS/FCCS data and calculating RH of nanoparticles in solution. 
For FCS measurements, a solution of fluorescent molecules/nanoparticles, usually 
in the nanomolar concentration range, is illuminated by a static femtoliter confocal 
volume on a commercial CLSM. The emitted photons of fluorescent objects 
present within this confocal volume at any given time point are recorded with high 
temporal resolution. The pinhole of the confocal setup ensures that out-of-focus 
light is not collected by the highly sensitive avalanche photo diodes (APDs). The 
recorded fluorescence intensity fluctuates over time, due to the above described 
Brownian motion of the suspended molecules/nanoparticles, which enter and 
leave the confocal volume faster or slower, depending on their size. Examples of 
raw intensity traces of FCS/FCCS measurements are given in Figure 9B,C. 
Intensity traces are subsequently auto-correlated (G(τ), single channel) for FCS 
and/or cross-correlated (Gx(τ), red to green channel) for FCCS:111 ! ! = 1 + !" !  ∙  !" ! + !! ! !                                  Equation 4 
 !! ! = !!! !  ∙  !!! ! + !!! !  ∙   !!(!)                                     Equation 5 
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with !" ! = ! ! − !(!)  being the intensity fluctuations with intensity ! !  at time 
point t, time average fluorescence intensity !(!) , and !" ! + !  the intensity at 
time ! + !. In the case of cross-correlation (Equation 5), !!(!) and !!(!) correspond 
to fluorescence intensities recorded by detection channel i (e.g. green) and j (e.g. 
red), respectively. The obtained auto- and cross-correlation curves are then fitted 
using appropriate models, e.g. free one-component 3D Brownian motion including 
triplet state (Equation 7, Chapter 10) or free two-component 3D Brownian motion 
(Equation 11, Chapter 10). These fits then yield diffusion times (τD), number of 
particles (N), fractions of molecules in triplet state, and fractions of molecules with 
corresponding diffusion time (for two-component fits). These values are then used 
to calculate hydrodynamic radii RH (Equations 8, 9, Chapter 10), molecular 
brightness (counts per molecules (CPM) in kHz), concentrations, number of 
encapsulated molecules, time-dependent release of molecules from 
nanostructures, surface coverage with targeting ligands, surface interaction 
parameters such as dissociation constant KD, colloid aggregation, and more as 
described in the Experimental Section (Chapter 10).97,103,104,107 A solution of free 
dye, for which the absolute diffusion coefficients is known,112 is first measured to 
calibrate the confocal volume x-y dimension (ωxy), which is needed to obtain RH in 
the end (Equations 8, 9, Chapter 10). 
Since the underlying theoretical description – used to calculate specific properties 
– assumes ideal conditions, such as a perfect Gaussian confocal volume, special 
attention to setup calibration and data evaluation has to be given to avoid possible 
artifacts.113-115 Especially, the problem of a disproportional effect of bright, and 
slow-diffusing nanostructures on the average autocorrelation curves114,115 poses 
hurdles for nanostructure evaluation. For example, a mixture of nanoparticles with 
diameters of 24 nm (99.4 %) and 100 nm (0.6%, 70 times brighter) yielded an 
autocorrelation curve characteristic for the 100 nm particles, which were only 
present in traces.114 Often, larger nanostructures (e.g. polymersomes), which 
diffuse slower, also contain more dye molecules, which highlights the significance 
of this problem. This can partly be solved by measuring more short intensity traces 
instead of few long measurements and exclusion of distorted autocorrelation 
curves from the averages.115 Nevertheless, this is subject to introducing subjective 
bias. Therefore, it should be ensured that only few percentages of all the curves are 
deleted and the selection process should be based on a number – an automated 
rejection of distorted curves would be optimal.115 Otherwise, all the measurements 
that e.g. yield CPM values 10 times higher than the average are manually excluded 
and the total percentage of affected curves are mentioned in the Experimental 
Section. 
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In case of analyzing colloidal stability and model dye release from drug delivery 
vehicles, two-component fits should be accompanied by CPM values (Chapter 10). 
CPM gives further indication, whether some molecules were released from the 
nanostructure, even if the fast-diffusing species does not appear as a second 
component due to the aforementioned problem. For FCCS measurements even 
more calibration data are needed. For example, cross-talk from green to red 
channel has to be minimized and overlap of red and green channel should be 
optimized.116 
Despite these hurdles, FCS/FCCS are powerful tools to investigate various 
nanostructure properties in detail. Especially, qualitative/relative evaluations are 
relatively simple, fast and often meaningful at a single molecule level. Our group 
pioneered to use a technique called z-scan FCS117 to study dynamics of membrane-
forming block copolymers, and embedded membrane proteins within giant 
polymersome membranes.105,106 In z-scan FCS, the confocal volume is placed at the 
top of an immobilized giant polymersome. Fluorescence intensity traces are 
recorded at varying relative z-position to finally calculate parameters of lateral 
dynamics of copolymers and membrane proteins within the membrane (Figure 
10). 
 
 
Figure 10. Schematic representation of z-scan FCS applied to measure lateral dynamics of membrane-forming 
copolymers and embedded membrane proteins (green cylinder). The left half of the immobilized giant (green) are experimental 
CLSM slices recorded with embedded fluorescently-labeled membrane protein. Hydrophobic mismatch between membrane 
hydrophobic part and membrane protein height is highlighted. Reprinted with permission from ref 105. Copyright (2015) 
American Chemical Society. 
 
Interestingly, our PMOXA-b-PDMS-b-PMOXA-based giant polymersome 
membranes revealed relatively fast lateral diffusivity of the copolymers within the 
membranes compared to other types of copolymer membranes.106 We argue that 
this high fluidity of PDMS-based membranes provides the basis for functional 
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incorporation of membrane proteins even in cases when a large mismatch between 
protein height and polymer hydrophobic membrane thickness exists.105 We found 
that various fluorescently labeled membrane proteins diffuse only about one order 
of magnitude slower within PDMS-based polymersome membranes compared to 
protein diffusion within their natural environment, lipid bilayers.105 This is the 
basis for the generation of polymeric, membrane-protein-based nanoreactors and 
artificial organelles. 
In the next chapter, the specific requirements of polymer-based nanostructures 
that should be met when intended for biomedical applications are summarized. 
1.3.4 Requirements of Polymer Nanostructures When Used in Medicine 
This subsection has been published and was reprinted and modified herein with 
permission from reference 118. Copyright (2013) Future Medicine. 
Najer, A.; Wu, D.; Vasquez, D.; Palivan, C. G.; Meier, W. Polymer 
Nanocompartments in Broad-Spectrum Medical Applications. Nanomedicine 
(London, U.K.) 2013, 8, 425–447. 
For use of polymer nanostructures in medicine, for example as drug carriers, 
nanoreactors or artificial organelles, a complex system of requirements must be 
fulfilled with reference to (i) the material, (ii) mechanical properties, (iii) size, (iv) 
shape, and (v) surface chemistry of the polymeric compartments. These properties 
determine blood circulation half-life, biodistribution, vascular dynamics, targeting, 
cell uptake, drug release, and subsequent degradation ((i, ii),119 (iii),120 (iv),121 
(v)122) (Figure 11). 
Information on cellular uptake mechanisms of nanocarriers (e.g. endocytosis or 
phagocytosis) can be found in a recent review.123 Toxicity and immunological 
aspects should be evaluated carefully, because even small changes in the above 
mentioned properties alter the properties of a drug delivery system (DDS) in a 
biological environment in vitro and in vivo.124 Because of the limited availability of 
information specific to polymeric compartments, we selected relevant information 
concerning the requirements of a DDS from stealth liposome-, general polymer 
therapeutics-, and nanoparticle literature.  
The properties related to the requirements mentioned above will differ drastically, 
depending on the desired site of action of a DDS or nanoreactor. For example, 
opposing properties must be exhibited when aiming at a slow-release drug 
reservoir within cells of the mononuclear phagocytic system (MPS), as compared 
to targeted drug delivery to a specific site. The former DDS has to be taken up by 
cells of the MPS, while the latter should be prepared to avoid uptake by these cells. 
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Specific requirements for nanoreactors in medical applications involve: use of no-, 
or very dilute organic solvents in order to retain biomolecule function, sufficient 
robustness of the nanoreactor – even after cellular uptake – and the 
substrates/products of the enzymatic reaction must be able to cross the polymer 
membrane of the nanoreactor.125,126 
 
 
Figure 11. Barriers (blood cells, liver, kidneys and spleen) encountered by polymer nanocompartments after injection and 
their two functions, either as drug/protein/nucleic acid delivery vehicles or as artificial organelles. (A) To reach target cells, 
polymer vesicles have to avoid recognition by blood cells, uptake in liver and spleen (phagocytosis or filtration) and renal 
clearance (kidneys). (B, C) After cellular uptake the polymer vesicles are trafficked in early endosomes. (D) Endocytosed 
material can be recycled to the cell surface and excreted. Release of cargo is desired for drug/protein/nucleic acid delivery 
vehicles. This occurs through vesicle degradation (stimuli-responsive vesicles) after fusion with (E) lysosomes or (F) endosomal 
escape. (i) For example, carriers – sensitive to the cytosolic, reductive environment – release their cargo through degradation 
after endosomal escape. (ii) Nanoreactors that act as artificial organelles should escape endosomes intact and degradation in 
the cellular environment must be avoided if activity as artificial organelles is to be carried out. Modified with permission from 
refs 127,128. Copyright (2011, 2012) Wiley and Sons. 
 
1.3.4.1 Biocompatibility and Biodegradability of the Nanostructure 
Material 
All polymers designed for use in vivo must be biocompatible. Toxicity related to 
the polymer must be avoided. In the case of a DDS, polymers should be 
biodegradable as well, or should at least be eliminated from the body. Current 
knowledge on administration, distribution, metabolism and elimination of general 
polymer-based therapeutics in vivo has recently been summarized.119 Compared to 
a polymer-drug conjugate, in which the drug is released e.g. upon stimuli-
responsive cleavage of the linker between the polymer and the drug, vesicles 
release their payloads through disruption of the vesicle structure or by transport 
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through naturally porous membranes or integrated protein channels.86,129,130 
Therefore, either the vesicle-forming polymers themselves should be 
biodegradable, or the macromolecular assembly should disintegrate into single 
polymer chains that can be excreted from the body. For example, single 
poly(ethylene glycol) (PEG) chains smaller than 30 kDa are readily cleared from 
the body by the kidneys.131  
DDS are often designed to be responsive to certain stimuli, so that their payload is 
released only upon proper stimulation at the desired site of action.86 Polymer 
assemblies responsive to physical, chemical or biological stimuli have been 
proposed.132 In principal, the degradation of a macromolecular assembly could 
lead to excretion of polymeric material, but the mechanism and the actual fate of 
these materials should be evaluated carefully. 
Other strategies to achieve degradation of the macromolecular assembly are based 
on the use of natural monomers or polymers such as amino acids, nucleotides, 
lipids, and carbohydrates to build vesicle-forming block copolymers. If the block 
copolymer consists of one block made of biological materials (e.g. polyglutamic 
acid, chitosan or dextran),89,133 and if the second block is made of a synthetic 
polymer (e.g. PEG, PMOXA), this is referred to as biohybrid material. The 
degradation products of the natural block enter the biochemical pathways in the 
body. If the remaining synthetic polymer is non-degradable, the kidney will excrete 
it, as long as the size of the remaining polymers does not exceed the renal excretion 
cut-off, which is estimated to be 5.5 nm for inorganic nanoparticles, for example.134  
In the case of artificial organelles, these vesicles must stay intact in the cell 
environment for effective periods of time in order to perform their tasks; rapid 
biodegradability is therefore not desirable or needs to be delayed. For example, 
PMOXA-b-PDMS-b-PMOXA nanoreactors that contain a dual-enzyme-mimic 
labeled with sulforhodamine B were stable in THP-1 cells for at least 48 hours.135 
However, as the concept of artificial organelles was introduced only recently and 
development and optimization inside cells involve extensive testing, there are no 
examples that report stability of the artificial organelles inside cells for more than 
48 hours. If even greater stability is required, cross-linking the polymer chains in 
the polymeric membrane after vesicle formation can, for example, be 
performed.130,136 
1.3.4.2 Surface Chemistry 
The surface chemistry of polymeric vesicles is of great importance, especially if in 
vivo applications are intended. For some time now it has been known that 
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PEGylation of liposomes increases their blood circulation times by reducing 
opsonisation and uptake of liposomes by MPS cells, because of the protein 
repellant property of PEG.137,138 But recently, certain problems have been 
attributed to the use of PEG; therefore, alternative strategies to PEGylation are 
gaining ever greater attention.124,139,140 Proposed, alternative inert surface coatings 
include PMOXA and poly(2-methacryloyloxyethyl phosphorylcholine).141,142 
Use of-, or mimicking of the RBC membrane is another strategy to obtain long-
circulating DDS. For example, poly(lactic-co-glycolic acid) nanoparticles covered 
with whole RBC membranes exhibited longer half-lives as compared to PEGylated 
nanoparticles.143 But, because human RBCs are immunogenic when transferred 
between patients with different blood groups, personalized DDS need be prepared, 
or antigens need be eliminated from the membrane.143 In another strategy to 
enhance circulation time, charge on the surface of polymersomes was tuned to 
mimic the negative surface potential of RBCs (-15 mV), whereby a different organ 
accumulation pattern was found for negatively charged polymersomes as 
compared to neutral ones, with the former accumulating mainly in the liver.144 The 
effect of surface charge on circulation time was studied in tumor-bearing mice 
using polymersomes made of PEG-b-poly(D,L-lactide).122 The longest circulation 
time (half-life 47.3 h), lowest liver uptake (27.9% of injected dose), and highest 
accumulation in the tumor (18.6% of injected dose) was found for 90 – 100 nm 
polymersomes with a slightly negative surface charge (zeta potential − 7.6 mV). 
Polymeric vesicles with a more negative surface charge (zeta potential – 38.7 mV) 
or stealth liposomes were less effective.122 For clinical therapy, the surface of the 
DDS should either be neutral or negatively charged, because exposed positive 
charges are problematic for in vivo applications.145 In order to achieve targeted 
drug delivery at a specific site, both passive and active targeting strategies are 
being examined. Using the “enhanced permeability and retention effect” (EPR) in 
solid tumors, long-circulating DDS will passively accumulate at these tumor sites; 
no specific surface modifications are necessary.146 Active targeting strategies 
require specific targeting ligands on the surface of the DDS. In this regard, 
different ways to functionalize polymersomes were recently summarized.92  
1.3.4.3 Size  
Vesicle size is another key factor determining biodistribution and circulation half-
life in blood.120,147 The first constraint to long-circulating nanoobjects in blood is 
the hepatosplenic filtration process. This can be circumvented by not exceeding a 
200 nm vesicle diameter, or by introducing flexibility to the assembly.148,149 The 
lower size limit depends mainly on the kidneys; only spherical particles with 
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hydrodynamic diameters greater than 5.5 nm can avoid renal clearance and 
urinary excretion.134 
For polymersomes administered in mice, a second size limitation (< 100 nm 
diameter) was found that was not true for liposomes, influencing biodistribution 
and circulation.120 It was observed that polymersomes made of PEG-b-
polybutadiene at a diameter of 120 nm accumulated far more in liver and spleen 
than 90 nm vesicles made of the same material (blood half-life of about 24 h). On 
the other hand, doubling the PEG layer did not alter the circulation time 
significantly.120 This strong dependence of pharmaceutical properties on the size of 
polymeric vesicles enhances the need for vesicle preparation methods that result in 
defined sizes with low size distributions. Polymer parameters, preparation 
procedures, and specific methods to obtain defined vesicular structures were 
summarized recently.150 Based on the current data, long-circulating polymer 
vesicles can be produced if prepared in the diameter range of 10 – 100 nm.120,147 In 
the case of PICsomes, an optimal size in terms of extended blood circulation and 
high tumor accumulation was determined to be around 150 nm.151  
1.3.4.4 Shape 
To date, mainly spherical micelles, elongated micelles and spherical vesicles have 
been investigated for their potential use in drug delivery. It has been determined 
that shape greatly affects biomedical properties such as toxicity, biodistribution, 
and cellular uptake of DDS.121 Worm-like polymeric vesicles were prepared and 
proposed as a theragnostic tool for cancer, while the influence of their shape on 
circulation time was not evaluated.152 Interestingly, when an active targeting 
strategy was applied by attaching targeting moieties to DDS, differences in shape 
lost importance.153 Therefore, it can be speculated that only for DDS with passive 
targeting strategies does the effect of shape become a significant factor.  
After introducing the limitations for polymer-based nanosystems to be applied in 
medicine, few examples of proposed polymersome-based biomedical applications 
are summarized in the next chapter. 
1.3.5 A Glimpse at Potential Polymersome Biomedical Applications 
This subsection has been published and was reprinted and modified herein with 
permission from reference 77. Copyright (2015) CRC Press. 
Einfalt, T.; Gunkel, G.; Spulber, M.; Najer, A.; Palivan, C. G. In CRC Concise 
Encyclopedia of Nanotechnology; Kharisov, B. I.; Kharissova, O. V.; Ortiz-
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Mendez, U., Eds.; CRC Press, Taylor and Francis Group: Boca Raton, 2016; pp. 
1055–1068. 
Applications of ABP-based micelles/nanoparticles can be found in other extensive 
reviews.154-157 The main application being the stabilization and delivery of 
hydrophobic drug molecules for cancer therapy. Compared to micelles, 
polymersomes have the advantage of allowing the encapsulation/entrapment of 
both hydrophilic and hydrophobic molecules in the same vesicle due to its intrinsic 
architecture based on an inner cavity surrounded by a membrane. The ability of 
polymersomes to simultaneously contain both hydrophobic and hydrophilic 
molecules allows for the construction of complex systems beyond traditional drug 
delivery vehicles,118,127 such as nanoreactors, artificial organelles,118,126-128,158-160 
active surfaces (e.g. biosensors)126 and multicompartment systems mimicking 
cellular functions.161 
Polymersomes are a potential candidate to be used as drug delivery system (Figure 
11). The robustness large size of their hydrophilic compartment, and their chemical 
versatility are main advantages of polymersomes compared to other delivery 
carriers.162 In addition, by an appropriate selection of the copolymers to contain 
stimuli-responsive blocks, it is possible to release cargo “on demand”. Common 
triggers used for stimuli-responsive release from polymersomes are pH, 
temperature, redox-potential, and concentration gradients of certain molecules 
(e.g. glucose).86,87,132 Another advantage of polymersomes for drug delivery is their 
long in vivo circulation time, 47.3 h half-life compared to 10.6 h for PEGylated 
liposomes in mice.122 The long circulation time was achieved by using the 
hydrophilic domain PEG, known to reduce adsorption of proteins and subsequent 
opsonisation by cells.138 Other factors that support the use of polymersomes for 
biomedical applications are the biocompatibility/biodegradability of the polymers, 
the size, shape and surface properties (Subchapter 1.3.4). 
Nanoreactors are engineered by encapsulation of active compounds (proteins, 
enzymes, mimics, or combinations thereof) that perform chemical/biochemical 
reactions inside the cavity of polymersomes. The membrane permeability allows 
an exchange of substrates/products with the environment and can be specifically 
tuned by the chemical nature of copolymers by chemical modifications163,164 or by 
incorporation of natural channel proteins.128,158 Nanoreactors evolved from one-
step reactions inside the polymersome,130,165 to two-step ATP synthesis,166 to more 
complex reactions such as three-enzyme cascade reactions,167,168 or transcription of 
DNA to mRNA and subsequent translation to yield fluorescent proteins.169 
Nanoreactors were also used to synthesize antibiotics on demand and on site.170 
Chapter 1  27 
Bacterial growth was inhibited by antibiotics (cephalexin), locally produced by 
nanoreactors containing penicillin acylase, and having a permeable membrane due 
to the insertion of bacterial outer membrane protein F (OmpF) to allow substrate 
and product permeation. 
The concept of artificial organelles was introduced by reports of nanoreactors 
performing their enzymatic reactions in situ inside cells (Figure 11).128,171-173 One 
example is the detoxification of reactive oxygen species (ROS) by artificial 
peroxisomes. Two enzymes acting in tandem inside the cavity of polymersomes 
equipped with channel proteins for membrane permeabilization, detoxified 
superoxide radicals and hydrogen peroxide in cells exposed to oxidative stress.  
These artificial organelles protected cells from oxidative stress to the same extent 
as natural peroxisomes.172 
Another direction of polymersome research is to establish multicompartment 
systems with a cytosol-mimicking interior including different organelles with the 
prospect of designing artificial cells.161,169,174 Controlled production and loading of 
giant polymersomes was realized by microfluidic techniques. These polymersomes 
were filled with the whole transcription- and translation machinery in order to 
synthesize fluorescent proteins from DNA plasmids.169 Others produced 
multicompartment systems that mimicked cytosol properties within giant 
polymersomes.161,175,176 They produced small polymersomes which were 
encapsulated in big polymersomes together with a crowding agent (alginate) to 
mimic the cytosol.176 Alginate completely arrested movement of the small 
polymersomes, whereas dextran only slowed down their diffusion. Cascade 
reactions were also implemented in a multicompartment polymersome system.168 
Two kinds of nanoreactors (containing two different kinds of enzymes) were 
encapsulated in micrometer-sized polymersomes together with a third enzyme 
(“cytosolic” enzyme), enabling cascade reactions in this compartmentalized 
structure with participation of all three enzymes.  
Interestingly, even directional movement of polymersome-like structures can be 
achieved.177 Polymer stomatocytes, (deformed polymersomes with an opening) 
encapsulated catalytically active platinum nanoparticles, which catalyzed the 
production of water and oxygen from hydrogen peroxide. The products were 
expelled through the controlled opening of stomatocytes, yielding directional 
movement, demonstrating production of miniature monopropellant rocket engines 
built from polymersomes.177 
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1.4 Nanotechnology for Infectious Disease Medicine 
Nanotechnology is also considered as one of the key technologies to overcome the 
mentioned threats associated with infectious diseases in the future. More specific, 
nanotechnology can be used to develop tools to fight drug resistant pathogens and 
to design more potent vaccines.178 One example is the use of “nanoantibiotics” 
against drug resistant bacteria.179,180 This is particularly important in the context of 
antibiotic discovery lagging behind rates of drug resistance.180 Therefore, a current 
alternative is the delivery of high local antibiotic concentrations to infected sites 
using DDS. This nanocarrier-based delivery should solve the problems of systemic 
administration, namely, systemic toxicity and insufficient antibiotic 
concentrations at the target sites; a known factor to promote antibiotic 
resistance.180 Entry inhibition of viruses and bacteria by multivalent 
nanostructures is a growing and promising strategy for treatment or prophylaxis of 
infections.181-185 In general, the inhibitory nanostructure should best be smaller 
than binder (pathogen).185 Another example of possible nanotechnology impact on 
infectious disease control is the formulation of nanovaccines with increased 
efficacy.186,187 Carrier systems have long been used for many vaccines in order to 
modulate the generated immune response, which strongly depends on the nature 
of the vaccine carrier. 
Few examples of polymersome-based anti-infectious strategies are highlighted 
below. Studies on the application of polymersomes and other polymer-based 
nanostructures in the field of nanomedicine for infections are clearly limited in 
contrast to a huge literature on anti-cancer applications. However, polymer-based 
nanostructures have a great potential to be broadly utilized in the field of anti-
infectious strategies as well. Specific advantages of polymer-based strategies are 
the relatively simple and diverse synthesis possibilities to produce a plethora of 
degradable/nondegradable polymers, facile post-synthesis modifications/ 
conjugations, affordability, scale-up, and introduction of stimuli-responsiveness. 
Triggered nanostructures that respond to a change in their environment (stimuli) 
are particular examples of sophisticated DDS achievable using polymer-based 
building blocks. 
1.4.1 Polymersome-Based Anti-Infectious Strategies 
This subsection has been published and was reprinted and modified herein with 
permission from reference 59. Copyright (2016) The Royal Society of Chemistry. 
Palivan, C. G.; Goers, R.; Najer, A.; Zhang, X.; Car, A.; Meier, W. Chem. Soc. 
Rev. 2016, 45, 377–411. 
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In addition to cancer therapy, which is the main area of applied polymersome 
research, there are other possible biomedical applications using triggered 
polymersomes for diagnostics and therapy. pH-sensitive polymersomes have been 
tested for the detection of pathogenic bacteria,188 and for possible intracellular 
antibiotic therapy.189,190 Hyaluronic acid-block-poly(ε-caprolactone) copolymers 
are prone to enzymatic degradation by bacteria and can be used for their detection. 
For example, upon enzymatic cleavage by hyaluronidase, which is common in 
Staphylococcus aureus, a reporter compound is released for detection.188 
Polymersomes based on peptide functionalized chitosan were able to encapsulate 
and release doxorubicin (DOX) upon proteolytic degradation and act antibacterial 
at the same time.191 Thus this system might be applied in the future to deliver 
drugs and simultaneously protect from bacterial infections. An additional example 
in the combat of bacterial infection has been proposed for immobilized 
nanoreactors on implants. They provide the required antibiotic ‘‘on site’’, and only 
the precursor needs to be administered, thus minimizing side effects.170 It was also 
shown that the number of intracellular Porphyromonas gingivalis, which infect 
oral epithelial cells, was reduced by intracellular delivery of metronidazole or 
doxycycline using acid-sensitive polymersomes,190 and Burkholderia 
pseudomallei-infected murine macrophages were successfully treated using 
another type of pH-sensitive polymersomes (Ceftazidim-loaded) that disassembled 
in endosomes for efficient intracellular drug release.189  
Oxidation-sensitive polymersomes have been introduced as a valuable vaccine 
delivery platform because antigen-cross presenting dendritic cells contain 
oxidative endosomes.192 In addition, the advantageous architecture of 
polymersomes allows simultaneous encapsulation of hydrophobic and hydrophilic 
antigens and adjuvants, and therefore serves as an improved delivery system.193 
First, it was demonstrated that dendritic cells engulfed loaded oxidation-
responsive polymersomes via endosomes, where they resided for more than 12 h, 
and then in a second step the payload escaped to the cytoplasm. Endosomal escape 
of antigen is desirable for entering the ‘cytosolic pathway’ of antigen cross-
presentation via major histocompatibility complex 1 (MHC 1), which might be 
advantageous for adjuvant-induced activation and antigen presentation. 
Furthermore, enhancement of T cell priming was found when dendritic cells were 
tested for processing, and cross-presentation of a model antigen on MHC 1 when 
these polymersomes were used for antigen delivery compared to delivering free 
antigen to dendritic cells.193 
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1.4.2 Nanotechnological Approaches for Malaria 
The current problems associated with malaria discussed in Subchapter 1.2 demand 
for innovative strategies for future control of this disease. Nanotechnology is 
increasingly acknowledged as a valuable tool to design novel diagnostic,194 
therapeutic,195-198 and prophylactic199,200 approaches for malaria. For detailed 
examples, readers are referred to the above-mentioned extensive reviews on this 
topic. Herein, only few examples are highlighted to demonstrate the broad 
applicability of nanotechnology for possibly controlling malaria in the future. 
1.4.2.1 Antimalarial Drug Delivery 
Similar to anticancer drug delivery, antimalarials are other valuable carrier 
molecules to be incorporated within nanoparticles for drug delivery to parasitized 
cells. In case of malaria, nanoparticle-based drug delivery is being evaluated to 
reduce drug-related toxicities, fight drug resistance development, increase drug 
performance, treat severe malaria, and block transmission as exemplified below. 
Up to now, the main carriers evaluated for antimalarial drug delivery have been 
liposomes, solid lipid nanoparticles, polymeric nanoparticles, cyclodextrins and 
dendrimers.197 
Currently, blood stage parasites are the main target of antimalarial drug delivery. 
Increasing the drug concentration within intracellular parasites through targeted 
nanostructure-based drug delivery is thought to be a valuable tool to fight 
establishment of drug resistance and treatment of drug resistant parasites.42,201 
However, it is an ongoing controversy through which mechanism nanostructures 
deliver antimalarials to iRBCs. The two main proposed mechanisms are a direct 
access of nanoparticles (< 80 nm diameter) to intracellular parasites via the 
“leakiness” of iRBCs,39,40,42,202 and membrane fusion of e.g. drug-loaded liposomes 
with iRBC membranes (iRBCM).203-205 The main difference between these two 
mechanisms is the role of the host cell cytosol. With the first mechanism, the DDS 
bypasses the host cytosol (Figure 12B,C), whereas membrane fusion demands 
subsequent crossing of the host cytosol by the drug molecule (Figure 12A). Possible 
explanations for these pathways are summarized in Figure 12.  
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Figure 12. Schematic representation of proposed iRBC morphology causing increased permeability of iRBCs compared to 
RBCs. (A) Traditional sequential pathway: solutes sequentially cross red blood cell membrane (RBCM), parasitophorous 
vacuole membrane (PVM), and parasite plasma membrane (PPM) to reach the parasite. (B,C) Alternative models “parallel 
pathways” for solute transport that does not involve the host cytosol: (B) (a) PVM and PPM are close to RBCM to facilitate 
solute uptake or (b) tubovesicular membrane (TVM) fuses with RBCM, which allows entry of solutes from extracellular medium. 
(C) Parasitophorous duct originating from merozoite entry connects the intracellular parasite with the external medium. This 
scheme is based on ref 206. Reprinted with permission from ref 197. Copyright (2013) Elsevier. 
 
The increased permeability of iRBCs to small solutes has been attributed to new 
permeation pathways (NPP) appearing on iRBC membranes (Figure 12A).37 
However, the size of these channels does not provide a pathway for nanoparticles. 
Possible sites for the entry of sub-80 nm nanoparticles into iRBCs are the sites 
where the iRBCM is in close proximity to the parasitophorous vacuole membrane 
(PVM) and parasite plasma membrane (PPM) (Figure 12B-a).206 Uptake of 
nanoparticles could also occur via the tubovesicular membrane (TVM) that fuses 
with the iRBCM (Figure 12B-b). Alternatively, the merozoite entry site might never 
completely close and therefore provide a parasitophorous duct that allows direct 
entry from the serum site (Figure 12C).206 
The second pathway, delivery via membrane fusion, calls for a membranous 
nanostructure, such as liposomes, and active targeting to iRBCs. iRBC-targeting 
antibodies and polysaccharides presented on liposome surfaces were 
demonstrated to increase fusion of the nanocarrier with membranes of infected 
cells.203,204,207 This strategy reduced the amount of drug needed to kill the 
intracellular parasites in vitro by more than 10-fold compared to free drug, but 
parasitemia could not completely be eliminated from the cultures.204 In contrast, 
targeting liposomes to all RBCs, including non-infected RBCs, also yielded some 
beneficial effect due to the residence of the antimalarial chloroquine (CQ) already 
before entry of the parasite.205,208 Dendrimers have been investigated for 
antimalarial delivery as well.42,201 Poly(amidoamine) dendrimers loaded with CQ 
were much more effective in an in vivo model of malaria compared to the free 
drug.42 This was attributed to the targeting effect of these dendrimers to iRBCs, 
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which specifically take up these drug-loaded nanocarriers. Another type of 
dendrimers, amphiphilic dendrimers, were also loaded with CQ and PQ, which 
yielded similar beneficial effects as the first example when tested in vitro and in 
vivo against malaria.201 Targeted delivery of high drug concentrations to iRBCs is 
considered a valuable strategy to tackle development of drug resistance.42,201 
Another avenue for antimalarial delivery via DDS is the optimization of drug 
performance of existing antimalarials. Nanostructure-based artemisinin delivery 
was evaluated in a malaria mouse model using PEGylated liposomes via parenteral 
administration. Delivery by this specific carrier showed highest efficiency 
compared to free artemisinin and conventional liposomal formulation of 
artemisinin.209,210 The artemisinin-loaded liposomes yielded much longer blood-
circulation times and more stable drug concentration levels in the blood compared 
to free artemisinin.209,210 Furthermore, the liposomal formulations had immediate 
effect on the parasites, whereas free artemisinin decreased parasitemia not before 
7 days after the treatment start.210 In conclusion, the efficacy of an existing drug 
could be optimized using liposomal nanocarriers.210 
A further strategy is the development of DDS to reduce the high mortality 
associated with severe malaria.211 Liposomes have been tested in a model of a 
severe pathological event, cerebral malaria.211,212 In contrast to previous examples, 
the DDS used in this case did not deliver an antimalarial, but a toxic glucocorticoid 
prodrug. This DDS reduced cerebral inflammation when administered to mice 
with experimental cerebral malaria. By first reducing the adverse effects related to 
the cerebral syndrome using this steroidal nano-drug, the time window for 
subsequent anti-parasite treatment with conventional antimalarial drugs was 
significantly increased.211,212 This sequential treatment completely cured mice from 
cerebral malaria. The authors conclude that this is a valuable treatment option for 
this severe form of malaria, even if patients would arrive at a late stage of disease. 
Stimuli-responsive nanoparticles that release their cargo upon a change in pH, 
temperature, redox potential, or concentration of a specific enzyme,59,213 have not 
yet been specifically applied to antimalarial drug delivery. The highly reducing 
cytosol of intracellular malaria parasites214 provides an endogenous trigger to 
initiate intracellular nanoparticle disassembly and drug release. This strategy is 
comparable to reduction-triggered anticancer drug release from DDS within the 
reducing cytosol of cancer cells.215 Interestingly, the cytosol of drug-resistant 
parasite strains (CQ-resistant) were even more reducing (higher glutathione (GSH) 
levels and glutathione S-transferase activity) compared to drug-sensitive strains.216 
More recent data also revealed the same elevated GSH levels within parasite 
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cytosols of artemisinin- and mefloquine-resistant strains.217 This reduction of 
drug-sensitivity might be overcompensated by delivery of high local 
concentrations of drugs using reduction-triggered nanoparticles. These triggered 
carriers might release their payload faster and more effective within the highly 
reducing-cytosol of drug-resistant parasites. 
Other parasite stages that are currently being addressed using nanostructure-
based delivery systems are the mosquito stages.218 One possible way would be the 
administration of these drug-loaded nanoparticles to humans, which would 
subsequently delivery the nanoparticles from their blood to the mosquito during 
their blood meal.218 
1.4.2.2  Nanostrategies for Malaria Vaccines 
Various nanostructures have been proposed and tested as delivery vehicles for 
malaria vaccines.199,200 In the context of vaccines, nanostructures are delivery 
platforms containing a cocktail of antigens (or DNA encoding for antigens), 
adjuvants, and immunomodulatory molecules. This complex design helps to 
generate and modulate the immune response.219 In fact, the most advanced 
malaria vaccine candidate RTS,S/AS01 from GSK is formulated in liposomes 
(AS01), which are nanovesicles.220 RTS,S/AS01 is an example of a subunit 
protein/peptide vaccine. It mainly consist of the circumsporozoite protein (CSP) of 
the pre-erythrocytic sporozoite form of P. falciparum formulated in a 
nanostructure (liposome). 
Another nanotechnological vaccination possibility that is being followed is the use 
of viral envelopes, called virosomes, for targeted delivery of incorporated 
antigens.221 This strategy was e.g. used to successfully induce production of 
parasite growth-inhibitory antibodies against AMA1 of blood-stage malaria 
parasites.221 In even more advanced formulations, epitopes are integrated into 
designer proteins that self-assemble into “virus-like” nanoparticles themselves.200 
This combines the high immunogenicity of virus-like nanoparticles with the purity 
of designer proteins; such a self-assembled nanoparticle – based on CSP epitopes 
– will enter human clinical trials in 2017.200 DNA vaccination is another 
alternative. In this case, DNA encoding for certain antigens is used for vaccination. 
Unfortunately, free DNA suffers from insufficient cellular uptake and low stability 
in biological fluids. This is circumvented by protection and delivery of the DNA via 
nanocarriers. However, the perfect carrier in combination with the best route of 
administration has not yet been found.199 
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In general, malaria blood stage protein-based vaccines are challenging to design, 
due to the difficulty to select and prioritize the antigen or combination of antigens 
that can induce maximum protective response. Future protein-based malaria 
vaccine development to achieve a highly effective vaccine, which can either prevent 
death, disease, or transmission, will need to include new strategies for 
identification, selection, and formulation of the vaccine.222 Conserved and essential 
antigens, which are not necessarily the main targets of naturally acquired 
immunity, should be selected in the future and most beneficial antigen 
combinations for protective efficacy should be found.222 Furthermore, finding 
improved protein vaccine delivery platforms (nanotechnology) and adjuvants to 
significantly fine-tune and enhance humoral and cellular immunity is another 
priority.222  
In conclusion, we have learned that formulation of an effective subunit protein 
vaccine for malaria is extremely challenging. For final eradication of malaria a 
combination of subunit protein vaccines and whole parasite vaccines (See 
Subchapter 1.2.3) might be the solution.223 
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   CHAPTER 2 
2 Motivation and Aim of this Thesis 
The ongoing challenges to fight infectious diseases, in the context of expanding 
antimicrobial resistance and the current lack of alternatives for treatment and 
prophylaxis (See Chapter 1), motivated me to establish nanotechnological 
approaches for antimicrobial applications, in particular for malaria. Especially 
since these diseases mainly threaten children, pregnant women, diseased-, 
malnourished-, and elderly people, I consider finding new ways to treat and/or 
prevent theses diseases being of highest priority. We will constantly need new 
drugs, drug/vaccine delivery systems, vaccines, vaccination strategies, or 
alternative measures to stay ahead of rapidly evolving pathogens. Promising types 
of biomedically applicable materials are polymer-based nanostructures. These 
materials can be designed to suit the particular demands by exploiting the broad 
chemical diversity achievable by polymer chemistry, which allows constructing 
complex assemblies with multifunctional properties. 
The overall aim of this thesis is the development of polymer-based nanostructures 
for the fight against malaria, while maintaining potential broad-spectrum 
applicability. The main aim followed herein is the development of functional 
polymer vesicles (polymersomes) that inhibit malaria parasites from entering 
RBCs, thereby presenting the extracellular form of the pathogen to the immune 
system. This strategy is designed to provide multifunctionality due to the 
combined drug- (invasion inhibition) and "vaccine-like" action (parasite exposed 
to immune system) (Figure 13). This is straightforwardly addressed by mimicking 
the host cell surface on the nanostructure. The advantage of this design is a 
potentially biocompatible structure, because the host is imitated (in this case 
human), which poses a lower risk of incompatibility with our own body. Moreover, 
this should allow prolonged circulation time of the nanostructures within the 
bloodstream. Secondly, the host-mimetic nature of the nanostructures might be 
advantageous in terms of complicating resistance development by the parasite. 
Our strategy will work as long as the pathogen binds the specific receptor 
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presented on nanomimics. In case the pathogen mutates such that it can no longer 
bind our nanostructure, consequently it cannot bind this specific receptor on the 
host cell either. Only if the pathogen can use other host cell receptors for 
attachment and invasion it will still be successful. In this case, the new receptors 
have to be identified and nanomimics redesigned with another receptor or a 
combination of several. 
For this thesis, the host cell receptor heparan sulfate was chosen to serve as 
pathogen docking sites on nanomimics. More specific, heparin, which is a 
polysaccharide very closely related to heparan sulfate, was used for the nanomimic 
design. This ensures applicability for malaria,25 but also broad spectrum potential 
due to the involvement of heparan sulfate in many human infections, e.g. HIV-1, 
hepatitis B and C, Dengue virus, West Nile virus, Mycobacterium tuberculosis, 
Staphylococcus aureus, and Trypanosoma cruzi.224 
 
 
Figure 13. Generalized schematic overview describing the nanomimic strategy, which aims to combine drug- and 
“vaccine-like” action in vivo. The strategy is intended to cure an infection and additionally boost the immune system to protect 
from secondary infections. This is achieved through inhibition of pathogen entry (drug action) and subsequent exposure and 
delivery of pathogens to immune cells ("vaccine-like" activity). 
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The specific experimental steps to realize these objectives are: 
- Design and synthesis of amphiphilic block copolymers with heparin as 
hydrophilic block and receptor molecule (various lengths). 
- Self-assembly and analysis of polymersomes obtained by mixing the 
heparin-based copolymer with vesicle-forming copolymer to yield 
nanomimics. 
- Characterization of interaction of a known heparin-binding parasite 
protein with nanomimics. 
- Establishment of an in vitro suspension assay to test nanomimics on 
suspended P. falciparum blood stage cultures. 
- Evaluation of nanomimics in the above-established assay and comparison 
to performance of soluble heparin. 
- Analysis of nanomimic-parasite interaction by fluorescence-based 
techniques and electron microscopy. 
- Verification of potential adverse effects of nanomimics: cellular toxicity, 
anticoagulation property, and endotoxin contamination. 
- Preliminary tests on in vivo applicability and "vaccine-like" action. 
The second aim is the evaluation of degradable, reduction-sensitive, polymer-
based nanoparticles for the delivery of an experimental drug candidate with 
solubility, and metabolic instability problems to Plasmodium-infected RBCs. The 
reducing cytosol of these iRBCs provides a suitable environment for intracellular 
nanoparticle disassembly and drug release. Specific steps for achieving this aim 
are: 
- Formulation of fluorescent dye-loaded nanoparticles using reduction-
sensitive and insensitive copolymers. 
- Evaluation of colloidal stability and reduction-triggered model compound 
release. 
- Loading of nanoparticles with an experimental antimalarial compound 
with the above-mentioned properties. 
- Evaluation of drug-loaded nanoparticles in various models of blood stage P. 
falciparum. 
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   CHAPTER 3 
3 Nanomimics of Host Cell Membranes Block Invasion 
and Expose Invasive Malaria Parasites 
This study represents the primary evaluation of nano-scaled red blood cell (RBC) 
membrane mimics (nanomimics) for the inhibition of RBC invasion by malaria 
parasites of the species Plasmodium falciparum, which is the most dangerous 
form of Plasmodium parasites that infects humans. 
 
 
 
This study has been published and was reprinted and modified herein with 
permission from reference 225. Copyright (2014) American Chemical Society. 
 
Najer, A.; Wu, D.; Bieri, A.; Brand, F.; Palivan, C. G.; Beck, H.- P.; Meier, W. 
ACS Nano. 2014, 8, 12560−12571.  
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3.1 Abstract 
The fight against most infectious diseases, including malaria, is often hampered by 
the emergence of drug resistance and lack or limited efficacies of vaccines. 
Therefore, new drugs, vaccines, or other strategies to control these diseases are 
needed. Here, we present an innovative nanotechnological strategy in which the 
nanostructure itself represents the active substance with no necessity to release 
compounds to attain therapeutic effect and which might act in a drug- and 
vaccine-like dual function. Invasion of Plasmodium falciparum parasites into red 
blood cells was selected as a biological model for the initial validation of this 
approach. Stable nanomimics – polymersomes presenting receptors required for 
parasite attachment to host cells – were designed to efficiently interrupt the life 
cycle of the parasite by inhibiting invasion. A simple way to build nanomimics 
without postformation modifications was established. First, a block copolymer of 
the receptor with a hydrophobic polymer was synthesized and then mixed with a 
polymersome-forming block copolymer. The resulting nanomimics bound 
parasite-derived ligands involved in the initial attachment to host cells and they 
efficiently blocked reinvasion of malaria parasites after their egress from host cells 
in vitro. They exhibited efficacies of more than 2 orders of magnitude higher than 
the soluble form of the receptor, which can be explained by multivalent 
interactions of several receptors on one nanomimic with multiple ligands on the 
infective parasite. In the future, our strategy might offer interesting treatment 
options for severe malaria or a way to modulate the immune response. 
3.2 Introduction 
Infectious diseases – causing about 25% of total annual deaths worldwide – are a 
major threat to public health, which is enhanced by the emergence of drug 
resistance and vaccine failures.1,226 In the case of malaria, there is no vaccine 
registered yet and drug susceptibility is decreasing; resistance to artemisinin 
derivatives, which in combination with other drugs are the recommended first-line 
treatments, is already spreading across mainland Southeast Asia.227 An emerging 
strategy for fighting infectious diseases is to inhibit the initial host-pathogen 
interaction,183,184 thus preventing cell invasion as presented here in the case of 
malaria. A large number of human pathogens use the cell surface heparan sulfate 
proteoglycan for recognition and primary interaction between host and 
pathogen.224 Plasmodium falciparum, which causes malaria and is responsible for 
> 600’000 deaths annually228 uses heparan sulfate as the receptor for initial 
binding of sporozoites to hepatocytes229 and merozoites to host red blood cells 
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(RBCs).25 Highly sulfated polysaccharides such as heparin (closely related to 
heparan sulfate) or K5 polysaccharide are potent inhibitors of merozoite invasion 
of RBCs in vitro. Although different strains of P. falciparum use different 
pathways for RBC invasion, six different parasite strains were tested and were 
inhibited by these sugars.25 It has been shown that soluble heparin in vitro and in 
vivo can also reverse binding required for sequestration and rosetting in P. 
falciparum infections which are the major pathogenic events.230,231 However, the 
use of these polysaccharides in malaria infections is hindered by short in vivo 
circulation half-lives (about 30 min to 2 h),232,233 limited efficacy, and 
anticoagulation properties, which led to intracranial bleedings (in the case of 
heparin).231,234 Naturally acquired immunity to malaria is largely directed against 
extracellular merozoites,235 and protects semi-immune individuals from 
developing severe forms of the disease. Yet, there is no drug that targets the 
process of invasion of erythrocytes,44 although some candidates are known.236 The 
recent advent of whole attenuated parasite vaccines is accompanied by concerns 
about production, distribution and safety,53 while the limited protection obtained 
after vaccination with subunit vaccines237,238 emphasizes the need for alternative 
treatment and vaccination strategies. 
Nanotechnology provides promising tools for designing innovative structures that 
could be used to combat complex infections,178,179,239 but as yet has been applied 
only sparsely to malaria, and was focused on systems for drug or vaccine 
delivery.195 With other pathogens, mainly bacteria and viruses, few lipid-based 
nanostructures have been evaluated for inhibition of host-pathogen interactions.183 
However, liposomes, which are the most simple membranous nanostructures that 
ensure lateral mobility of receptors for multivalent ligand interaction, possess poor 
stability and structural integrity in vivo.183 Polymer-based vesicles (polymersomes) 
composed of amphiphilic block copolymers represent an alternative 3D 
membranous structure for host cell membrane-nanomimics to interact with or to 
neutralize pathogens in the bloodstream. They have the advantage of a biomimetic 
membrane structure, a higher stability than liposomes,240 and long in vivo 
circulation times.122 Polymersomes have been extensively studied as carriers for 
active compounds ranging from low molecular mass drugs to proteins and nucleic 
acids, and they can compartmentalize in situ reactions resulting in the 
development of nanoreactors and artificial organelles.118 So far, polymersomes 
have been designed to present viral receptors on their surface for virus-assisted 
loading of polymersomes241 or to study viral protein binding.242 In addition, 
heparin has been used at the surface of solid nanoparticles to achieve long 
circulation times in bloodstream for drug delivery in cancer therapy.243,244 
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Here, we introduce nanomimics based on polymersomes that present attachment 
receptors and thus mimic RBC membranes as a nanotechnological strategy for 
blocking invasion (drug action) and increased exposure of the infective form of P. 
falciparum to the immune system (vaccine-like action) (Scheme 1).  
 
 
Scheme 1. Schematic presentation of the nanomimic concept. (Left) Life cycle of P. falciparum in the human host: an 
Anopheles mosquito injects sporozoites, which pass through Kupffer cells and invade hepatocytes in which merozoites develop 
and are released into the bloodstream to invade red blood cells (RBCs) after specific attachment to heparan sulfate.25 In 
infected RBCs (iRBCs) merozoites develop through schizogeny releasing 16 – 32 daughter merozoites after 48 h, which 
subsequently invade new RBCs (asexual blood-stage). (Right) Schematic merozoite invasion into RBCs. (A) Initial attachment 
through binding of the processed ligand MSP142 to heparan sulfate on RBCs.25 Competing nanomimics (red circles) block 
fresh merozoites before they enter new RBCs  (white arrow) (modified with permission from ref 20). 
 
Nanomimics were built by self-assembly of a mixture of a polymersome-forming 
block copolymer with a copolymer based on a hydrophobic block and the host cell 
receptor as hydrophilic domain. We used Plasmodium merozoites as a model to 
exemplify the concept of efficient blockage of pathogen reinvasion after egress 
from their host cells in vitro. The intrinsic 3D architecture of nanomimics 
combined with the specificity of heparin selected as receptor represents an 
essential step to gain efficacy by exposing multiple receptors on one nanomimic, 
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which serve to block the parasite in a multivalent binding fashion. Due to the use 
of this key receptor of host cell membranes, it is expected to open efficient 
directions in addressing other infections that rely on the same receptor and have a 
similar way of reproduction. 
3.3 Results and Discussion 
3.3.1 Block Copolymer Synthesis 
Heparan sulfate has been shown to play a critical role as a receptor for the initial 
attachment of merozoites to RBCs;25,28 therefore we selected the closely related 
heparin, which is a potent inhibitor of merozoite invasion of RBCs in vitro,25 for 
exposure on the exterior surface of nanomimics. Heparin is commercially readily 
available and has a closely related chemical structure to other sugar chains that 
have been reported as bioactive without anticoagulation property (e.g., K5 
polysaccharide).25 We prefer heparin as a receptor model to be exposed on 
nanomimics, as it is a very well-known macromolecule, which serves as a 
straightforward proof of concept; related polysaccharides such as K5 or 
nonanticoagulant heparin will be then used for the optimization of nanomimics. 
To produce model nanomimics, two different block copolymers were synthesized. 
The biocompatible, polymersome-forming ABA block copolymer poly(2-methyl-2-
oxazoline)-block-poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline) 
(PMOXA-b-PDMS-b-PMOXA, Table 1, Figure 15A, 1) was synthesized as 
previously published,136,245 and the PDMS-b-heparin block copolymer (Figure 15A, 
2) was synthesized by coupling a commercial PDMS block with the commercial 
heparin polysaccharide (Scheme 2). 
 
Table 1. Polymer characteristics. Mw/Mn was calculated using the corresponding GPC data. Block lengths and molecular 
weight were determined from 1H NMR. 
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Scheme 2. Scheme for PDMS-b-heparin (2 ) synthesis. Tetrabutylammonium salt of heparin reacted with PDMS(NH2)2 in 
DCM with 2-picoline borane as reducing agent for 7 days yielded PDMS-b-heparin. 
 
A critical step was the solubilization of heparin in organic solvents, which is not 
possible with commercial sodium salt of heparin, but was needed for PDMS-b-
heparin synthesis and nanomimic formation. Therefore, it was first hydrophobized 
by ion exchange from sodium to tetrabutylammonium,246 which exchanged again 
with sodium during nanomimic purification. 1H NMR after reaction, purification, 
and ion exchange indicated successful coupling of PDMS with heparin (Figure 
14C). 
The reductive amination used for PDMS-b-heparin synthesis is a mild reaction; 
the reducing agent is specific to imines.247 This specific reaction ensured that 
heparin was modified with PDMS only at its natural anchor point – leaving the 
rest of the chain unmodified. Farndale microassays, in which positively charged 
dye molecules align on heparin chains resulting in a metachromatic shift in the 
absorption spectrum, were performed in ethanol to obtain a rough estimation of 
the number of saccharide units per PDMS chain (5 kDa). Tetrabutylammonium 
heparin in ethanol was used to generate a calibration curve, and by comparing to 
the absorption values found for PDMS-b-heparin the number of saccharide units 
per PDMS chain was calculated to be about 25 (in total 11 kDa).  
Chapter 3   45  
 
Figure 14. Comparison of 1H NMR (400 MHz, δ) spectra of PDMS(NH2)2 (A, CDCl3), tetrabutylammonium salt of heparin (B, 
D2O) and PDMS-b-heparin after purification and ion exchange to Na+ (2, C, D2O/acetone-d6 (3:1)). Red squares indicate 
anomeric protons (5.6 – 5.0 ppm), fingerprint region (4.5 – 3.4 ppm), and N-acetyl (CH3) of heparin. Blue squares show the 
protons of tetrabutylammonium. Green square represents protons of siloxane units and adjacent methylene protons. Integrals 
and corresponding numbers of protons are not indicated, because solubilization of the product (2) was not optimal; the two 
blocks have opposite characteristics (hydrophobic, very hydrophilic). D2O was needed to observe the characteristic heparin 
peaks in the copolymer, but this is a bad solvent for PDMS, leading to line broadening for the PDMS part. Nevertheless, the 
characteristic peaks of heparin (anomeric-, fingerprint-, N-acetyl protons) and PDMS were observed after reaction, purification 
and ion exchange. 
 
3.3.2 Preparation and Characterization of Nanomimics  
Nanomimics were self-assembled by the bulk rehydration technique using a 
mixture of PMOXA-b-PDMS-b-PMOXA with 25 % (w/w) PDMS-b-heparin block 
copolymer. Since heparin (mean 11 kDa, 25 saccharide units) of PDMS-b-heparin 
is a longer polymer than PMOXA (max. 0.8 kDa, 5 to 9 oxazoline units) of 
PMOXA-b-PDMS-b-PMOXA and PDMS blocks were similar in both copolymers 
(mean 5 kDa, 63 siloxane units), only a small part of heparin was shielded by 
PMOXA, while the rest was accessible for protein interaction (Figure 15D,E). 
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Figure 15. Characteristics of nanomimics. (A) Chemical structure of PMOXA-b-PDMS-b-PMOXA (1) and PDMS-b-heparin 
(2). R is either a proton or another heparin chain. (B) TEM image of nanomimics. (C) Cryo-TEM of the same nanomimics. Scale 
bars 200 nm. (D) Normalized autocorrelation curves from FCS data in PBS: free OG488 (red), free PfMSP142-OG488 (blue), 
control polymersomes with PfMSP142-OG488 (green), and nanomimics with PfMSP142-OG488 (yellow). (E) Hydrodynamic 
diameters (DH) obtained from mixtures of PfMSP142-OG488 with controls (free heparin or control polymersomes) and 
nanomimics (gray bars).  Data from dynamic light scattering are included for the nanostructures for comparison (white bars). 
Only when heparin was present on the surface of nanostructures (micelles, nanomimics) and mixed with PfMSP142-OG488 did 
the diffusion time shift to the corresponding nanostructure–size, indicating that PfMSP142-OG488 bound to the 
nanostructures. Mixtures with free heparin or control polymersomes yielded no difference from free PfMSP142-OG488 
diffusion (errors are ± standard deviation). 
 
Dynamic light scattering (DLS) revealed hydrodynamic nanomimic diameters (DH) 
of about 132 ± 34 nm (average of eight independent samples ± standard deviation) 
(Table 2). DLS and static light scattering (SLS) performed on four representative 
nanomimic samples provided Rg/RH values of ρ = 0.90 – 0.99, as expected close to 
the value of 1.0 for ideal hollow spheres (vesicles),248 and thus indicating the 
vesicular structure of nanomimics (Table 2).  
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Table 2. Sample characteristics: heparin content (Farndale microassays), hydrodynamic diameters (DH) from FCS and DLS 
measurements. DH and diameter of gyration (Dg) and corresponding ρ-value from DLS/SLS measurements. Diameters from 
TEM and cryo-TEM images. (Values are mean ± standard deviation) 
 
 
Transmission electron microscopy (TEM) and cryogenic-TEM (cryo-TEM) 
confirmed these vesicle sizes and illustrated the membranous structure of these 
nanomimics (Figure 15B,C, Figure 16). TEM micrographs showed collapsed 
nanomimics (D = 111 ± 38 nm, Figure 15B), which clearly distinguished them from 
filled nanoparticles. Nanomimics retained their spherical structure (D = 101 ± 33 
nm, Figure 15C) during cryo-TEM imaging and revealed a vesicle-in-vesicle 
structure and a membrane thickness of 10.9 ± 1.4 nm. By increasing the PDMS-b-
heparin content in nanomimics a transition to micelles was observed. Nanomimics 
prepared with increasing PDMS-b-heparin content (35 % - 65 % w/w) yielded 
mixtures of polymersomes and worm-like micelles (35 %, 45 %) and finally 
aggregated micelles (55 %, 65 %) (Figure 17). Self-assembly of PDMS-b-heparin 
copolymer alone yielded aggregated micelles with a DH of about 83 ± 26 nm (DLS) 
(Table 2, Figure 16D,H). This demonstrates that nanomimics (25 % w/w) consist 
of a real mixture of both copolymers; otherwise we would have observed 
aggregated micelles in the samples containing those nanomimics. Nanomimics 
with 25 % (w/w) PDMS-b-heparin were used in all subsequent experiments. 
Furthermore, stopped-flow measurements on nanomimics revealed their 
permeability for water but not solutes. This was concluded due to nanomimic 
shrinkage upon applied osmotic pressure by doubling the salt concentration 
outside of nanomimics.35 
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Figure 16. Transmission electron microscopy (TEM) of different preparations of nanomimics and micelles. (A) Control 
polymersomes built from PMOXA-b-PDMS-b-PMOXA. (B, C, E-G) Nanomimics (25% (w/w) PDMS-b-heparin) prepared from 
different mixtures of different batches for both polymers. (D, H) PDMS-b-heparin aggregated micelles. (Scale bars 200 nm) 
 
 
Figure 17. Transmission electron microscopy (TEM) of nanomimic preparations using higher ratios of PDMS-b-heparin to 
PMOXA-b-PDMS-b-PMOXA. Nanomimics with 35% (w/w) PDMS-b-heparin (A), 45% (w/w) PDMS-b-heparin (B), 55% (w/w) 
PDMS-b-heparin (C), and 65% (w/w) PDMS-b-heparin (D). (Scale bars 200 nm) 
 
Hydrophilic sulforhodamine B (SRB) was encapsulated in the aqueous core of 
nanomimics for visualization and both DH and the concentration of the 
nanomimics were obtained with fluorescence correlation spectroscopy (FCS) by 
comparing diffusion time of the free dye with that of the encapsulated dye. The 
concentration of the nanomimics obtained by FCS was 71 ± 18 nM (2.8 mg/mL 
PMOXA-b-PDMS-b-PMOXA, 0.93 mg/mL PDMS-b-heparin); this value was 
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subsequently used to calculate the number of nanomimics necessary to obtain an 
effect in the antimalarial assay (Figure 22). 
Farndale microassays in aqueous solution were performed to quantify the amount 
of surface-accessible heparin on nanomimics after purification (Figure 18). 
Calibration curves (Figure 18A) were produced with the same heparin solution that 
was subsequently used in in vitro assays (Figure 22) to ensure comparability of 
assays. PMOXA-b-PDMS-b-PMOXA polymersomes did not influence the 
absorbance spectrum of the dye in the range of interest (Figure 18B). Due to the 
random character of the self-assembly process underlying nanomimic formation, 
not all PDMS-b-heparin added led to surface-exposed heparin in the final 
nanomimics; a fraction of the heparin chains will face toward the vesicle core, few 
will be hidden in the membrane or in the nanomimic core (vesicle-in-vesicle 
structures), and a few free PDMS-b-heparin or free heparin chains not 
incorporated in the membrane were removed during purification. However, 
Farndale microassays allowed us to quantify the amount of heparin exposed at the 
outer surface of the nanomimics.  
 
 
Figure 18. Farndale microassay. (A) Calibration curve produced with a series of free heparin concentrations in duplicates. 
(B) Example of a UV-Vis absorbance curve for nanomimics (black squares), control polymersomes (black triangles), and control 
polymersomes with encapsulated tetrabutylammonium heparin (black crosses). Baseline was corrected due to light scattering 
of the nanomimic-samples (red curve). 
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Importantly, nanomimic formation yielded detectable amounts of heparin being 
incorporated in the membrane after purification, whereas formation with PMOXA-
b-PDMS-b-PMOXA and the tetrabutylammonium salt of heparin did not (Figure 
18B). In total, three independent PDMS-b-heparin and three PMOXA-b-PDMS-b-
PMOXA batches were used (Table 1). Nanomimics1 and micelles1 were built from 
the same batch of PDMS-b-heparin; nanomimics2 and micelles2 were made from 
two other batches of PDMS-b-heparin. Typical nanomimic samples, theoretically 
containing 2.5 mg/mL PMOXA-b-PDMS-b-PMOXA and 0.83 mg/mL PDMS-b-
heparin copolymer, yielded 57 ± 13 µg/mL (mean ± standard deviation) surface-
exposed heparin after purification (Table 2). If combined with the nanomimic 
concentrations obtained by FCS measurements, there are about 74 ± 30 heparin 
chains (11 kDa) exposed on the outer surface of one nanomimic. Zeta potential 
measurements performed on nanomimics (-32.4 ± 4.1 mV, average of eight 
nanomimic samples) and control polymersomes (+5.4 ± 0.2 mV) confirmed the 
presence of negatively charged groups on nanomimics in contrast to pure PMOXA-
b-PDMS-b-PMOXA vesicles. 
To validate the toxicity of nanomimics on cultured cells, a cell viability test was 
performed using HeLa cells and a representative nanomimic sample (2.9 mg/L 
PMOXA-b-PDMS-b-PMOXA, 49.3 µg/mL accessible heparin) (Figure 19). This test 
demonstrated the absence of any cell toxicity of nanomimics up to the maximum 
concentration of 290 µg/mL PMOXA-b-PDMS-b-PMOXA and 4.9 µg/mL surface-
exposed heparin, which was an even higher concentration than the highest 
concentration used in the antimalarial assays (Figure 22). 
 
 
Figure 19. Cell toxicity test with nanomimics. HeLa cell viability is shown versus polymer (bottom) and heparin (top) 
concentration using a representative nanomimic sample. 
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3.3.3 Nanomimics Bind Plasmodium Merozoite Proteins Involved in 
Initial Attachment  
FCS also allows the analysis of protein binding to nanoobjects by comparing 
diffusion times of freely diffusing and bound proteins labeled with fluorescent 
molecules.97 For the FCS measurements, OregonGreen was used to label the P. 
falciparum (clone 3D7) major surface protein 1-42 (PfMSP142-OG488), which has 
been identified as the ligand for heparin-like receptors.25 The difference in 
diffusion times between PfMSP142-OG488 and PfMSP142-OG488 bound to 
nanomimics was used to verify that the surface of nanomimics contained 
accessible heparin molecules, and that they were able to bind merozoite proteins 
(Figure 15D,E). No binding of PfMSP142-OG488 occurred with polymersomes 
without heparin. In contrast, nanomimics and PDMS-b-heparin micelles bound 
significant amounts of PfMSP142-OG488 (from 5 up to 12 PfMSP142-OG488 per 
nanomimic, Figure 15D,E). Therefore, strong multivalent binding of several 
PfMSP142-OG488 on one parasite with several heparin chains on one nanomimic is 
possible, which is an important parameter for invasion inhibition. Furthermore, 
the interaction of PfMSP142-OG488 with heparin on artificial membranes seems to 
be a high-affinity interaction; otherwise no binding would have been observed by 
FCS.98 Although heparin has a slightly different structure compared to heparan 
sulfate, the FCS results provided evidence for high-affinity binding in contrast to 
previous suggestions that the initial attachment of merozoites to RBCs is a low-
affinity interaction.20 Thus, it is possible that the low abundance of heparan sulfate 
on RBCs (~2000 chains per RBC)28 providing only one or a few sugar chains per 
merozoite for initial attachment is sufficiently strong not only to attach to the RBC 
but also to allow for subsequent interaction with other receptors for stronger 
attachment and subsequent reorientation (Scheme 1). 
3.3.4 Nanomimics Block Invasion of and Expose Plasmodium Merozoites 
To test whether our nanomimics could competitively bind freshly egressed 
merozoites and therefore block RBC invasion in vitro, we incubated a mixture of 
RBCs and late stages of infected RBCs (iRBCs) with these nanomimics for 3 h. 
During this time, merozoites start to be released and invade new RBCs. After 
incubation with fluorescent nanomimics fluorescence imaging showed both 
binding of nanomimics to merozoites and lack of RBC invasion (Figure 20C-E). 
Extracellular merozoites lose their invasive capacity after 5 min at 37 °C;249 
therefore if merozoites with surface-bound nanomimics appear in culture, they 
already lost their ability to infect new RBCs (Figure 20C-E). In addition, 
agglutination of merozoites and nanomimics (Figure 20C) and nanomimic binding 
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to iRBC just during merozoite egress were observed (Figure 20B), whereas intact 
iRBCs and RBCs did not bind nanomimics. Polymersomes without heparin did not 
bind any of the cells present (RBCs, iRBCs, or merozoites) and could therefore not 
block invasion; only very few merozoites can be found in the controls (Figure 20A). 
 
 
Figure 20. Inhibition of merozoite invasion by nanomimics. (A) Control polymersomes (PMOXA-b-PDMS-b-PMOXA only) 
did not bind to merozoites, RBCs, and iRBCs. (B) SRB-filled nanomimics (red) bound to schizonts during merozoite egress, but 
not to intact iRBCs (all stages) and RBCs; iRBCs and RBC appear normal. (C-E) Merozoites (blue) were inhibited by 
nanomimics (red) from entering into fresh RBCs. Left: DIC, middle: DAPI (blue) and SRB (red), right: merge. In these images 
and all the following images with in vitro malaria cultures, RBCs serve as the scale bar. RBC diameter is about 7 µm. iRBCs 
can be distinguished from RBCs by black appearing hemozoin crystals present within iRBCs, originating from hemoglobin 
digestion and subsequent hematin crystallization. 
 
The merozoite-nanomimic interaction was further examined by super–resolution 
3D structured illumination microscopy (3D-SIM), and electron microscopy (EM) 
of ultrathin sections of merozoite-nanomimic complexes (Figure 21). 3D 
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reconstruction of merozoites with surface-bound nanomimics showed that several 
dozens of nanomimics bound to a single merozoite (Figure 21A). The EM images of 
ultrathin sections revealed nanomimics attached to the outer membrane of 
merozoites (Figure 21C), which was not found in a preparation without 
nanomimics (Figure 21B). This revealed that nanomimics blocked the docking 
sites on merozoites, whereas no fusion of nanomimic- and parasite membrane 
occurred. 
 
 
Figure 21. Merozoites bound with nanomimics. (A) Projections of merozoites (DAPI, blue) blocked by SRB-filled 
nanomimics (red, scale bars, 1 µm) recorded with super–resolution 3D structured illumination microscopy (3D-SIM). (B) TEM 
of an ultrathin section of a control merozoite (scale bar, 500 nm). (C) TEM of ultrathin sections of merozoites with nanomimics 
on the surface (scale bars, 500 nm) and higher magnification of a surface-bound nanomimic (scale bar 50 nm). Lipid 
membranes (light) can be distinguished from the polymer membrane of nanomimics (dark) and the size of the surface-bound 
nanomimics is in agreement with the diameters of nanomimics (Figure 15B,C). Rhoptries (rh), nucleus (nu) and dense 
granules (dg) of merozoites can be seen clearly. Some nanomimics are indicated with a black arrow.  
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3.3.5 Efficacy of Invasion Inhibition by Nanomimics  
The inhibitory effect of nanomimics on the parasite life cycle was determined by a 
growth inhibition assay using a P. falciparum (clone 3D7) suspension culture in 
24-well plates, which better mimics the in vivo situation by using suspension 
cultures with a higher hematocrit than usually used for measurements of drug 
effects (typically 1 %).250 Invasion–inhibition curves with free heparin, 
nanomimics, and PDMS-b-heparin micelles (Figure 22) show a significant 
difference in IC50 values between free heparin and nanomimics or PDMS-b-
heparin micelles (Figure 22A).  
 
 
Figure 22. Growth inhibition by free heparin and nanomimics. (A) Free heparin inhibits growth of P. falciparum (3D7) in the 
suspension assay. Micelles built from PDMS-b-heparin and nanomimics inhibit merozoite invasion more efficiently than free 
heparin (data from five independent invasion inhibition experiments, all data points are mean growth ± standard error from at 
least three duplicate assays for each), presented as percentage of control (PBS)). (B) IC50 values for free heparin (n = 7) 
compared to heparin-loaded nanomimics (n1 = 9, n2 = 12) or micelles (n1 = 4, n2 = 3) indicating the importance of 
nanostructured heparin for increased activity. Nanomimics1 and micelles1 were built from the same batch of PDMS-b-
heparin; nanomimics2 were made from two other batches of PDMS-b-heparin (mean values ± standard error for three 
independent experiments for each sample). (C) Comparison of nanomimics and micelles expressed as factor of x difference in 
IC50 values for nanostructures compared to free heparin (mean values ± standard error for three independent experiments for 
each sample). Statistics were analyzed using Student’s t-test: ★p< 0.05, ★★p< 0.01, ★★★p< 0.001. 
 
All parasites were blocked at the highest heparin, nanomimic, or micelle 
concentrations. IC50 values dramatically decreased from 37.4 ± 4.7 µg/mL (2.5 µM 
for free heparin) to 0.197 ± 0.047 µg/mL for the best preparation of nanomimics 
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(13 nM of heparin on nanomimics2) (Figure 22B). This corresponded to a decrease 
in IC50 value of more than 2 orders of magnitude (Figure 22C), which indicates a 
very highly efficient inhibitory effect of the nanomimics. The highest concentration 
of nanomimics tested contained about 60 µg/mL of the polymersome-forming 
PMOXA-b-PDMS-b-PMOXA and about 1 µg/mL surface-accessible heparin. 
Polymersomes consisting of PMOXA-b-PDMS-b-PMOXA without PDMS-b-
heparin or PMOXA-b-PDMS-b-PMOXA vesicles with encapsulated 
tetrabutylammonium heparin had no effect on the parasite life cycle at similar 
concentrations (60 µg/mL); parasitemia reached the same values as in control 
wells with PBS only. A solution of free tetrabutylammonium heparin after size 
exclusion chromatography (as we do with nanomimics) was also not active at 
concentrations similar to the highest heparin concentration used in the case of 
nanomimics (about 1 µg/mL). The IC50 value for free heparin was 2-fold higher 
than previously published,25 most probably due to the higher hematocrit (5%) and 
suspension culture. Nanomimics with different ratios of PDMS-b-heparin to 
PMOXA-b-PDMS-b-PMOXA were also tested in order to find the optimum 
mixture. Nanomimics containing 25 % (w/w) PDMS-b-heparin provided the best 
balance in terms of efficacy and control over self-assembly (exclusively spherical 
vesicles). Nanomimics were also significantly more effective than micelles self-
assembled from PDMS-b-heparin only, most likely because the membranous 
structure of the nanomimics allowed lateral diffusion of receptors for multivalent 
interactions.183 This demonstrates the advantage of using membranous 
nanomimics compared to micellar or solid nanostructures. 
Considering that the active inhibitors are nanomimics themselves – no drug is 
released from the nanostructure – then IC50 value can also be presented in 
“nanomimic-concentrations”. The nanomimic concentration was determined by 
FCS in PBS (71 ± 18 nM for nanomimics at 2.8 mg/mL PMOXA-b-PDMS-b-
PMOXA and 0.93 mg/mL PDMS-b-heparin concentrations). Combining this value 
with the antimalarial assay results in an IC50 value of 0.27 ± 0.09 nM for the 
nanomimics (five independent samples, three invasion inhibition assays). 
Therefore, one nanomimic is about as active as 10’000 heparin chains. This 
significantly higher inhibitory activity of nanomimics compared to free heparin (> 
2 orders of magnitude) is explained by multivalent interactions between a 
multitude of heparin molecules exposed on a single nanomimic with a multitude of 
PfMSP142 molecules on each merozoite (max. 12 PfMSP142-OG488 per nanomimic 
measured), confirming results from binding assays. Indeed, nanomimics represent 
“macroscopic” objects when compared to free heparin, and thus the binding of a 
few nanomimics was sufficient to block merozoites from entering fresh RBCs, 
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while a very large number of free heparin molecules (~10’000 times more) was 
required for such an effect. Our nanomimics block pathogens using the combined 
effect of a spatial architecture with a specific, exposed receptor of host cell 
membranes. 
3.4 Conclusions 
Nanomimics of host cell membranes were successfully produced by a simple self-
assembly procedure without postformation modifications, which uses a mixture of 
polymersome-forming block copolymer with a copolymer that consists of a 
hydrophobic block and a specific host cell receptor. The resulting 3D-nanoobjects 
(nanomimics) very efficiently blocked invasion of RBCs by P. falciparum 
merozoites as compared to soluble receptors, which can be explained by strong 
multivalent binding of nanomimics to merozoites. This might offer an interesting 
treatment option for severe malaria when prevention of reinvasion of parasites is 
of highest priority. Simultaneously, similar to soluble heparin such nanomimics 
treatment would be expected to reverse the two major pathogenic events in P. 
falciparum infections – sequestration and rosetting – in vitro and in vivo and thus 
immediately would reduce pathology.230,231 
As an additional benefit, our nanomimic strategy will keep a large number of 
merozoites artificially extracellular after egress. Circulation of a large number of 
free merozoites does not naturally occur, and it might be speculated whether these 
merozoites bound to nanomimics represent a strong immunogen and might elicit a 
strong immune response against all merozoite antigens. Because this would 
happen during a natural or controlled251 infection, it would avoid many problems 
associated with subunit or attenuated merozoite vaccines.53 However, it remains to 
be tested as to whether such induced immunity is superior to responses derived 
from any natural infection or from recombinant antigens.  
Thus, our strategy of interrupting the parasite life cycle using nanomimics and 
then subsequently eliciting an immune response represents a promising 
alternative to current drug treatment and vaccination strategies.251 Further, 
nanomimics offer theoretically a unique possibility of encapsulating high 
concentrations of adjuvants or other immune modulators, which could be released 
after phagocytosis to enhance immunogenicity. We have used these nanomimics to 
interrupt the life cycle of malaria parasites as a proof of principle, but a variety of 
other pathogens also use host cell heparan sulfate for initial attachment;224 
therefore this technology might be much more widely applied to inhibit other 
infections. 
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   CHAPTER 4 
4 Analysis of Molecular Parameters Determining the 
Antimalarial Activity of Polymer-Based Nanomimics 
This chapter contains the description of nanomimic variants with more, less, or 
shorter receptor molecules presented on the surface and the corresponding effect 
on antimalarial activity. Furthermore, interaction parameters of the nanomimic 
receptor with the parasite ligand was studied in detail and revealed high affinity 
interactions. 
 
 
 
This study has been published and was reprinted and modified herein with 
permission from reference 252. Copyright (2015) Wiley and Sons. 
 
Najer, A.; Thamboo, S.; Duskey, J. T.; Palivan, C. G.; Beck, H.-P.; Meier, W. 
Macromol. Rapid Commun. 2015, 36, 1923–1928.  
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4.1 Abstract 
Malaria and other infectious diseases are major global public health problems, 
which need to be tackled using new technologies to cope with the lack of 
efficacious vaccines and emerging drug resistance. A recently developed anti-
infectious concept based on nanomimics tested with Plasmodium falciparum was 
analyzed for the molecular parameters determining its applicability. Nanomimics 
– nano-scaled polymer-based mimics of host cell membranes – were designed 
with a reduced number of surface-exposed malaria parasite receptor molecules 
(heparin), resulting in less potent invasion inhibition as determined in 
antimalarial assays. In contrast, when shorter receptor molecules were used to 
form nanomimics, more molecules were needed to obtain nanomimic potency 
similar to nanomimics with longer receptor molecules. The interaction of heparin 
on nanomimics with the processed Plasmodium falciparum merozoite surface 
protein 1-42 (PfMSP142) had a high affinity, Kd = 12.1 ± 1.6 nM, as measured by 
fluorescence cross-correlation spectroscopy (FCCS). This detailed characterization 
of nanomimics and their molecular variants is an important step towards defining 
and optimizing possible nanomimic therapies for infectious diseases. 
4.2 Introduction 
Polymer vesicles (polymersomes)240 made form amphiphilic block copolymers are 
suitable nanocompartments for many biomedical applications such as drug 
delivery,61,253 sensing,254,255 performing reactions in confined spaces 
(nanoreactors),118 artificial organelles,172 and very simplified cell mimics (Chapter 
3).161 To apply polymersomes in the biomedical domain, the introduction, or 
modification, of surface functionality on the polymersome structure is of great 
importance in order to prevent deleterious interactions with non-target cells while 
promoting targeting interactions,93 obtain long-circulating polymersomes,144 or 
block invading pathogens (Chapter 3). Different methods to prepare functionalized 
polymersomes are based on either introducing the functionality before self-
assembly, or modifying pre-formed vesicles.93 Usually, biomolecules (e.g. targeting 
ligands) are attached to the hydrophilic blocks of block copolymers, but we have 
shown that using a biomolecule (in this case heparin) as the sole hydrophilic block 
is another suitable strategy (Chapter 3). However, this strategy requires a 
sufficiently long – longer than the hydrophilic block of the membrane-forming 
block copolymer – and hydrophilic receptor molecule in order to yield modified 
vesicles with surface-exposed receptors; too short or hydrophobic molecules might 
be hidden in the membrane and would not be accessible for surface interactions. 
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Because of the difficulties to develop efficacious vaccines against malaria256 and 
other infectious diseases, and the constant threat of emerging drug resistance,9 
innovative approaches to curb these diseases are needed and new technologies will 
play an important role.178,239 Malaria is caused by apicomplexan parasites 
Plasmodium spp. and is responsible for more than 600’000 deaths each year.257 
When the parasite reaches the blood-stage in human hosts, the invasive parasite 
form, called merozoites, invade and reproduce in human red blood cells (RBCs).20 
In the previous Chapter 3, we demonstrated the successful design of host RBC 
membrane nanomimics, which are polymersomes exposing heparin on the surface, 
to block malaria parasites from entering host RBCs. This nanomimic concept is 
based on the interaction of heparin molecules on the surface of nanomimics and 
merozoite surface proteins (Subchapter 3.3.3). Different merozoite proteins are 
known to bind to heparan sulfate (HS) on RBCs and soluble heparin, which is a 
sulfated polysaccharide very closely related to HS.25,30-32  
Here, we analyzed in detail the interactions of heparin exposed on nanomimics 
with Plasmodium falciparum merozoite surface protein 1 (PfMSP1), in particular 
the processed 42 kDa fragment PfMSP142, which is one of the most abundant 
merozoite surface protein that binds HS and heparin.25,32 We selected fluorescence 
cross-correlation spectroscopy (FCCS) as a suitable single-molecule detection 
method to evaluate receptor-ligand interactions.97,98,258,259 The interaction 
parameters found allowed to describe the potent invasion inhibitory activity of 
nanomimics. Furthermore, we studied whether the invasion inhibitory effect of 
nanomimics against Plasmodium parasites was dependent on the total amount, 
and the length, of surface-accessible heparin exposed on nanomimics. The 
interaction parameters and activity of modified nanomimics are important to 
establish a comprehensive framework for future optimization and application of 
nanomimics against infections. 
4.3 Results and Discussion 
4.3.1 Effect of Amount and Length of Receptor Molecule of Nanomimics 
on Antimalarial Activity 
To study how the length of the receptor molecule (heparin) exposed on 
nanomimics affects their antimalarial activity, different PDMS-heparin block 
copolymers were synthesized based on our previously established method 
(Chapter 3) and then mixed with polymersome-forming PMOXA-b-PDMS-b-
PMOXA to yield nanomimics. The synthesis of PDMS-b-Heparin was first 
conducted using full-length heparin (mean MW = 15 kDa) to get PDMS-b-Hep and 
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second using low molecular weight heparin (LMWH, mean MW = 5 kDa) to obtain 
PDMS-b-ShortHep, while the hydrophobic block poly(dimethylsiloxane) (PDMS) 
was kept constant in both block copolymers (5 kDa, 65 repeating units). After 
purification, 1H-NMR of PDMS-b-ShortHep showed characteristic peaks for 
PDMS- and heparin block demonstrating successful connection of the two blocks, 
similar to PDMS-b-Hep (Chapter 3, Figure 14). Due to solubility problems, peaks 
from 1H-NMR were not used to calculate the number of repeating units for heparin 
containing block copolymers. Another method, a Farndale microassay in ethanol, 
was used to estimate the length of heparin chains and the corresponding number 
of repeating units per PDMS block (Table 3). For PDMS-b-Hep and PDMS-b-
ShortHep, the average of three different batches form three independent syntheses 
is given. For PMOXA-b-PDMS-b-PMOXA, the average number of repeat units was 
calculated by 1H-NMR and are only presented for one hydrophilic PMOXA-block, 
to compare to PDMS-Heparins. Clearly, PDMS-b-Hep contained a 3- to 4-fold 
longer heparin chain compared to PDMS-b-ShortHep, while the hydrophobic 
blocks were similar. 
 
Table 3. Average relative lengths of individual blocks of block copolymers used to form nanomimics.  
Block 
Hydrophobic 
units 
Hydrophilic 
units 
Hydrophilic  
part [kDa] 
PMOXA-b-PDMS-b-PMOXA 63 6 0.5 
PDMS-b-Hep 65 23 ± 10 10.1 ± 4.1 
PDMS-b-ShortHep 65 6 ± 3 2.6 ± 1.3  
To expose long or short heparin chains on nanomimics, they were formed using 
mixtures of 75 wt% PMOXA-b-PDMS-b-PMOXA with 25 wt% PDMS-b-Hep 
(nanomimics-25%) or 25 wt% PDMS-b-ShortHep (nanomimics-ShortHep-25%). 
To test the effect of the number of heparin chains on nanomimic antimalarial 
potency, another mixing ratio of the functional copolymer (heparin-containing) 
and polymersome-forming copolymer was used with 95 wt% PMOXA-b-PDMS-b-
PMOXA and 5 wt% PDMS-b-Hep (nanomimics-5%). For comparison, pure PDMS-
b-ShortHep-based micelles (100 wt% PDMS-b-ShortHep) were formed as well. 
Transmission electron micrographs (TEM) of the corresponding nanomimics and 
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micelles were taken and hydrodynamic diameters (DH) were determined using 
dynamic light scattering (DLS) (Figure 23).  
TEM images of nanomimics-25% and nanomimics-5% revealed vesicular character 
of the nanostructures with diameters of 70 – 200 nm  (Figure 23A,B); the two 
block copolymers mixed well during film formation, otherwise more micelles 
similar to PDMS-b-ShortHep micelles (Figure 23D) would have been observed, 
which were already described for PDMS-b-Hep (Chapter 3). Nanomimics-
ShortHep-25% also mainly formed vesicles, but some micelles were found (Figure 
23C) similar to nanomimics formed using more than 25 wt% PDMS-b-Hep 
(Chapter 3, Figure 17). In fact, nanomimics-ShortHep-25% contain shorter, but 
also more heparin chains on the surface compared to nanomimics-25%, because 
the molecular weight of PDMS-b-ShortHep is lower than that of PDMS-b-Hep 
(Table 3), which explains the morphological differences between these samples. 
DLS data confirmed nanomimic sizes found in TEM (Figure 23A-C) also in 
solution. The schematic images (Figure 23) illustrate the morphology, as well as 
number and length, of heparins exposed on various nanomimics. Cryo-TEM 
images of nanomimics-25% confirmed the membranous structure (Chapter 3, 
Figure 15C) and collapsed nanomimics presented in TEM images (Figure 23A-C) 
were spherical vesicles in solution as visualized by cryo-TEM. Due to the aqueous 
core of nanomimics, the drying procedure and ultra-high vacuum used in 
conventional TEM explains the collapsed structures seen in Figure 23A-C. In 
conclusion, polymersomes were successfully prepared, which appeared similar to 
previous nanomimics (Chapter 3), using shorter or fewer receptor molecule-
containing (heparin) copolymers. 
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Figure 23. TEM images, hydrodynamic diameters (DH) from DLS measurements and schematic representations of the 
nanostructures are shown for (A) nanomimics-25%, (B) nanomimics-5%, (C) nanomimics-ShortHep-25%, and (D) PDMS-
ShortHep micelles. The scale bars are 500 nm. 
 
4.3.2 Detailed Analysis of Parasite Protein Interaction with Nanomimics 
To further characterize the invasion inhibition mechanism for nanomimics, the 
interaction of heparin on nanomimics with PfMSP142 was analyzed in detail by 
fluorescence correlation spectroscopy (FCS) and FCCS (Figure 24).  
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Figure 24. FCS and FCCS data for the evaluation of the nanomimic-PfMSP142 interaction. (A) FCS and corresponding 
FCCS curve (black) for a mixture of the two used dyes (OG488 (blue) and Bodipy630 (red)) and (B) for a standard sample (IBA 
standard, double labeled DNA) to obtain the relative minimum (about 3 %) and maximum cross-correlation amplitude (about 
33 %). (C) Non-functionalized vesicles (FCS, red) mixed with PfMSP142-OG488 (FCS, blue) and corresponding cross-
correlation curve (black); (E) Nanomimics-25% (FCS, red) mixed with OG488 (FCS, blue) and corresponding cross-correlation 
curve (black); (D) Nanomimics-25% (FCS, red) mixed with PfMSP142-OG488 (FCS, blue) and corresponding cross-correlation 
curve representing three different PfMSP142-OG488 concentrations: crosses (22.2 nM), diamonds (18.5 nM), triangles 
pointing down (2.8 nM). (F) Fractional occupancy of heparin on nanomimics-25% by PfMSP142-OG488 normalized versus total 
PfMSP142-OG488 ligand concentration. Fit was obtained by applying Equation (14, Chapter 10) to the data points in order to 
obtain Kd. 
 
First, FCCS calibration data were recorded (Figure 24A,B). Both, pure PMOXA-b-
PDMS-b-PMOXA polymersomes-Bodipy630 mixed with PfMSP142–OG488, and 
nanomimics-25%-Bodipy630 incubated with free Oregon Green 488 (OG488) 
yielded no significant cross-correlation amplitudes (Figure 24C,E). Therefore, no 
unspecific binding of PfMSP142–OG488 to the surface of non-functionalized 
polymersomes (without heparin) was observed, nor did the dye OG488 bind 
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nanomimics. To study the interaction of PfMSP142 with heparin on nanomimics, 
red fluorescent nanomimics-25%-Bodipy630 were mixed with different 
concentrations of green fluorescent PfMSP142–OG488, and the diffusion of 
fluorescent species were recorded in two detection channels simultaneously 
(Figure 24D). Titration of PfMSP142–OG488 into a solution of nanomimics, and 
analysis of the corresponding relative cross-correlation amplitudes yielded a 
typical ligand-receptor saturation curve (Figure 24F).97,98,258,259 Different mixtures 
of PfMSP142–OG488 with nanomimics-25%-Bodipy630 yielded various cross-
correlation amplitudes depending on the respective PfMSP142–OG488 
concentration used (Figure 24D). Additionally, these binding events were observed 
in the auto-correlation curves (FCS). For mixtures of nanostructures with 
fluorescent molecules that did not interact with the nanostructure (Figure 24C,E), 
the auto-correlation curves represented two distinct diffusion times (triangles: free 
PfMSP142–OG488 or OG488, circles: polymersome/nanomimic diffusion). When 
PfMSP142–OG488 was mixed with nanomimics-25%-Bodipy630 (Figure 24D), 
both auto-correlation curves showed nanomimic diffusion, demonstrating 
diffusion of nanomimics and PfMSP142–OG488 as one single component. At the 
highest PfMSP142-OG488 concentration tested, four PfMSP142–OG488 were 
bound to each nanomimic, which was calculated by comparing the signal per 
molecule (CPM = 6.8 kHz) of PfMSP142–OG488 to CPM of the nanomimic-
PfMSP142–OG488 complex (CPM = 29 kHz). A constant concentration of 2.8 nM 
PfMSP142–OG488-binding heparins on nanomimics in the titration experiment 
was calculated. This value was fixed for the fitting of the normalized ligand-
receptor saturation curve (Figure 24F). 
Fitting the saturation curve of PfMSP142-OG488 with heparin on nanomimics-
Bodipy630 (Figure 24F) yielded a Kd of 12.1 ± 1.6 nM for the interaction, 
confirming the hypothesis that the interaction of PfMSP142 with nanomimics is 
based on a high affinity interaction (Chapter 3). This also explains the efficient 
invasion inhibitory effect of nanomimics against malaria parasites (Figure 26C,D). 
Interestingly, the interaction strength of another merozoite ligand (BAEBL/EBA-
140) with HS was estimated to have a Kd of 8.18 ± 2.54 nM,30 which is very similar 
to the binding affinity determined here.  
4.3.3 Antimalarial Activity of Modified Nanomimics 
We further tested the invasion inhibition process and potency of the modified 
nanomimics (shorter or less heparin on the surface) and compared them to 
nanomimics-25% by analyzing invasion inhibition using fluorescence microscopy 
(Figure 25) and testing the dose-response in antimalarial suspension assays 
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(Figure 26). Fluorescence imaging, after incubation of late stage Plasmodium 
falciparum-infected RBCs (iRBCs), RBCs, and modified nanomimics, revealed 
invasion inhibition as demonstrated by modified nanomimic binding to merozoites 
and subsequent trapping of the malaria parasite in its extracellular merozoite form 
(Figure 25). In quantitative anti-malarial suspension experiments, all tested 
nanomimics were very potent invasion inhibitors with much lower IC50 values 
compared to soluble heparin chains (Figure 26). Nevertheless, in more complex 
fluids (e.g. human whole blood), it might be necessary to modify the surface-
exposed heparin or exchange it with a more specific receptor of the malaria 
parasite to circumvent unspecific binding, which would interfere with the 
antimalarial activity and could also produce side effects. 
 
 
Figure 25. Fluorescence imaging of RBCs, and merozoites (blue) blocked by nanomimics (red) after incubation of late 
iRBCs, RBCs and fluorescent nanomimics, (A,C,D) nanomimics-ShortHep-25%; and (B,E) nanomimics-5%. (Left: DIC, middle 
left: merozoite DNA stain, middle right: nanomimics, right: merge) 
66 Adrian Najer  
 
Figure 26. Dose-response curves from antimalarial suspension assays. All data points are mean growth ± standard error, 
from at least two duplicate assays for each sample, presented as percentage of control (PBS). (A) Dose-response curves for 
nanomimics-25% and nanomimics-5% represented based on the heparin concentration. (B) Dose-response curves for 
nanomimics-25% and nanomimics-5% represented based on nanomimic concentration. (C) Dose-response curves for 
comparison of all nanomimics and free heparin. (D) Comparison of the IC50 concentration of free heparin or nanostructured-
heparin to inhibit parasite growth based on total heparin amount (µg/mL). Statistics were analyzed using Student's t-test: ★★★p 
< 0.001, not significant (n.s.). 
 
When less heparin chains were exposed on a single nanomimic, which was the case 
for nanomimics-5%, more nanomimics were needed to obtain the same 
antimalarial effect as with nanomimics-25%, which becomes visible when these 
samples are compared based on the nanomimic concentration rather than the 
heparin content (Figure 26A,B). Therefore, nanomimics with less heparin chains, 
but with identical lengths, are less potent invasion inhibitors in comparison to 
nanomimics with more heparin chains on the surface. 
Interestingly, nanomimic-ShortHep was very potent in invasion inhibition, 
although the exposed heparin chains were short (Table 3). The antimalarial 
activity of these nanomimics with short, but more heparin chains on the surface 
was similar to nanomimics-25%, which were assembled using less, but longer 
heparin block copolymers. For soluble heparin it has previously been reported that 
the antimalarial activity drops for very short chains with a number of repeat units 
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(monosaccharides) below six.25 Our findings of very potent ShortHep-based 
nanomimics can be explained by the multivalent presentation of heparin chains on 
a single nanomimic, which allow strong enough interactions to block invasion. In 
case of both, long and short heparin block copolymers, the known flexibility and 
fluidity of PDMS-based membranes –106 the fundamental basis for the lateral 
diffusion of biomolecules (membrane proteins) embedded within PDMS-based 
membranes as described recently –105 can further promote recruitment of more 
heparin chains upon initial binding of one chain to the parasite by diffusion of 
PDMS-heparin within the nanomimic membrane to yield stronger multivalent 
binding. 
4.4 Conclusions 
Modified nanomimics with fewer or shorter malaria receptor molecules (heparin) 
on the surface were successfully self-assembled. All these modified nanomimics 
were efficient invasion inhibitory nanostructures in the anti-malarial suspension 
assay. Based on the heparin concentration, all had similar activity, but exposing 
fewer heparin chains per nanomimic reduced the potency of the nanostructure and 
for shorter heparins, more chains were needed to yield nanomimics with similar 
activity to nanomimics with long heparins. Furthermore, the interaction of a 
merozoite surface protein (PfMSP142), a known heparin-binding protein, with 
nanomimics was studied and a high affinity interaction was obtained. This high 
affinity binding is essential to understand and optimize the antimalarial activity of 
nanomimics in the future. 
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   CHAPTER 5 
5 Giant Host Red Blood Cell Membrane Mimicking 
Polymersomes Bind Parasite Proteins and Malaria 
Parasites 
This chapter describes the interaction of giant versions of the nanostructures of 
Chapters 3, 4 with the same malaria parasite proteins and whole malaria 
parasites. This demonstrates the suitability of giant polymersomes as a model to 
study membrane mimics and confirms data obtained with the corresponding 
nanostructures. 
 
 
 
This study has been published and was reprinted and modified herein with 
permission from reference 260. Copyright (2016) Neue Schweizerische Chemische 
Gesellschaft. 
 
Najer, A.; Thamboo, S.; Palivan, C. G.; Beck, H.-P.; Meier, W. CHIMIA. 2016, 70, 
288–291.  
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5.1 Abstract 
Malaria is an infectious disease that needs to be addressed using innovative 
approaches to counteract spread of drug resistance and to establish or optimize 
vaccination strategies. With our approach, we aim for a dual action with drug- and 
“vaccine-like” activity against malaria. By inhibiting entry of malaria parasites into 
host red blood cells (RBCs) – using polymer vesicle-based (polymersome) 
nanomimics of RBC membranes – the life cycle of the parasite is interrupted and 
the exposed parasites are accessible to the host immune system. Here, we present 
that host cell-sized RBC membrane mimics, formed with the same block 
copolymers as nanomimics, also bind the corresponding malaria parasite ligand 
and whole malaria parasites, similar to nanomimics. This was demonstrated using 
fluorescence imaging techniques and confirms the suitability of giant 
polymersomes (GUVs) as simple mimics for RBC membranes.  
5.2 Introduction 
Block copolymer-based vesicles, called polymersomes78 – due to their increased 
mechanical stability compared to liposomes and broad chemical versatility to 
introduce e.g. stimuli-responsiveness – are considered ideal candidates for drug 
delivery purposes, as nanoreactors, as artificial organelles inside cells, or as simple 
cell mimics.59,253 Our above described nanomimic strategy against infectious 
diseases is based on such polymer vesicles imitating a host cell membrane at the 
nanoscale (nanomimics), which was achieved by mixing two distinct block 
copolymers: vesicle-forming PMOXA-b-PDMS-b-PMOXA, and PDMS-b-heparin 
(Chapters 3, 4). Giant polymersomes (giant unilamellar vesicles, GUVs), with 
several micrometers in diameter, are increasingly acknowledged as interesting 
model systems of very simplified cell mimics.161 
Malaria, a disease caused by Plasmodium spp. parasites that are transmitted by 
Anopheles mosquitoes – killing more than 600’000 people each year –257 is our 
current target. When reaching the blood stage cycle, the malaria parasite form 
called merozoite attach to and enter red blood cells (RBCs), where the parasite 
asexually divides to form more parasites, which egress from the infected RBC 
(iRBC) after about 48 hours and infect more RBCs.19 Heparan sulfate (very similar 
to heparin) on RBCs is considered as being responsible for the initial attachment of 
merozoite to the RBC by interaction with Plasmodium falciparum merozoite 
surface protein 1-42 (PfMSP142).25 With our approach we block the malaria blood 
stage life cycle using RBC-membrane-mimicking polymersomes, which block the 
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parasite after egress from iRBCs, inhibit invasion, and expose the infective 
merozoites to the immune system. If successful in vivo, this artificial inhibition of 
merozoite invasion might lead to an immune boost against extracellular 
merozoites (Chapter 3). 
Here, we demonstrate that RBC membrane mimics formed at a larger size, but 
similar hollow sphere architecture (heparin GUVs), can also bind the parasite 
protein Plasmodium falciparum merozoite surface protein 1-42 (PfMSP142) and 
the whole Plasmodium parasite (merozoite form) in a similar fashion as their 
nano-sized counterparts, the nanomimics (Chapters 3, 4). This indicates that 
GUVs indeed represent a suitable model of small polymersomes, with the 
advantage of a size close to that of RBCs. Certain aspects, e.g. binding of PfMSP142 
to polymersomes can be studied with GUVs using methods that would not be 
suitable for the nanostructure (e.g. CLSM to study protein binding).  
5.3 Results and Discussion 
5.3.1 Giant Host RBC Membrane Mimicking Polymersomes Bind 
Plasmodium Proteins 
In the previous Chapters 3, 4, we demonstrated that polymersome-based 
nanomimics of host RBC membranes efficiently block malaria parasite invasion 
into host RBCs in vitro; nanomimics were more than two orders of magnitude 
more potent invasion inhibitors compared to soluble receptor-like molecules 
(heparin), when IC50 values were compared based on the heparin concentration in 
the assays. Furthermore, we measured that several heparin chains on a single 
nanomimic bound parasite ligands PfMSP142-OG488 with a high affinity (Kd of 
12.1 ± 1.6 nM) using fluorescence cross-correlation spectroscopy (FCCS) of green 
labeled ligand and red labeled nanomimics. This multiple binding with high 
affinity is the basis for a strong multivalent interaction of nanomimic and 
merozoite, explaining the potent invasion inhibition by nanomimics. 
Herein, host RBC membrane-mimicking polymersomes were formed at a larger 
size (micrometer scale, heparin GUVs) to study malaria protein and whole parasite 
interaction with RBC-sized polymersome-based mimics. The same two block 
copolymers previously used for nanomimic formation were also used to form these 
giant mimics. PDMS65-b-heparin12 was mixed with PMOXA5-b-PDMS58-b-
PMOXA5 (or PMOXA9-b-PDMS67-b-PMOXA9) using 15 wt% of the first block 
copolymer and subsequent electroformation, yielding heparin GUVs. GUVs made 
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from PMOXA5-b-PDMS58-b-PMOXA5 without the heparin-functionalized 
copolymer were used as controls. 
Formation of GUVs and heparin GUVs was successfully achieved in both cases 
using electroformation. Usually, a large number of mainly unilamellar, 
univesicular polymersomes were formed, whereas only few giants with 
multivesicular structures were found. Interestingly, these artificial and flexible 
membranes possess a thickness of about 11 nm (Subchapter 3.3.2), while all the 
membrane components can laterally diffuse within the membrane,105,106 but still 
form stable vesicles with several tens of micrometers in diameter. We performed 
CLSM to study the interaction of fluorescently labeled Plasmodium ligand 
PfMSP142-OG488 and heparin, the receptor-like molecule known to bind 
PfMSP142,25 on the surface of heparin GUVs. This is only possible with GUVs and 
not with the nanomimics, because of resolution limitations. The membrane of 
control GUVs and heparin GUVs were labeled with the hydrophobic dye 
Bodipy630 for visualizing all the membranes in the red channel (Figure 27). The 
hydrophobic dye spontaneously incorporates into the hydrophobic part of the 
membranes (PDMS). 
The receptor-ligand interaction was followed after mixing control GUVs and 
heparin GUVs with green-labeled PfMSP142-OG488, respectively. In the control 
experiments, where GUVs without the receptor-like saccharide were used, no 
significant interaction with the parasite protein was observed as expected (Figure 
27C,D). Only the heparin GUVs, which mimic the host RBC membrane, were 
covered with PfMSP142-OG488 proteins on the surface, which appeared as green 
rings, while the exact same imaging settings as in the experiments with GUVs were 
used (Figure 27A,B). Therefore, we could successfully observe the interaction of 
heparin on GUVs with the Plasmodium ligands PfMSP142 using conventional 
CLSM imaging.  
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Figure 27. CLSM images of heparin GUVs (A, B) and control GUVs (C, D), which were mixed with the Plasmodium parasite 
ligand PfMSP142-OG488 to investigate the ligand-receptor interaction; only when the receptor was presented on the surface 
(heparin GUVs), the parasite ligand bound to the GUVs, control GUVs showed no non-specific interaction with the protein. Left: 
DIC image. Middle left: Bodipy630 in the hydrophobic part of the GUV membranes. Middle right: OG488 on PfMSP142. Right: 
Merge. Scale bars: 10 µm. 
 
This confirms measurements performed using nanomimics and fluorescence-
based diffusion measurements (fluorescence correlation spectroscopy (FCS), and 
FCCS) with the same PfMSP142-OG488 ligands of merozoites (Chapters 3, 4). This 
indicates that the membrane-bound receptor-like molecules (heparin) were also 
exposed on the large heparin GUVs after electroformation, similarly to the nano-
scaled versions thereof (nanomimics). Therefore, GUVs are well suited to study 
certain biophysical aspects of the interaction between the parasite proteins and 
membrane mimics with a size relevant biologically, which support the conclusions 
already reported for the corresponding nanoversion system (nanomimics) 
(Chapters 3, 4). 
74 Adrian Najer  
5.3.2 Giant Host RBC Membrane Mimicking Polymersomes Bind 
Plasmodium Merozoites 
Successful binding of parasite proteins to heparin GUVs encouraged performing 
experiments with whole Plasmodium merozoites to check for binding of viable 
parasites to heparin GUVs. This was studied using fluorescence microscopy after 
incubation of heparin GUVs with purified, viable Plasmodium falciparum 
merozoites, which is the most aggressive, life-threatening species of malaria 
parasites. The membrane of heparin GUVs was again visualized by red, 
hydrophobic dye (Bodipy630). Fluorescence images clearly demonstrate that 
merozoites also bind to RBC-sized host membrane-mimetic polymersomes (Figure 
28). In both examples shown, the merozoites slightly indented the membrane of 
heparin GUVs upon binding. This deformation of the polymersome structure upon 
merozoite binding was also seen with nanomimics as previously demonstrated by 
electron microscopy of ultrathin slices of merozoite-nanomimic complexes 
(Chapters 3, Figure 21). 
 
 
Figure 28. Fluorescence microscopy images of giant host RBC-mimicking polymersomes (red) that bound Plasmodium 
merozoites (blue, DNA stain). Left: DIC image. Middle left: Hoechst, DNA stain. Middle right: Bodipy630, staining polymersome 
membranes. Right: Merge. Merozoites are about 1.5 µm long. 
 
This confirms that large scaled polymer vesicles can mimic – at a very primitive 
stage – the membrane of the host RBC to such an extent that binding of 
Plasmodium proteins and whole malaria parasites is achieved. The large size of 
GUVs allows the analysis of certain aspects by conventional imaging methods. 
Naturally, for a real in vivo application the nano-scaled versions are preferable, 
but certain aspects are difficult to analyze using only nano-sized structures. 
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5.4 Conclusions 
Host RBC-membrane-mimicking polymersomes (heparin GUVs) were successfully 
formed at a corresponding RBC size (about 7 µm disk diameter) using two block 
copolymers and electroformation technique. Only when the second copolymer, 
containing the receptor-like molecule (heparin), was present in the GUV 
membrane, the parasite ligand PfMSP142 bound to the GUVs. Furthermore, whole, 
viable, and RBC-infecting Plasmodium falciparum merozoite interacted and 
deformed these large-sized RBC membrane mimics (heparin GUVs). These are 
important steps towards understanding and defining this concept and to advance 
closer to a real biomedical application.  
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   CHAPTER 6 
6 Further Evaluation of Nanomimics with Respect to 
Biomedical Applicability 
This chapter summarizes additional data characterizing nanomimics properties 
in prospect of biomedical applications. This includes anticoagulation property, 
estimation of endotoxin contamination, and initial in vivo tests regarding 
invasion inhibition and secondary “vaccine-like” activity of the nanomimic 
strategy. Parts of this chapter are being prepared for publication. 
6.1 Results and Discussion 
6.1.1 Anticoagulation Property of Nanomimics 
When heparin is intended for a medical purpose other than preventing blood clots, 
such as anti-infection applications, its anticoagulation property turns out to be a 
major drawback. Furthermore, heparin-induced bleeding, which is directly linked 
to its anticoagulation effect, is the most important adverse effect when heparin is 
used in medical applications.261 Soluble heparin has previously been used as 
adjunct therapy for severe malaria, but it was discontinued due to serious side 
effects, such as intracranial bleeding.231,262 Therefore, heparin-containing samples 
(nanomimics) were tested for anticoagulation property. The obtained values were 
related to the amount of surface-exposed heparin as measured by Farndale 
microassays. 
Control vesicles (only PMOXA-b-PDMS-b-PMOXA), four independent samples of 
nanomimics-25% (26, 78, 102, and 146 µg/mL surface-exposed heparin) and one 
sample nanomimics-12.5% (50 µg/mL) were tested. Only one sample, 
nanomimics-25% (102 µg/mL heparin), showed a slight anticoagulation activity 
(0.15 UI/mL); all other samples did not reach activities above the detection limit 
(0.1 UI/mL). In order to calculate the maximum expectable percentage of 
anticoagulation activity possible in nanomimic samples, the heparin concentration 
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was converted from 102 µg/mL to 19.7 UI/mL based on the initial activity of the 
heparin used for polymer synthesis (193 UI/mg). The measured activity (0.15 
UI/mL) revealed that nanomimics-25% (102 µg/mL) exhibit only 0.8 % of the 
calculated activity. The whole procedure of synthesis and nanomimic formation 
yielded final nanostructures with much reduced anticoagulation property (only 0.8 
% of the expected activity was left). The anticoagulation activity of heparin 
depends on the interaction of antithrombin III with a specific heparin 
pentasequence, which is only present in about one third of all the heparin chains of 
the sodium salt starting material used for synthesis.263 Moreover, the 
pentasequence is likely to be occluded in the nanomimics. In conclusions, PDMS-
b-heparin synthesis and the nanomimic formation technique are responsible for 
the much reduced anticoagulation activity. 
In mice, the minimum blood concentration of soluble heparin, needed to achieve 
anticoagulation property, was found to be at least 4 µg/mL.207 Thus, based on our 
calculations, nanomimics could be injected up to a blood concentration of about 
500 µg/mL heparin concentration without reaching the threshold concentration 
needed for anticoagulation activity in mice. This indicates that anticoagulation 
property of our nanomimics can be neglected at the current development stage, 
but has to be kept in mind and tested more thoroughly. However, heparin on 
nanomimics might specifically interact with other heparin-binding proteins, which 
might lead to a reduction of circulation time and/or anti-infectious activity. To 
overcome this drawback, modified or alternative receptor molecules that have less 
interaction partners than heparin might be considered as building block for 
nanomimics. 
6.1.2 Estimation of Endotoxin Contamination 
Most engineered biomaterials suffer from contamination with endotoxins, better 
known as lipopolysaccharides (LPS), originating from the outer cell membrane of 
Gram-negative bacteria. Our body strongly reacts to very low endotoxin 
concentrations, which can cause endotoxin shock and even death. Therefore, FDA 
regulations strictly demand that all medical solutions intended for intravenous 
application have to be tested for endotoxins and confirmed to contain less than 0.5 
EU/mL endotoxin, which corresponds to only 0.05 ng/mL LPS.264 
The chromogenic kinetic limulus amebocyte lysate (LAL) assay is a standard 
method to estimate endotoxin levels, but it is in general rather tricky to perform 
these assays with nanoparticle-containing solutions.265 Spiking nanoparticle 
samples with known amounts of endotoxin is used to determine interference of the 
sample with the assay; spike recovery of 50 – 200 % indicates suitability of the 
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assay.265 Heparin is also known to interfere with the assay, but this can be 
overcome by adding MgCl2.266 Furthermore, when high concentrations of 
nanoparticles are added to the assay solution, light scattering by the nanoparticles 
influences the absorbance measurements. This is corrected by redefining the onset 
time (normally the time to reach 0.2 A.U.) by the time to increase by 0.2 A.U., 
which equals a baseline correction at time point 0. Despite these difficulties, we 
tested our nanostructures for endotoxin contamination using standard LAL 
chromogenic kinetic assays (Lonza).267 Initial measurements of nanoparticle 
samples that were prepared under standard sterile conditions yielded large 
amounts of endotoxins (> 5 EU/mL). The main source of endotoxin contamination 
was found to be the column material used for nanostructure purification and the 
plastic column itself. After incrementally testing each preparation step, strategies 
to avoid high endotoxin contaminations in polymersome and nanomimics 
production were established as follows. 
Ultra-pure, endotoxin-free water should be used in all steps of synthesis, assembly, 
and purification. Endotoxins are eliminated from glassware by heating at 250 °C 
overnight. Alternatively, glassware and magnetic stirrers are decontaminated by 
washing in 0.5 M NaOH overnight and subsequent rinsing with EtOH and/or 
sterile, endotoxin-tested PBS in a sterile hood. Column material, Sepharose 2B, 
has to be washed in 0.5 M NaOH overnight and then rinsed with sterile, 
endotoxin-tested PBS. The column is packed within a sterile hood using sterile 
syringes, needles, and a sterile 10 mL plastic pipette, which served as column 
(Figure 29). For nanomimic extrusion, the extruder parts are first washed in 0.5 M 
NaOH overnight and rinsed with sterile, endotoxin-tested PBS before use.  
Following these procedures, we obtained nanomimic (146 µg/mL accessible 
heparin, ~ 5 mg/mL polymer, DH = 91 ± 24 nm) and polymersome samples that 
contained less than 0.005 EU/mL endotoxins, which is well below the FDA-limit 
of 0.5 EU/mL. Spike recovery with a nanomimic sample yielded about 86 % (0.05 
EU/mL added), which is within the acceptable range confirming suitability of this 
assay for our samples.265 More detailed analysis of endotoxin contamination will 
be needed, if projects involving polymersomes and nanomimics are continued in 
the direction of biomedicine. 
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Figure 29. Digital image of the column set-up used for nanomimic purification to avoid high endotoxin contamination. 
Sterile 10 mL plastic pipettes, syringes, needles, and freshly cleaned column material (washed in 0.5 M NaOH overnight) had 
to be used to yield nanomimic samples with endotoxin contamination below 0.005 EU/mL. 
 
6.1.3 In vivo Activity and “Vaccine-Like” Action 
Encouraged by the promising in vitro data we decided to run preliminary tests of 
the activity of nanomimics in an acute malaria mouse model. 200 µL of a 
nanomimics-25% (DH = 85 ± 26 nm, Zeta-Potential = –36.3 ± 1.1 mV, 78 µg/mL 
heparin) or a nanomimics-12.5% (DH = 108 ± 33 nm, 50 µg/mL heparin) solution 
in PBS was injected twice a day for four days after mice have been infected with P. 
berghei. Unfortunately, parasitemia in the test mice reached similar values as in 
control mice. Although we could not yet demonstrate in vivo activity of these 
nanomimics with P. berghei no apparent toxic effects of nanomimics injections 
were found and all mice survived throughout the assay. It is possible that the lack 
of effect on P. berghei is due to a short circulation time of the nanomimics, which 
has not yet been tested. Synchronized parasites (as is the case in natural human 
malaria) and timed nanomimic injection could be used to account for the short 
circulation time. Additionally, huge numbers of parasites are typically used in this 
acute malaria mouse model. Even if many parasites were blocked by nanomimics, 
this might not become visible at high parasitemia. Moreover, P. berghei might not 
be the best model to test whether or not structures inhibit invasion, as indicated by 
a failure to achieve parasite reduction despite high antibody titers induced by 
vaccination.268 
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Following our idea of a dual drug- and “vaccine-like” action, another research 
group recently attempted to inhibit merozoite entry using sulfated 
polysaccharides.269 This study showed antimalarial activity of heparin-like sulfated 
polysaccharides from marine organisms, with IC50 values in the range of heparin, 
but with reduced anticoagulation property. It also reported some in vivo activity 
and the induction of antibody production, but only in one mouse.269 Clearly, more 
work is needed to evaluate the in vivo effect of sulfated polysaccharides on malaria 
infection.  Structures with increased inhibitory properties have to be formulated or 
found to exploit the full potential of the nanomimic strategy. 
Interestingly, the aforementioned group also formulated a primaquine-loaded 
nanostructure with heparin non-covalently attached to the surface, mainly for 
targeting iRBCs.207 The nanostructure was a liposome with positive surface charges 
that bound heparin chains to the surface by electrostatic interactions. A 
concentration of 10 µM heparin was needed for reaching the IC80 (growth at 20 % 
compared to a control), when no drug was additionally encapsulated.207 In our 
case, 27 nM of surface-exposed heparin on nanomimics was sufficient to achieve 
IC80 (Subchapter 3.3.5). The 370-fold lower heparin concentration results from the 
nature of the nanostructure and the different chemical conjugation of heparin. On 
nanomimics, heparin is covalently attached in its natural conformation via its 
reducing end, which allows for strong multivalent interactions of the nanomimics 
with the merozoites. Liposomes207 with heparin electrostatically wrapped around 
the positively charged surface might not warrant a stable and structurally optimal 
nanostructure for the inhibition of merozoites. 
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In the scope of this thesis, another preliminary experiment was performed to 
assess the “vaccine-like” action of nanomimics. For simplicity, only one merozoite 
protein rather than the whole pathogen was used for this initial test. The 
nanomimic-PfMSP142 complexes were injected intravenously to mimic the 
situation when merozoites would be inhibited in the human bloodstream (Figure 
30). Enzyme-linked immunosorbent assay (ELISA) endpoint titers clearly show 
that anti-PfMSP142 IgG antibodies were produced after intravenous injection of 
nanomimic-PfMSP142 complexes (Figure 31). 
 
 
Figure 30. Experimental procedure to test “vaccine-like” activity of the nanomimic strategy.  
 
 
Figure 31. Determination of anti-PfMSP142 IgG antibodies by ELISA. Curves correspond to mouse sera taken on day 31 
after immunization. Adj. M1/M2 belong to procedure A (Figure 30), PBS M1/M2 to B, and Nano M1/M2 to C. 
 
However, when parasite invasion is inhibited in vivo, not only one protein (as 
demonstrated here with PfMSP142) but in fact the whole pathogen – with all its 
antigenic proteins – will be exposed in the bloodstream. Thus, even if antibody 
levels would be as low as induced with PfMSP142 alone, the diversity of antibodies 
against a multitude of merozoite proteins could still be highly inhibitory. However, 
Chapter 6 83 
if the whole pathogen were to be exposed on nanomimics, the fate of the complex 
would be dominated by the pathogen because it is much bigger than the 
nanomimics, whereas the PfMSP142 complex is dominated by the nanomimics due 
to the smaller size of the protein alone compared to nanomimics. Size and 
antigenic diversity could affect the host immune response against merozoites when 
blocked by nanomimics in vivo. 
Initial experiments to examine whether the sera of mice previously injected with 
nanomimics-PfMSP142 interfere with malaria parasites, we carried out in vitro 
growth inhibition assays using P. falciparum in suspension. Immune sera were 
compared to preimmunization sera and to sera of untreated BALB/c mice (Figure 
32). 
 
 
Figure 32. In vitro growth inhibition of Plasmodium falciparum by mouse sera before and after immunization. The 
immunization procedure is shown in Figure 30. (n = 2) 
 
Interestingly, all post-immunization sera did inhibit parasite growth in this 
preliminary test when compared to pre-immunization sera (Figure 32). Although 
only two independent experiments could be performed with the limited amount of 
serum available, the different immunization schedules did not reveal sera with 
significantly different effect on P. falciparum growth inhibition. The nature of the 
inhibitory structures present in these sera remains to be identified. Nevertheless, 
these preliminary data suggest that the nanomimic strategy might indeed produce 
an immune response that could potentially protect from a secondary infection. 
This promising concept will be further explored in the future. 
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   CHAPTER 7 
7 An Amphiphilic Graft Copolymer-Based 
Nanoparticle Platform for Reduction-Responsive 
Anticancer and Antimalarial Drug Delivery 
This chapter demonstrates how environment-sensitive, biodegradable 
nanoparticles can be used to stabilize an experimental antimalarial compound. 
Further, our nanoparticle platform delivers the compound to Plasmodium-
infected red blood cells. 
 
 
 
This chapter is part of a study270 that has been submitted. 
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7.1 Abstract 
Medical applications of anticancer and antimalarial drugs often suffer from low 
aqueous solubility, high systemic toxicity, and metabolic instability. Smart 
nanocarrier-based drug delivery systems provide means of solving these problems 
at once. Herein, we present such a smart nanoparticle platform based on self-
assembled, reduction-responsive amphiphilic graft copolymers, which were 
successfully synthesized through thiol-disulfide exchange reaction between 
thiolated hydrophilic block and pyridyl disulfide functionalized hydrophobic block. 
These amphiphilic graft copolymers self-assembled into nanoparticles with mean 
diameters of about 30 – 50 nm and readily incorporated hydrophobic guest 
molecules. Fluorescence correlation spectroscopy (FCS) was used to study 
nanoparticle stability and triggered release of a model compound in detail. Long-
term colloidal stability and model compound retention within the nanoparticles 
was found when analyzed in cell media at body temperature. In contrast, rapid, 
complete reduction-triggered disassembly and model compound release was 
achieved within a physiological reducing environment. The synthesized 
copolymers revealed no intrinsic cellular toxicity up to 1 mg/mL. Drug-loaded 
reduction-sensitive nanoparticles delivered a hydrophobic model anticancer drug 
(doxorubicin, DOX) to cancer cells (HeLa cells) and an experimental, metabolically 
unstable antimalarial drug (the serine hydroxymethyltransferase (SHMT) inhibitor 
(±)-1) to Plasmodium falciparum-infected red blood cells (iRBCs), with higher 
efficacy compared to similar, non-sensitive drug-loaded nanoparticles. These 
responsive copolymer-based nanoparticles represent a promising candidate as 
smart nanocarrier platform for various drugs to be applied to different diseases, 
due to the biocompatibility and biodegradability of the hydrophobic block, and the 
protein-repellant hydrophilic block.  
7.2 Introduction 
Nanoparticle-assisted drug delivery allows for tuning pharmacokinetics, toxicity, 
absorption, distribution, metabolism, and excretion profile of drugs leading to 
different needs for dosage and duration of treatment.271 This concept has been 
widely applied for improving clinical outcome of anticancer therapy through 
increasing drug accumulation at the target site while decreasing drug distribution 
to off-target sites.272,273 Passive targeting of tumor tissue can be obtained using 
non-functionalized, drug-loaded nanoparticles via the enhanced permeability and 
retention (EPR) effect, which allows nanoparticle accumulation in tumors after 
intravenous application.146,274 In terms of size, passive accumulation within tumor 
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tissue via the EPR effect is efficiently achieved with long-circulating nanoparticles 
ranging from 10 to 100 nm in diameter.149 However, small sized nanoparticles 
(sub-50 nm diameter) have been shown to better target e.g. lymph node metastatic 
cancer.275  
Amphiphilic block copolymer (ABP)-based nanomaterials are one promising type 
of materials with broad applicability in drug delivery.272,273 Various self-assembled 
nanostructures ranging from micelles to worm-like micelles to polymer vesicles 
can be obtained in aqueous environments by carefully choosing the type, 
architecture, lengths, and hydrophilic/hydrophobic block ratio of ABPs.61,72,276 
ABP-based nanoparticles benefit from lower critical micelle concentrations (CMC), 
higher mechanical stability, simple introduction of stimuli-responsiveness within 
the ABP architecture, and modification with targeting moieties when compared to 
lipid based systems such as liposomes.59,273,277 Degradability of ABP-based 
nanoparticles is introduced by using polypeptides or polyesters, such as poly(ε-
caprolactone) (PCL), as ABP hydrophobic building blocks.278 Poly(ethylene glycol) 
(PEG) and poly(2-methyl-2-oxazoline) (PMOXA) are two readily used 
biocompatible polymers for the hydrophilic part of ABPs; both provide non-fouling 
properties needed for long-circulating nanoparticles.279  
Another challenging aspect of nanoparticle-based drug delivery is the efficient 
release of the drug in the target cell, while retaining the drug inside the 
nanostructure in the extracellular environment. This is elegantly addressed by 
spatiotemporal- and dosage-controlled delivery using stimuli-responsive materials 
and corresponding nanostructures.213,280,281 Commonly used endogenous triggers 
for stimuli-responsive delivery are changes in pH, redox potential, and enzyme 
concentration.213 Reduction-responsive ABP-based nanoparticles represent a 
unique class of smart materials based on their effective delivery mechanism for a 
wide range of molecules, such as nucleic acids282,283 and low molecular weight 
chemical drugs.284-287 The building blocks of these nanostructures contain one or 
more disulfide linkage/s in their main- or side-chains. This allows forming drug-
loaded nanoparticles with stable morphology in circulation and extracellular 
environments. After cellular uptake, rapid cleavage of the disulfide linkage/s and 
subsequent nanoparticle disassembly in the reductive cell cytosol promote drug 
release.288 The large gradient of the reducing agent glutathione (GSH) across cell 
membranes – the cytosolic concentration (2 – 10 mM) is three orders of 
magnitude higher than the extracellular concentration – serves as the basis for 
reduction-responsive anticancer drug delivery.215  
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Solubility, stability and toxicity problems are well known for anticancer drugs,289 
but the same problems equally apply to anti-infectious agents, such as 
antimalarials.290,291 Malaria is an infectious disease caused by Plasmodium spp. 
parasites, transmitted by Anopheles mosquitoes. The disease causing stages of the 
parasite infect and asexually divide inside of human red blood cells (RBCs).19 The 
need for novel antimalarials or strategies against resistance development is 
increasingly recognized. Especially since the recent development and spread of 
resistance against the first-line treatment with artemisinin combination,9 which 
already led to treatment failures.46 One proposed approach to overcome the 
development of resistance is the delivery of high local concentrations of 
antimalarials using e.g. nanoparticles.42,201 Current antimalarial drug delivery 
strategies are focused on commercial antimalarials that have already been 
optimized for in vivo applications.195,196  
Surprisingly, there is evidence that proteins, such as antibodies,41 and small 
nanoparticles up to about 80 nm diameter have direct access to the parasite inside 
the RBC.39,40,42 Similarly to passive tumor targeting via the EPR effect, this 
controversial “leakiness” of Plasmodium-infected RBCs (iRBCs)39,40,42 can be 
exploited via a passive targeting strategy using non-functionalized, antimalarial-
loaded nanoparticles. Also here, smaller sized nanoparticles (sub-80 nm diameter) 
are needed, because the size-cutoff to efficiently reach intracellular malaria 
parasites of iRBCs is about 80 nm.39,40,42 The highly reducing parasite cytosol of 
iRBCs214 equally represents a valuable trigger for smart drug delivery of 
antimalarials via reduction-triggerable nanoparticles, similar to reduction-
triggered anticancer drug delivery. 
Herein, we report the synthesis of a library of biodegradable, reduction-responsive 
ABPs composed of hydrophilic PMOXA and hydrophobic PCL with grafted 
molecular architecture, poly(2-methyl-2-oxazoline)-graft(SS)-poly(ε-
caprolactone) (PMOXA-g(SS)-PCL), in which the reduction-responsive disulfide 
group acts as the linker between PMOXA and PCL. Aqueous self-assembly of these 
graft copolymers into nanoparticles and loading of cargo using model hydrophobic 
dye molecules (Bodipy630, NileRed), anticancer drug (doxorubicin, DOX), and 
antimalarial (serine hydroxymethyltransferase (SHMT) inhibitor (±)-1)291 were 
studied (Figure 33). A single molecule detection method, FCS, was used to 
demonstrate high stability and model dye retention within self-assembled 
nanoparticles in protein-containing cell media over four days and fast disassembly 
and model compound release upon treatment with reducing agent. Furthermore, 
the biocompatibility of these copolymers was tested on HeLa cells in the range of 
0.1 mg/mL to 1 mg/mL. Anticancer drug-loaded reduction-sensitive nanoparticles 
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were evaluated for delivery of their payload to cancer cells (Hela) and compared to 
non-sensitive nanoparticles based on similar polymers with linear architecture, 
PMOXA-b-PCL. Similarly, we explored the nanoparticle-based delivery of a non-
optimized, hydrophobic, and metabolically unstable antimalarial compound, 
which is in preclinical drug development stage, to iRBCs. We consider this as a 
valuable additional avenue to medicinal chemistry traditionally used to modify 
pharmacokinetic properties of compounds via changing the chemical structure of 
the compound itself. 
 
 
Figure 33. Chemical structures of model hydrophobic cargo molecules used for incorporation in nanoparticles. 
 
7.3 Results and Discussion 
7.3.1 Chemical Structure of Graft Copolymers and Self-Assembly 
Only a short summary is given here. Full synthesis of the graft copolymer, 
polymer characterization, aqueous self-assembly, reduction-triggered 
disassembly, and anticancer activity can be found elsewhere: Dalin Wu, PhD 
Thesis. Amphiphilic Block Copolymers: Synthesis, Self-assembly and 
Applications, Basel, CH, 2015. 
A library of reduction-sensitive graft copolymers PMOXA-g(SS)-PCL and 
reduction-insensitive linear copolymer PMOXA-b-PCL was synthesized (Table 4, 
Figure 34). Chemical structures were analyzed by 1H NMR, FTIR, and GPC. 
Aqueous self-assembly of the graft copolymers yielded mean diameters ranging 
from about 27 nm to 51 nm with narrow PDI of 0.09 to 0.18 for all three graft 
copolymers according to dynamic light scattering (DLS) measurements in PBS 
(Figure 34). Transmission electron micrographs (TEM) confirmed the size and 
morphology of the assembled spherical nanoparticles (Figure 34C). These obtained 
nanoparticle sizes lie within the optimum range of 10 to 100 nm to be used as 
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passively targeted drug delivery vehicles.149 The relatively small average size of 
maximum 50 nm provides the basis for targeting cancer metastasis275 and iRBCs in 
case of malaria.39,40,42 
Table 4. Chemical Characteristics of synthesized PMOXA-g(SS)-PCL. 
Polymer 
 
1H NMR 
 
GPC 
 
CMC 
Block 
ratio 
Mn f(PMOXA)a Mw Mn PDI mg/mL 
PMOXA-
g(SS)-PCL-2 
88:238 34800 22% 22300 13000 1.72 0.05*10-3 
PMOXA-
g(SS)-PCL-1 
127:165 30000 36% 18400 13260 1.38 0.20*10-3 
PMOXA-
g(SS)-PCL-3 
135:135 27000 43% –b – – 0.29*10-3 
a The values of f(PMOXA) were calculated by the equation !" !" !"#$%!" !" !!!"# !"#"$%&'( 
b Due to solubility problems of PMOXA-g(SS)-PCL 3 in THF, no GPC data were obtained. 
 
 
Figure 34. Chemical structure of PMOXA-g(SS)-PCL (A), PMOXA-b-PCL (B), and schematic self-assembly in aqueous 
solution. (C) Morphology of nanoparticles self-assembled from PMOXA-g(SS)-PCL 2 imaged by transmission electron 
microscopy (TEM). (D) Hydrodynamic diameter and number distribution of nanoparticles in PBS measured by DLS. More TEM 
images, and DLS size distributions are shown in Figure 36, 37. 
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7.3.2 Loading of Various Hydrophobic Model Molecules within 
Nanoparticles 
Various hydrophobic cargo molecules were chosen to be incorporated within the 
hydrophobic core of self-assembled nanostructures for stabilization and protection 
purposes. The fluorescent dye molecules Bodipy630 and NileRed, the anticancer 
drug doxorubicin (DOX), and the experimental, metabolically unstable 
antimalarial (SHMT inhibitor (±)-1)291 were the selected compounds for 
encapsulation in nanoparticles formed by reduction-sensitive PMOXA-g(SS)-PCLs 
and PMOXA-b-PCL. Non-triggered PMOXA-b-PCL-based nanoparticles served as 
biodegradable, but reduction insensitive control nanostructures. All these 
hydrophobic molecules were readily incorporated into the hydrophobic core of all 
the different nanoparticles. Drug loading efficiencies (DLE) of 15%, 30%, 40%, and 
55% for NileRed, Bodipy630, DOX, and SHMT inhibitor (±)-1, respectively, were 
measured by fluorescence (DOX) and UV-Vis absorbance (dyes and antimalarial, 
Figure 35) measurements for reduction-sensitive nanoparticles. DLS 
measurements of drug/dye-loaded nanoparticles revealed typical average 
diameters of 42 ± 11 nm for reduction-sensitive nanoparticles and 74 ± 24 nm for 
similar, non-sensitive nanoparticles (Figure 37). TEM images confirmed these 
sizes (Figure 36, 37). 
 
 
Figure 35. Calibration curve for Bodipy630 in PBS and SHMT inhibitor (±)-1 in PBS used to calculate amount of 
encapsulated dye/drug in nanoparticle samples. Due to drug aggregation, the values for SHMT inhibitor (±)-1 absorbance at 
peak maximum (310 nm) had to be corrected for light scattering by subtracting the value at 200 nm; nanoparticle calculations 
were performed similarly. 
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Figure 36. TEM images of Bodipy630 (1 µM)-loaded nanoparticles – used for triggered release studies – self-assembled 
from (A) PMOXA-b-PCL, (B) PMOXA-g(SS)-PCL 1, (C) PMOXA-g(SS)-PCL 2, and (D) PMOXA-g(SS)-PCL 3. 
 
 
Figure 37. Morphology of drug-loaded (SHMT inhibitor (±)-1) nanoparticles self-assembled from PMOXA-b-PCL (A), and 
PMOXA-g(SS)-PCL 3 recorded by transmission electron microscopy (TEM). (C) Hydrodynamic diameter and number 
distribution of dye- (NileRed) and drug-loaded (SHMT inhibitor (±)-1) nanoparticles in PBS measured by DLS.  
 
7.3.3 Reduction-Triggered Model Compound Release and Stability of 
Nanoparticles in Cell Media 
The design of smart drug delivery vehicles demands for stable nanostructures, 
which do not aggregate, keep the drug within the carrier prior to cellular uptake, 
and subsequently release the payload upon reaching cellular compartments that 
provide the desired trigger. Fluorescence correlation spectroscopy (FCS) is a 
method that allows to study dye encapsulation, stability and triggered release on a 
single molecule level.97,292 FCS was used herein to first follow the reduction-
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triggered release behavior of a model hydrophobic cargo (Bodipy630) upon 
dithiothreitol (DTT)-induced disintegration of reduction-responsive nanoparticles 
formed from PMOXA-g(SS)-PCLs. It can be determined whether the dye is 
encapsulated or freely diffusing by following the diffusion times (τD) of fluorescent 
molecules. Time series of FCS curves were recorded in the presence or absence of 
reducing agent to follow reduction-triggered model compound release from 
triggered nanoparticles compared to a non-triggered nanoparticle version (Figure 
38, 39).  
 
 
Figure 38. Reduction-triggered disassembly and dye release from PMOXA-g(SS)-PCL nanoparticles and nanoparticle cell 
medium stability studied by fluorescence correlation spectroscopy (FCS). (A) Schematic disassembly and dye release from 
reduction-sensitive nanoparticles. (B) Normalized autocorrelation curves (symbols) and fits (lines) from FCS measurements 
using Bodipy630-loaded PMOXA-g(SS)-PCL 1 nanoparticles in absence and presence of 10 mM DTT in PBS: t = 0 min (blue 
circles, 0% free dye fraction), t = 24 min (red crosses, 46% free dye fraction), t = 24 h (black diamonds, 100% free dye 
fraction), t = 24 h without DTT (magenta triangles, 0% free dye fraction). (C) Time series of the percentage of free dye fraction 
from FCS curves of nanoparticles with the following conditions: PMOXA-g(SS)-PCL 1 in PBS without DTT at 37 °C (magenta 
triangles), PMOXA-g(SS)-PCL 1 in PBS containing 10 mM DTT at 37 °C (black triangles), and PMOXA-b-PCL in PBS 
containing 10 mM DTT at 37 °C (blue circles). Free dye was only appearing for PMOXA-g(SS)-PCL in presence of 10 mM DTT, 
whereas incubation in PBS or non-sensitive PMOXA-b-PCL-nanoparticles in 10 mM DTT did not show free dye up to 24 h 
incubation. Values are mean of three independent measurements ± SEM for each time point. (D) Stability of PMOXA-g(SS)-
PCL 3 Bodipy630-loaded nanoparticles in malaria culture medium (MCM) at 37 °C under shaking conditions for four days; 
nanoparticle fraction from two-component autocorrelation curve fitting compared to time point 0 (grey diamonds), change in 
number of dye molecules per nanoparticles calculated from molecular brightness (CPM) data compared to time point 0 (black 
squares), and hydrodynamic nanoparticle diameter (Dh) calculated from obtained diffusion times (blue triangles). Values are 
mean of 30 curves ± SD at each time point. Statistics was analyzed using two-tailed Student’s t-test. 
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The fraction of free dye versus encapsulated dye was followed using a two-
component fit of the obtained autocorrelation curves (Figure 38B). 
Simultaneously, the hydrodynamic diameters of the nanoparticles and the number 
of dye molecules per single nanoparticle were calculated from the diffusion times 
(τD) and molecular brightness (counts per molecule, CPM in kHz), respectively, by 
comparing values of nanoparticles to values obtained for free dye. The obtained 
nanoparticle hydrodynamic diameters using FCS (Figure 38D, 39C, 40) are in 
good agreement with values measured by DLS and TEM (Figure 34, 36, 37). 
Furthermore, the reducing agent-induced increase of nanoparticle sizes for the 
reduction-sensitive copolymers was confirmed by FCS (Figure 39C).  
 
 
Figure 39. (A) Time series of the percentage of free dye (Bodipy630) fraction from FCS curves of nanoparticles with the 
following conditions: PMOXA-g(SS)-PCL 2 in PBS without DTT at 37 °C (magenta triangles), PMOXA-g(SS)-PCL 2 in PBS 
containing 10 mM DTT at 37 °C (black triangles). (B) Same as (A) but for PMOXA-g(SS)-PCL 3. Values are mean of three 
independent measurements ± SEM for each time point. (C) Development of hydrodynamic diameters calculated from FCS 
diffusion times: PMOXA-g(SS)-PCL 1 (down triangles), PMOXA-g(SS)-PCL 2 (squares), PMOXA-g(SS)-PCL 3  (circles) in PBS 
containing 10 mM DTT at 37°C under shaking condition (grey symbols and curves), and in PBS without DTT at 37°C under 
shaking condition (black symbols and curves). Diameters of aggregates above 350 nm are shown at 350 nm, because 
accurate size information is only possible for particles/aggregates smaller than the confocal volume.  
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The reduction-triggered release of a model cargo (Bodipy630) from all reduction-
sensitive nanoparticles compared to stable, non-sensitive nanoparticles was 
successfully achieved as demonstrated by FCS measurements (Figure 38B, C, 39A, 
B). The free dye population obtained from two component fits was only increasing 
over time – reaching more than 90% free dye after 1.5 h – in case of PMOXA-
g(SS)-PCL nanoparticles in the presence of DTT (10 mM). The same samples 
incubated without DTT or non-sensitive nanoparticles (PMOXA-b-PCL) with DTT 
(10 mM) did not reveal a free dye population in FCS curves even after 24 h. This 
smart drug release from nanoparticles at physiological, cytosolic reducing agent 
concentration at 37 °C sets the basis for triggered delivery of hydrophobic and 
unstable drug molecules to cancer cells and malaria parasite infected RBCs. Before 
cell experiments were conducted, the stability of the loaded nanocarriers was 
studied in detail on a single molecule level using FCS. These measurements were 
performed at physiological temperature (37 °C) under shaking conditions in the 
complete cell media (containing proteins), which were subsequently used for 
assays with cancer cells and malaria parasites. Reduction-sensitive and non-
sensitive nanoparticles were both highly stable in terms of nanoparticle size, 
colloidal stability, and dye retention within the nanoparticles in both cell media for 
the whole tested time window of four days (Figure 38D, 40), which was the 
maximum incubation time used in cell assays. 
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Figure 40. Stability of dye-loaded (Bodipy630) nanoparticles in cancer cell medium (left) and malaria culture medium 
(right) at 37 °C under shaking condition for 4 days: nanoparticle fraction from two-component autocorrelation curve fitting 
compared to time point 0 (grey diamonds), change in number of dye molecules per nanoparticles calculated from molecular 
brightness (CPM) data compared to time point 0 (black squares), and hydrodynamic nanoparticle diameter calculated from 
obtained diffusion times (blue triangles). (A,E) PMOXA-b-PCL nanoparticles (stock containing 2.5 µM Bodipy630). (B,F) 
PMOXA-b-PCL nanoparticles (133 µM Bodipy630). (C,G) PMOXA-g(SS)-PCL 2 nanoparticles (2.5 µM Bodipy630). (D) PMOXA-
g(SS)-PCL 3 nanoparticles (56 µM Bodipy630). Values are mean of 30 curves ± SD at each time point. Statistics were 
analyzed using two-tailed Student’s t-test. 
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Overall, all the nanoparticle samples did not reveal any dye release throughout the 
whole assay time as calculated from two component fits of autocorrelation curves, 
which did not yield any significant fractions of fast diffusing species (grey 
diamonds, Figure 38D, 40). The diffusion time of this fast diffusing component 
was fixed to typical values of about 300 µs, which is different to free dye diffusion 
due to interaction of media proteins with hydrophobic dye molecules as calibrated 
by FCS of dye in complete cell media. An average of 18% and 2% dye release was 
calculated at the end of the four-day assay in case of reduction-sensitive and non-
sensitive nanoparticles, respectively, when comparing the change in the number of 
dye molecules per nanoparticle, via CPM comparison of free dye to nanoparticle 
values over time. But these small differences compared to time point zero were 
mostly not significant (Figure 40). The nanoparticle hydrodynamic diameters (Dh) 
remained similar for all samples over the whole time course of four days, 
remaining in the optimal size window of Dh = 10 to 100 nm needed for optimal 
drug delivery via passive targeting.149 This was expected due to the protein-
repellant PMOXA139,140 hydrophilic blocks exposed on the nanoparticle surfaces. 
This is an important aspect, since nanoparticle aggregation would significantly 
hamper accessibility of nanoparticles to tumor sites and iRBCs. Blood circulation 
times in vivo – needed for efficient passive accumulation of the drug-loaded 
nanoparticles at tumor sites or within iRBCs – would also be reduced due to 
increased hepatosplenic filtration. This demonstrates the high potential of 
triggered nanoparticles based on PMOXA hydrophilic blocks that can be seen as 
valuable alternatives to overcome problems associated with PEG-based 
nanoparticles.124 
7.3.4 Drug Delivery to Plasmodium falciparum-Infected Red Blood Cells  
Another disease model was used to study the broad applicability of the reduction-
sensitive PMOXA-g(SS)-PCL nanoparticle platform for smart drug delivery. First, 
a model hydrophobic molecule, NileRed, was encapsulated in reduction-sensitive 
PMOXA-g(SS)-PCL 3 nanoparticles and PMOXA-b-PCL nanoparticles to study 
delivery of a model compound via fluorescence microscopy. This hydrophobic dye 
molecule additionally serves as a model for drug molecules with very low aqueous 
solubility, a property of many experimental drugs at early stages of drug 
development. After a short 2 h incubation of either free dye or encapsulated dye 
with a mixture of RBCs and iRBCs (about 4%), a clear intracellular parasite 
staining was observed in all cases, demonstrating the possible delivery of a model 
molecule to iRBCs using small nanoparticles (Figure 41B, 42). This fast delivery of 
a model compound to iRBCs without any targeting ligands on the nanoparticle 
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surface indicates the potential of inert, protein-repellant PMOXA-coated 
nanoparticles for passively targeted antimalarial delivery to Plasmodium-infected 
RBCs.  
 
 
Figure 41. Dye and drug delivery to Plasmodium-infected red blood cells (iRBCs). (A) Schematic representation of SHMT 
inhibitor (±)-1 delivery to iRBCs using reduction-responsive PMOXA-g(SS)-PCL nanoparticles. (B) Fluorescence imaging 
demonstrating delivery of hydrophobic model molecule, NileRed, using PMOXA-g(SS)-PCL 3 nanoparticles: DIC (top left), 
Hoechst DNA-stain (top right), NileRed signal (bottom left), merge (bottom right). (C) Example of dose-response curves for one-
day suspension antimalarial assay with free SHMT inhibitor (±)-1 or nanoparticle-based delivery. (D) Comparison of IC50 values 
for all the different antimalarial assay conditions and samples presented as the average ± SEM (n ≥ 3). Statistics were 
analyzed using two-tailed Student’s t-test: *p<0.05, **p<0.01, ***p<0.001. 
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Figure 42. Fluorescence imaging demonstrating delivery of hydrophobic model molecule, NileRed, to iRBCs using no 
carrier (A, B); PMOXA-g(SS)-PCL 3 nanoparticles (C, D); PMOXA-b-PCL nanoparticles (E, F): DIC (left), Hoechst DNA-stain 
(middle left), NileRed signal (middle right), merge (right). Same dye concentrations (final 2.5 µM) and microscopy settings were 
used for all images. 
 
Fluorescence intensities were in general higher within schizonts compared to 
trophozoite stage parasites (Figure 42). The staining pattern shows accumulation 
of the dye in certain parasite compartments. This specific dye is known to 
accumulate in neutral lipid bodies, which were proposed to be storage organelles 
for lipid intermediates.293 The observation of this lipid body staining also in 
nanoparticle samples suggests successful release of the dye from nanoparticles. 
Combined with the high medium stability of both particles for several days (Figure 
38D, 40) it can be speculated that nanoparticles are taken up and the dye is 
subsequently released. This delivery mechanism was also proposed by other 
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research groups.39,40,42 To reflect the potency of nanoparticle-based stabilization 
and delivery of small compounds, a one-day-old NileRed aqueous solution was 
additionally tested in the same way and compared to a fresh NileRed solution. It 
clearly showed that this model hydrophobic compound was not stable enough in 
solution for one day; it did not readily appear in the iRBCs compared to fresh dye 
(Figure 43). 
 
 
Figure 43. Fluorescence imaging demonstrating uptake of hydrophobic dye by iRBCs using freshly prepared NileRed 
solution in PBS (A, B), and 1 day incubated NileRed solution in PBS: DIC (left), Hoechst DNA-stain (middle left), NileRed signal 
(middle right), merge (right). Same dye concentrations (final 2.5 µM) and microscopy settings were used for all images. 
 
Similarly, an experimental antimalarial compound (SHMT inhibitor (±)-1, Figure 
33),291 which is very active in vitro, but with an intrinsic solubility and metabolic 
stability problem that hampers successful in vivo application,291 was incorporated 
within reduction-sensitive and non-sensitive nanoparticles. With our 
nanoparticles, we could stabilize the drug up to concentrations of about 300 µM, 
whereas the free drug was not readily soluble in PBS, it visibly precipitated as 
shown in digital images at a concentration of 10 µM drug in PBS (Figure 44). 
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Figure 44. Digital image of a PBS solution (A) and a 10 µM SHMT inhibitor (±)-1 in PBS (B) after 30 minutes at RT, 
prepared from a 10 mM stock in DMSO, demonstrating precipitation of the hydrophobic drug in aqueous solution. 
 
iRBCs and uninfected RBCs under shaking conditions were used as an in vitro 
system that more closely simulates the in vivo situation compared to standard 
static drug testing for antimalarials (Subchapter 3.3.5), which was additionally 
performed (Figure 41C, D). Only PMOXA-g(SS)-PCL 3 and PMOXA-b-PCL 
nanoparticles were used for antimalarial testing, because there were no significant 
differences found for the three graft copolymers in terms of drug delivery to cancer 
cells. Solubilization and potential protection from metabolic degradation are the 
main reasons for SHMT inhibitor (±)-1 encapsulation in nanoparticles. We 
demonstrated that over two parasite cycles (four day suspension assay, 5% 
hematocrit) the drug reached its full potential when delivered via nanoparticles 
(Figure 41D). For shorter incubation times (one day suspension assay, 10% 
hematocrit, Figure 41C, D), which better mimic the natural situation, the drug was 
more active followed by drug delivery via reduction-sensitive nanoparticles and 
non-sensitive nanoparticles. The results were similar when tested in standard 
antimalarial drug testing assays (three day static assay, 1.25% hematocrit). In this 
in vitro setting, where no other cells apart from RBCs and iRBCs were present, 
developed antimalarials intrinsically target the iRBCs and uptake of bigger 
nanoparticles is slower compared to small molecule uptake. This explains the 
delivery profile obtained with our drug delivery system. Our nanoparticle platform 
holds the promise to efficiently solubilize and delay fast liver degradation of this 
experimental drug,291 by providing a hydrophobic core to shield it from the 
environment and deliver it to iRBC in the bloodstream. These observations provide 
the basis for further optimization and application of nanoparticles for stabilizing, 
protecting, and delivering water-insoluble, labile drugs already at early stages of 
drug development. This represents a highly promising alternative to optimization 
of the drug itself and can be applied to other anticancer or anti-infectious drugs. 
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7.4 Conclusions 
A library of reduction responsive PMOXA-g(SS)-PCL amphiphilic block 
copolymers was synthesized through the thiol-disulfide exchange reaction between 
thiolated PMOXA (PMOXA-SH) and pyridyl disulfide functionalized poly(ε-
caprolactone) (PCL-co-PPCL). This type of copolymers self-assembled into 
nanoparticles with sizes around 50 nm. These nanoparticles did not reveal any 
cytotoxicity in the tested concentration range, providing a biocompatible, 
biodegradable, and reduction-triggerable platform for smart drug delivery. 
Detailed stability and release studies using nanoparticle-incorporated model 
compounds demonstrated high colloidal stability and guest molecule retention 
within the nanostructures when incubated in various cell media at physiological 
temperature for four days. Rapid release of the guest molecules was achieved upon 
treatment with biologically relevant reducing agent concentrations. This designed 
nanoparticle platform was successfully used to delivery hydrophobic, toxic 
anticancer drugs to cancer cells. Additionally, this nanoparticle platform was 
evaluated to solubilize and deliver a hydrophobic, metabolically unstable, 
experimental antimalarial drug to Plasmodium-infected RBCs, which was 
successfully achieved. Our new reduction-sensitive amphiphilic copolymers are 
promising candidate materials for targeted drug delivery purposes to tackle cancer 
and malaria with a sophisticated smart delivery platform. 
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   CHAPTER 8 
8 Supplementary Experiments on Antimalarial Drug 
Delivery 
This chapter contains more data on antimalarial drug delivery to iRBCs 
including first in vivo trials. In particular, dye uptake and nanoparticle-assisted 
delivery to iRBCs is examined in more detail. Parts of this chapter are being 
prepared for publication. 
8.1 Results and Discussion 
8.1.1 Dye Participation to Plasmodium-Infected Red Blood Cells 
In the previous Chapter 7, staining of iRBCs with the hydrophobic dye NileRed was 
demonstrated. In fact, most small molecular compounds (dyes, drugs) that were 
used within this study accumulated within iRBCs compared to normal RBCs. We 
speculate that this is the case for most antimalarial compounds and established 
drugs. Here, selected examples of dye/drug accumulation in iRBCs are presented 
(Figure 45). In essence, in vitro cultures of P. falciparum were mixed and 
incubated for a few hours with dye/drug solutions, and then examined by live 
imaging without any washing steps.  
Rhodamine 6G, Bodipy630, and DNA-intercalating Hoechst 33342, as well as the 
cytotoxic anticancer drug DOX were taken up by the parasites. The uptake of DOX 
by iRBCs reveals why several anticancer drugs are also potent antimalarials and 
vice versa.294,295 Reason for the increased uptake of various compounds by iRBCs 
might be NPPs activated on iRBC membranes, which take up molecules with 
various chemical makeups from the surrounding medium.37 Furthermore, the 
controversial “leakiness” of iRBCs might provide openings that allow for passive 
accumulation of these compounds within iRBCs.39,40,42 
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Figure 45. Uptake of various dye molecules by iRBCs revealed by live cell fluorescence imaging without washing steps. (A) 
50 nM Rhodamine 6G, (B) 7.5 µM Bodipy630, (C) 2.5 µM Hoechst 33342, and (D) 50 nM DOX. DIC (left), corresponding 
fluorescence channel (middle), merged images (right). 
 
Only one specific dye, SRB, did not specifically accumulate within iRBCs. Before 
washing the culture, the cell-surrounding medium was as bright as iRBCs (Figure 
48A). Before washing, homogenous fluorescence was predominantly observed in 
the medium and within iRBCs in cultures incubated with SRB. Only after washing, 
it became apparent that SRB also entered iRBCs, albeit without accumulating over 
time. Therefore, SRB serves as a model compound to compare uptake of free dye 
versus dye-loaded nanostructures as further described below. 
8.1.2 Nanostructure-Based Delivery to Plasmodium-Infected Red Blood 
Cells 
Uptake of molecules, antibodies, and nanoparticles (up to about 80 nm diameter) 
by iRBCs has previously been demonstrated by several groups.39-42 Nevertheless, 
these data remain a controversy, especially due to the specific dye uptake by iRBCs 
even without conjugation or incorporation to/within nanoparticles (Figure 42, 45). 
Based on previous reports that demonstrated specific uptake of polystyrene 
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nanobeads by iRBCs,39 we first repeated uptake experiments with commercial, 
fluorescently labeled polystyrene nanobeads (Sigma, L5155). 
Size distribution and diameters of the commercial nanobeads were examined by 
TEM (Figure 46A) and FCS, yielding bead diameters of 25 ± 6 nm and 24 nm 
(CPM = 20 kHz), respectively. Fluorescence imaging after a two-hour incubation 
with nanobeads clearly showed that only Plasmodium-infected RBCs were labeled 
(Figure 46B). 
 
 
Figure 46. (A) TEM image of green fluorescent polystyrene beads (25 ± 6 nm, Sigma, L5155). (B) Uptake of green 
fluorescent polystyrene beads (Sigma, L5155) by P. falciparum-infected red blood cells (iRBCs). DIC (left), green fluorescence 
channel (middle), merged image (right). 
 
It is also possible that the fluorescent dye leaks from the nanostructures, which 
would lead to staining of iRBCs provided the free dye accumulates in iRBCs 
(Figure 42, 45). SRB is an exception because being a highly hydrophilic dye; it can 
be stably encapsulated by nanostructures forming a hydrophilic compartment (e.g. 
polymersomes and nanomimics). Therefore, SRB can be used to compare delivery 
of loaded nanostructures versus free dye. Various SRB-loaded polymersomes and 
nanomimics were tested for uptake by iRBCs (Figure 47, 48, 49). Samples were 
diluted 1 to 10 within the final parasite culture medium. 
 
 
Figure 47. TEM micrographs of (A) large PMOXA-b-PDMS polymersomes, and (B) small nanomimics used for uptake 
experiment shown below. Scale bars are 500 nm. 
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Figure 48. Fluorescence live cell imaging of SRB uptake by P. falciparum-infected RBCs. Samples were incubated for 21 
hours with free and encapsulated SRB and directly imaged without washing. (A) 500 nM SRB, (B) large, SRB-loaded PMOXA-
b-PDMS-based polymersomes (DH = 225 nm, 170 nM SRB), (C) middle-sized, SRB-loaded PMOXA-b-PDMS-based 
polymersomes (DH = 140 nm, 90 nM SRB), (D) small, SRB-loaded nanomimics (DH = 56 nm, 360 nM SRB). DIC (left), SRB 
channel (middle), merge (right). Imaging parameters were identical for all images. 
 
Fluorescence images of parasite cultures incubated with different SRB-loaded 
vesicles revealed the same trend that has previously been found:39,40,42 Small sized 
nanostructures (< 80 nm diameter) readily reached intracellular parasites 
(nanomimics, 56 nm mean diameter, Figure 48D), followed by middle-sized 
polymersomes (140 nm mean diameter, Figure 48C). In contrast, large 
polymersomes (225 nm mean diameter) did not end up within iRBCs but are 
detected in a different focal plane (Figure 48B). Importantly, free SRB – added at 
higher concentration than SRB concentrations of all nanostructure samples – did 
not reveal clear parasite staining before washing (Figure 48A).  
The efficient delivery of SRB to parasites via nanomimics might be related to the 
heparin-mediated targeting of the nanostructures to iRBC as has been 
demonstrated by others.207 However, we observed only partial targeting of iRBCs 
by nanomimics (Chapter 3). We consider the difference in size between 
nanomimics and polymersomes to a more likely explanation for the increased 
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delivery efficiency. Despite extensive extrusion using 50 nm pores, only 
nanomimics remained close to this size whereas polymersomes usually rearranged 
to larger sizes after extrusion. Some more detailed images of washed samples 
incubated with nanomimics also revealed early stage parasite staining of a triple-
infected RBC (Figure 49). 
 
 
Figure 49. Fluorescence live cell imaging of samples incubated for 21 hours containing (A) 500 nM SRB, and (B) small 
nanomimics (DH = 56 nm, 360 nM SRB), without including washing steps after incubation. (C, D) Imaging of nanomimic-
assisted SRB delivery (DH = 56 nm, 360 nM SRB). Parasite-infected RBC cultures were incubated for three days, washed 
twice with PBS and then imaged. Panels: DIC (left), Hoechst (middle left), SRB channel (middle right), merge (right). 
 
An antimalarial drug candidate that exhibits a similar distribution pattern as SRB 
is likely to benefit from nanoparticle-assisted delivery as lower amounts of the 
drug would be needed to achieve a similar effect as with the free drug. Additional 
advantages offered by nanoparticle-assisted antimalarial drug delivery include 
solubilization, stabilization, and protection from metabolic degradation. 
To follow the uptake of nanocarriers by iRBCs, SRB-conjugated copolymers were 
used in the assembly of the nanostructure rather than encapsulating the dye. 
PMOXA-b-PDMS-b-PMOXA micelles were formed using the solvent injection 
method (from EtOH to PBS) with 95 wt% unlabeled copolymer and 5 wt% SRB-
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labeled copolymer.106 Importantly, micelles do not provide a hydrophilic 
compartment for encapsulation of any residual free SRB present in the solution. 
Accordingly, SRB visualized in iRBCs is part of the micelle itself. FCS 
measurements revealed hydrodynamic diameter of about 26 nm and about five 
dye-conjugated copolymers per micelle. Consistent with other reports on 
nanoparticle uptake by iRBCs,39-42 faint iRBC staining was observed (Figure 50) 
after a 2h incubation of SRB-nanoparticles with a parasite culture. 
 
 
Figure 50. Uptake of PMOXA-b-PDMS-b-PMOXA micelles consisting of 5 wt% SRB-conjugated copolymer. iRBCs 
appeared reddish after two hours incubation and 2 x PBS wash. DIC (left), Hoechst DNA-stain (middle left), SRB signal (middle 
right), merge (right). 
 
8.1.3 Additional Data on SHMT Inhibitor Delivery 
SHMT inhibitor (±)-1-loaded PMOXA-b-PDMS-b-PMOXA micelles (DH = 34 ± 10 
nm) were also tested in in vitro suspension growth inhibition assays with P. 
falciparum (4 day assays). Data showed IC50 values of about 3 – 4 nM, which is 
similar to the values obtained for inhibitor delivery via other nanoparticles 
(Chapter 7). 
First in vivo experiments using a Plasmodium berghei acute malaria mouse model 
were carried out with micelles (PMOXA-b-PDMS-b-PMOXA, 550 µM loaded 
SHMT inhibitor (±)-1, DH = 26 ± 7 nm), reduction-sensitive nanoparticles 
(PMOXA-g(SS)-PCL, 50 µM and 5 µM loaded SHMT inhibitor (±)-1, DH = 52 ± 14 
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nm), and insensitive nanoparticles (PMOXA-b-PCL, 300 µM, 50 µM and 5 µM 
loaded SHMT inhibitor (±)-1, DH = 70 ± 22 nm). Despite rather high drug doses, 
none of the samples led to a significant reduction in parasitemia after four days. 
The mouse malaria parasite P. berghei, unfortunately, cannot be cultured in vitro. 
Therefore, it is difficult to establish whether nanoparticle stability and circulation 
time in vivo were inadequate or whether P. berghei is not a corresponding model 
for in vivo testing of in vitro activity previously observed with P. falciparum. For 
instance, P. berghei-infected mouse RBCs might not provide the same “leakiness” 
as human P. falciparum-infected RBCs, which might significantly hamper 
accessibility of nanoparticles to iRBCs. Moreover, the mouse parasites might not 
be susceptible to SHMT inhibitor(±)-1. Accordingly, the drug failed to reduce 
parasitemia when applied without a carrier, although this has mainly been 
attributed to the rapid metabolic degradation of the drug.291 Nevertheless, no 
apparent toxic effects of the i.v. applied drug-loaded nanoparticles were observed; 
all mice survived until the end of the assay. This indicates the large potential for a 
broad use of such nanostructures in biomedical applications. Future studies must 
assess nanoparticle stability, drug-retention and circulation time in vivo before 
final conclusions on the suitability of this nanoparticle platform for the delivery of 
antimalarials can be drawn. 
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   CHAPTER 9 
9 General Conclusion and Outlook 
In this thesis, two alternative nanotechnological approaches for potential malaria 
treatment/prophylaxis were established. The first approach, called ‘nanomimic 
strategy’ involved the synthesis of simple, functional polymersome with potent 
parasite invasion inhibitory property. These polymersomes served as nanomimics 
of RBC membranes to bind to malaria parasites and thereby blocking RBC 
invasion. In in vitro P. falciparum blood stage suspension cultures, these 
nanomimics performed about two orders of magnitude better than soluble 
receptor molecules. The multivalent presentation of receptor molecules on 
nanomimics allows strong parasite-nanomimic interactions, which explains the 
highly potent performance of nanomimics. Furthermore, a high affinity interaction 
of heparin on nanomimics with PfMSP142 was measured, which provides 
important information on the parasite invasion mechanism. In contrast to the 
currently accepted common view, our data suggest that initial attachment might 
already be of high affinity. We further showed that cellular toxicity, 
anticoagulation property, and endotoxin contamination is very low for 
nanomimics, which render them ideal candidates for biomedical applications. 
Preliminary data on the secondary “vaccine-like” activity are very promising and 
warrant further, comprehensive exploration. The nanomimic concept clearly 
provides an interesting alternative to conventional drugs and vaccines. 
Considering the limited efficacy of malaria vaccine candidates and the difficulties 
associated with antimalarial drug resistance, the nanomimic strategy might be a 
valuable option to treat children, having one of their first infections, and thereby, 
boosting the immune system to generate semi-immunity more rapidly than 
multiple natural infections do. 
As a next step, in vivo applicability of nanomimics needs to be extensively 
explored. Specifically, blood circulation time of nanomimics has to be scrutinized. 
This information will help to determine whether synchronous parasites, where all 
infected cells would burst at about the same time, and timed nanomimics injection 
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are sufficient to potentially ensure that enough nanomimics are present in the 
bloodstream, when parasites are egressing from iRBCs. Alternatively, other 
receptor/receptor-like molecules might be considered in the design of nanomimics 
to yield more specific pathogen inhibition and longer blood circulation times.  
The secondary "vaccine-like" activity has to be examined in more detail, 
preferentially with whole merozoites. If the immune response is not sufficient to 
protect from secondary infections, adjuvants, secondary targeting ligands (for 
specific immune cells), and immunostimulatory molecules might be integrated in 
the nanomimic formulation. This is readily accomplished by taking advantage of 
the polymersome-nature of nanomimics, which provides a hydrophobic membrane 
and a hydrophilic core for incorporation of various hydrophilic and/or 
hydrophobic substances. On the other hand, if the “vaccine-like” activity can be 
confirmed, but the infection, which is used to generate the immune response, is 
not sufficiently treated by nanomimics (based on the large number of parasites in 
the bloodstream), it might be necessary to combine nanomimics with a common 
antimalarial, which is not a problem. 
Other interesting future analyses include detailed studies of the processes induced 
or inhibited in merozoites by nanomimic-binding, and of the stage(s) at which the 
merozoite is arrested. Merozoites are primed to invade RBCs; several sequential 
alterations on the merozoite occur during egress and subsequent invasion of fresh 
RBCs.21-24 Therefore, binding of nanomimics to merozoites might either prevent 
binding of RBCs, or it might inhibit shedding of MSP1 by SUB2, for example. This 
is especially important in the context of the secondary "vaccine-like" activity, 
which will depend on the state of the merozoite surface-proteins. In other words, 
this nanomimic approach can be regarded as a platform for the antigenic display of 
whole merozoites produced during a natural infection. Problems associated with 
merozoite protein-based vaccination strategies, in particular the difficulty to find 
the best antigen or mixture of antigens and delivery vehicle21 to induce maximum 
long-term protective response, might be circumvented. However, the nanomimic 
approach might only induce clone-specific immunity and infection with another 
clone might not be inhibited. Due to the current design of our nanomimics, which 
present a receptor that is used by all yet tested clones, such a new infection with a 
different clone could be treated with the same nanomimics again. 
The design of the current nanomimics should entail broad-spectrum activity. 
Therefore, nanomimics should be tested on several other pathogens that use 
heparan sulfate for host cell interactions, e.g. HIV-1, hepatitis B and C, Dengue 
virus, West Nile virus, Mycobacterium tuberculosis, Staphylococcus aureus, and 
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Trypanosoma cruzi.224 If surface binding alone cannot interfere with the life cycle 
of these pathogens, additional hydrophilic/hydrophobic drugs can easily be 
incorporated within nanomimics. Such nanomimics can be considered targeted 
drug delivery systems, which first bind to the extracellular pathogen, and then 
release toxic compounds within the host cell after cellular uptake of nanomimic-
pathogen complexes. 
In the second part of the thesis it was demonstrated that reduction-triggered, 
degradable, polymer-based nanoparticles stabilize an experimental antimalarial 
drug candidate and deliver it to infected RBCs. Excellent nanoparticle stability and 
reduction-triggered release properties were found for our nanoparticle drug 
delivery platform. The anticipated trigger for nanoparticle disassembly, the 
reducing cytosol of iRBCs, provides a basis for future optimization of carrier 
chemistry and loading. Moreover, we hypothesize that experimental antimalarial 
drugs in particular might benefit from nanoparticle-based delivery. Compounds 
identified to inhibit parasite growth in vitro often exhibit low aqueous solubility 
and instability, which hampers biomedical applications. An elegant way to tackle 
these problems is by incorporation within nanostructures: amphiphile-based 
nanostructures provide a hydrophobic core for solubilization of the drug and 
protection from the environment. However, if nanoparticle-assisted drug delivery 
is to be developed for treatment of uncomplicated malaria, another significant 
hurdle has to be considered, namely how orally administered nanoparticles reach 
the bloodstream. The transport of nanoparticles from an oral dose into the 
bloodstream is a considerable challenge, but it might be a valuable avenue to 
pursue. For cases of severe malaria associated with high mortality, where oral 
bioavailability is neither required nor applicable the formulation of nanoparticle-
based drugs should be adapted correspondingly. Another avenue of possible 
nanoparticle-based antimalarial delivery is the fight of antimicrobial resistance. 
Other interesting candidates for targeted drug delivery via nanocarriers are P. 
falciparum gametocytes and P. vivax hypnozoites. This is particularly relevant 
with regard to malaria eradication.296 In the last steps of eradication, P. vivax 
hypnozoites must be totally eliminated to avoid relapse of infection in a few 
people, which might restart transmission to mosquitoes and cause further 
infections. Additionally, P. falciparum gametocytes should be attacked to block 
transmission from human to mosquito. One marketed drug, primaquine (PQ), can 
kill both, P. falciparum gametocytes and P. vivax hypnozoites, but its use is 
limited due to severe side effects.296 PQ can lead to hemolysis in glucose 6-
dehydrogenase (G6PD)-deficient patients, which are as frequent as 5 to 20 % in 
populations in malaria endemic areas of Sub-Saharan Africa and Asia.297 
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Nanoparticle-based delivery of PQ to hypnozoites and/or gametocytes is a 
promising strategy as it allows for much lower drug concentrations which, in turn, 
would largely reduce side effects.298 Results on blood stage malaria, where CQ-
concentration could be reduced 10-fold when delivered via nanostructures support 
this notion.204 
This thesis has clearly demonstrated that a vast range of possibilities exist to tackle 
infectious diseases, in particular malaria, using nanomedicine approaches, which 
is much underexplored to date, but should be actively continued to finally find 
novel alternatives to treat/prevent infections in the future. 
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   CHAPTER 10 
10 Experimental Section 
This chapter contains all experimental procedures, which were reproduced and 
modified with permission from the corresponding references 225,252,260,270. 
 
PMOXA-b-PDMS-b-PMOXA (1) Synthesis. PMOXA-b-PDMS-b-PMOXA (1) 
was synthesized according to previously published protocols.74,136,245 Briefly, 
bifunctional poly(dimethylsiloxane) (PDMS from ABCR GmbH, Karlsruhe, 
Germany) was vacuum stripped in a Schlenkflask overnight. Anhydrous hexane 
was subsequently added, and the stirred solution was dried by bubbling argon 
through it for 1 h. After bubbling, freshly distilled triethylamine (TEA) was added, 
and the mixture was cooled to –20 °C. PDMS was then reacted with 
trifluoromethanesulfonic acid (Tfsa) for 3 h at –20 °C, resulting in a bifunctional 
triflic PDMS macroinitiator. The reaction mixture was filtered through a cooled G4 
filter under argon. From the filtrate hexane was removed under vacuum and 
replaced by dry ethyl acetate. Adding distilled 2-methyl-2-oxazoline resulted in a 
cationic ring-opening polymerization of poly(2-methyl-2-oxazoline) (PMOXA) on 
the PDMS macroinitiator. Termination was performed after 60 h at 40 °C by 
adding a 2:8 mixture of TEA/water resulting in bifunctional OH-terminated 
PMOXA-b-PDMS-b-PMOXA. Finally, the solvent was removed by vacuum 
distillation. Purification was performed by resolubilizing the polymer in 1:1 
ethanol/water mixture and ultrafiltration through a 5 kDa membrane. The final 
product was dried under vacuum.  
PDMS-b-heparin (2) Synthesis. Heparin sodium salt from porcine intestinal 
mucosa (15 kDa, 197 U/mg, 375095) was purchased from Merck KGaA 
(Darmstadt, Germany), and aminopropyl-terminated poly(dimethylsiloxane) 
(PDMS(NH2)2) (5 kDa, AB109371) from ABCR GmbH (Karlsruhe, Germany).  
The tetrabutylammonium salt of heparin was obtained using a published 
protocol.246 Briefly, 500 mg of heparin sodium salt was dissolved in a minimum 
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amount of water (approximately 3 mL) and passed through a freshly packed 
Dowex Marathon MSC column (H+ form, 6 mL, Sigma-Aldrich, 428787). The pH 
was adjusted to pH 7 using a tetrabutylammonium hydroxide solution (54.0-
56.0% in H2O, Sigma-Aldrich, 86863). After reducing the volume on a rotary 
vacuum evaporator, the product was dialyzed against water for at least 48 h 
(Spectrum Laboratories Inc., Rancho Dominguez, CA, USA, MWCO 3.5 – 5 kDa). 
The product was subsequently dried under vacuum. To use as a control in the 
antimalarial assay, tetrabutylammonium heparin was first precipitated in cold 
diethyl ether, dried under vacuum, dissolved in PBS, and then passed through a 
size exclusion column (Sepharose 2B, Sigma-Aldrich, 2B300) equilibrated in PBS. 
The final concentration of heparin was then determined using the Farndale 
microassay. 
For PDMS-b-heparin (2, Scheme 2, Chapter 3) synthesis, 100 mg of 
tetrabutylammonium heparin (~ 22 kDa) was dissolved in a 50 mL round-bottom 
flask in 25 mL dichloromethane (DCM), and a hundred-fold excess of 
PDMS(NH2)2 was added under stirring. Furthermore, a 10-fold excess of 2-
picoline borane (Sigma-Aldrich, 654213) was dissolved in a small amount of DCM, 
added to the reaction mixture, and stirred for 7 days at room temperature (25 °C). 
After the third and fifth day of the reaction another 10-fold excess of 2-picoline 
borane was added, respectively. After 7 days, DCM was evaporated on a rotary 
evaporator and the product was washed in diethyl ether. The washed product was 
dried under vacuum and redissolved in a minimum amount of ethanol. Adding the 
solution dropwise into 4 x 15 mL diethyl ether in glass centrifugal tubes 
precipitated the product; unreacted PDMS(NH2)2 and reducing agent were soluble 
in diethyl ether. The precipitate was collected by centrifugation for 5 min (2000 
RCF) and discarding the supernatant. This precipitation process was repeated two 
times. The final product was dissolved in ethanol, filtered and dried under 
vacuum. For 1H NMR about 20 mg of the product was dissolved in 10% ethanol 
and passed through a freshly packed Dowex Marathon MSC column (Na+ form, 2 
mL, Sigma-Aldrich, 428787), and the volume was reduced to about 2 mL on a 
rotary evaporator, dialyzed against water for 24 h (Spectrum Laboratories Inc., 
Rancho Dominguez, CA, USA, MWCO 8-10 kDa), dried under vacuum and 
redissolved in D2O/acetone-d6 (v/v 3:1).  
PDMS-block-Short-Heparin (PDMS-b-ShortHep) was synthesized similarly to 
PDMS-b-heparin, but using shorter heparin (ShortHep, 4 – 6 kDa) for the 
synthesis instead of full-length heparin (15 kDa). 
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Polymersome and Nanomimic Formation. Control polymersomes 
(PMOXA-b-PDMS-b-PMOXA only) were formed by the film rehydration 
technique.74 A 1 mL amount of PMOXA-b-PDMS-b-PMOXA (6 mg/mL in ethanol) 
was put in a 5 mL round-bottom flask, and ethanol was removed on a rotary 
evaporator (100 mbar, 40 °C, 120 rpm). Subsequently, the thin polymer film was 
rehydrated using PBS or 1 mM SRB (Sigma-Aldrich, S1402) in PBS and stirred at 
least overnight.  
Nanomimics were prepared using the bulk rehydration technique.74 PMOXA-b-
PDMS-b-PMOXA (6 mg/mL) and PDMS-b-heparin (4 mg/mL) were dissolved in 
ethanol (both yielded clear solutions) and mixed in a 5 mL round-bottom flask in 
the desired ratio. The solvent was evaporated on a rotary evaporator (100 mbar, 40 
°C, 120 rpm) and the film was further dried at high vacuum overnight. The 
polymer film was subsequently destroyed using a spatula. The bulk polymer was 
hydrated in PBS and stirred for at least 12 h. To yield fluorescent polymersomes 
and nanomimics, they were incubated with 200 nM Bodipy630 (hydrophobic dye) 
in PBS after the vesicle formation procedure for FCS/FCCS, or the polymer 
mixture was hydrated using a 1 mM SRB (Sigma-Aldrich, S1402) solution in PBS. 
To use as a control in the antimalarial assay, tetrabutylammonium heparin, which 
was first precipitated in diethyl ether, dried under vacuum and dissolved in 
ethanol, was encapsulated in control polymersomes by adding 0.54 mL (4 mg/mL 
in ethanol) of the tetrabutylammonium heparin solution to 1 mL of PMOXA-b-
PDMS-b-PMOXA (6 mg/mL in ethanol) with subsequent vesicle formation as 
described above for nanomimics (bulk rehydration44). 
Micelle Formation. PDMS-b-heparin and PDMS-b-ShortHep micelles were 
formed similar to nanomimics but by using only PDMS-b-heparin or PDMS-b-
ShortHep (100%) instead of a mixture with PMOXA-b-PDMS-b-PMOXA.  
Nanostructure Extrusion and Purification. The polymersome, nanomimic, 
and micelle solutions were extruded at least 15 times through a 0.1 µm Nucleopore 
track-etch membrane (Whatman, GE Healthcare, UK) using a LIPEX extruder 
(Northern Lipids Inc., Canada). The final solution of nanostructures was passed 
through a size-exclusion column containing Sepharose 2B (Sigma-Aldrich, 2B300) 
equilibrated with PBS. 
Giant Polymersome Formation. Giant polymersome (GUV) formation was 
accomplished according to the standard electroformation technique299 using a 
Nanion Vesicle Prep Pro setup (Nanion Technologies, Munich, Germany). A 
freshly cleaned ITO-coated glass slide was first plasma-treated (Plasma Cleaner, 
PDC-002, Harrick Plasma, Ithaca, New York, USA), and then, a thin polymer film 
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was deposited on it. For control GUVs (only PMOXA-b-PDMS-b-PMOXA) a 
solution of PMOXA-b-PDMS-b-PMOXA in ethanol (6 mg/mL, 40 µl) was 
dispersed on the ITO-coated side of the glass slide and ethanol was subsequently 
evaporated using a vacuum chamber for 30 min (Plasma Cleaner, PDC-002, 
Harrick Plasma, Ithaca, New York, USA). For the heparin GUVs a mixture of 
PMOXA-b-PDMS-b-PMOXA in ethanol (6 mg/mL, 40 µl) and PDMS-b-heparin in 
ethanol (4 mg/mL, 10 µl) corresponding to a ratio of wt/wt 85:15 was used. 
Afterwards, a greased O-ring was put around the polymer film on the glass slide to 
form a chamber and then an aqueous sucrose solution (300 mM, 600 µl) was 
added to hydrate the polymer film. After covering by another ITO-coated glass 
slide, the sample was exposed to an ac current (3.0 V, 3.0 Hz) at room 
temperature. For control GUVs we performed electroformation overnight and for 
heparin GUVs electroformation was conducted for one hour. Finally, the GUV 
solutions were transferred to Eppendorf tubes and stored at 4 °C. 
Protein Labeling. Water-soluble proteins were fluorescently labeled via amine 
groups using Oregon Green 488 carboxylic acid, succinimidyl ester, 5-isomer 
(OG488-NHS, Invitrogen, Carlsbad, CA, USA, O-6147) using established protocols 
(Invitrogen). The buffer of P. falciparum major surface protein 1-42 (PfMSP142 
(3D7)) was exchanged with 0.1 M carbonate buffer (pH 8.3) at a concentration of 2 
mg/mL by using Amicon Ultra-0.5 mL (10K) centrifugal filters. OG488-NHS was 
dissolved in water-free DMSO (19.6 mM) and a 12-fold excess of OG488-NHS was 
added to the protein solution. After shaking for at least 2 h at room temperature, 
free OG488 was separated from labeled proteins on HiTrap desalting columns 
(Sephadex G25) using PBS as running buffer. The labeled proteins were stored in 
aliquots at –20 °C. 
Nanoparticle Formation and Critical Micelles Concentration (CMC). 
Nanoparticles of PMOXA-g(SS)-PCL were prepared by first dissolving 5 mg of 
copolymer in 300 µL DMF, then 1 mL of filtered PBS buffer was added drop wise 
under continuous stirring. The solution was subsequently dialyzed against PBS 
buffer for 24 h with changing PBS buffer solution three times.  
The critical micelle concentration (CMC) values of three PMOXA-g(SS)-PCL 
samples were determined by  using pyrene as the fluorescence probe. The 
concentration of graft copolymers was varied from 1*10-5 mg/mL to 0.5 mg/mL, 
while preserving the same concentration of pyrene at 0.8 µM. After mixing the 
graft copolymer solution with pyrene, the solution was kept in the dark at 37 °C for 
12 h before measuring. Fluorescence spectra were recorded using fluorescence 
spectroscopy at an excitation wavelength of 330 nm. Fluorescence emission at 372 
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and 383 nm were monitored. The CMC was estimated as the cross-point when 
extrapolating the intensity ratio I383 / I372 at low and high concentration regions.  
Loading of Nanoparticles Formed by PMOXA-g(SS)-PCL and PMOXA-
b-PCL. SHMT inhibitor (±)-1-, Bodipy630-, and NileRed were loaded into 
PMOXA-g(SS)-PCL and PMOXA-b-PCL by the solvent switch technique. First, 
PMOXA-g(SS)-PCL was dissolved in DMF (150 µL), and PMOXA-b-PCL in THF 
(150 µL). Subsequently, the drug or dye was dissolved in DMSO (SHMT inhibitor 
(±)-1, 10 mM, Bodipy630, 7.9 mM) or THF (NileRed, 8 mM) and added to the 
dissolved polymers in the desired ratio. In case of PMOXA-g(SS)-PCL, 0.5 mL PBS 
was then added dropwise under stirring. For PMOXA-b-PCL, the polymer-
drug/dye mixture was dropwise added to 0.5 mL stirred PBS. The mixtures were 
transferred into dialysis tubes (Spectrum Laboratories Inc., Rancho Dominguez, 
CA, USA, MWCO 300 kDa) and extensively dialyzed against 0.15 M NaCl for at 
least three days, while changing the solution at least eight times, and in the last 
step of purification dialysis was performed against PBS (Sigma). After purification, 
samples were sterile filtered using sterile 0.45 µm syringe filters. 
Drug loading efficiency (DLE) and drug loading content (DLC) were calculated 
according to the following formulas: 
DLE (%) = (weight of loaded drug / weight in feed) * 100% 
DLC (wt%) = (weight of loaded drug / weight of polymer+drug) * 100% 
Loading content in SHMT inhibitor (±)-1-, Bodipy630-, and NileRed-loaded 
nanoparticles was determined using UV-Vis absorption measurements at 
corresponding absorbance maxima and comparing to drug/dye calibration curves 
in PBS (Figure 35). 
Farndale Microassay. Farndale microassays were performed based on Farndale 
et al.300 with slight modifications. To obtain the amount of saccharide units per 
PDMS chain (5 kDa) an ethanolic solution of dimethylmethylene blue (DMMB) 
was prepared (15.8 µg/mL). A 250 µL sample of this solution was pipetted into 
each well of a 96-well plate and 50 µL of ethanol (blank), tetrabutylammonium 
heparin in ethanol (100, 50, 25, 10 µg/mL), and PDMS-b-heparin in ethanol (100, 
50 µg/mL) were mixed into each well in duplicates. The UV-vis absorbance was 
measured from 495 nm to 605 nm immediately after mixing. The 
tetrabutylammonium heparin standard curve was generated using the absorbance 
at the peak maximum at 565 nm. Absorbance at 565 nm of the PDMS-b-heparin 
samples and the calibration curve were used to calculate the relative 
tetrabutylammonium heparin content (R) in PDMS-b-heparin and the molecular 
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weight of tetrabutylammonium heparin (MW) per PDMS while assuming a 
constant length of PDMS (5 kDa) and using ! = !(!""!#)!(!""#!) = !"!" + 5!"#                               Equation 6 
The number of tetrabutylammonium saccharide units per PDMS chain was 
obtained using MW and a tetrabutylammonium saccharide unit molecular weight 
of 440 g/mol (300 g/mol36 x 3/2). 
For Farndale microassays in aqueous solutions, the DMMB-solution was prepared 
as suggested.301 A 250 µL sample of the DMMB solution was pipetted into 96-well 
plates. A 50 µL amount of PBS, heparin standards (20, 10, 7.5, 5, 2.5 µg/mL), and 
diluted nanomimic and control polymersome samples (typically 5-fold diluted) 
were mixed with the DMMB solution in duplicates. The UV-vis absorbance was 
measured from 395 nm to 595 nm immediately after mixing. The heparin standard 
curve was generated using the absorbance at 525 nm, and this curve was used as a 
calibration curve. In the nanomimic samples a baseline correction (exponential 
decay) was performed and the corrected absorbance value at 525 nm was used to 
calculate the amount of surface-accessible heparin. 
UV–Vis Spectrometry. UV–vis absorbance measurements were performed on a 
SpectraMax Plus M5e (Molecular Devices, Sunnyvale, CA, USA) using 0.1 mL 
cuvettes or 96-flat-bottom-well plates.  
Nuclear Magnetic Resonance. 1H NMR spectra were recorded on a Bruker 
DPX-400 NMR spectrometer in D2O, D2O/acetone-d6-mixture or CDCl3 at room 
temperature. The spectrometer was operated at 400 MHz and 16 or 128 NMR 
cycles were recorded for each sample. 
Gel Permeation Chromatography. Gel permeation chromatography (GPC) 
was performed on a Viscotek GPCmax system equipped with two PLgel Mixed-c 5 
µm columns (300 x 7.5 mm) and THF as eluent (flow rate = 1 mL min-1) at 40 °C 
and recorded by refractive index. Polymer molecular weights and polydispersity 
indices (PDI) were determined using polystyrene standards for calibration.  
Transmission Electron Microscopy. Nanostructure samples were negatively 
stained with 2% uranyl acetate for TEM imaging. Ultrathin sections of parasites 
were stained with a mixture of 4% uranyl acetate/methylcellulose (ratio 1:9). 
Imaging was carried out on a transmission electron microscope (Philips CM100) at 
an acceleration voltage of 80 kV. Size measurements were performed using ImageJ 
software. 
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Cryogenic Transmission Electron Microcopy. A 4 µL amount of nanomimic 
sample (3 mg/mL) was adsorbed on a holey carbon-coated grid (Quantifoil, 
Germany), blotted with a Whatman 1 filter paper and vitrified in liquid nitrogen-
cooled liquid ethane using an FEI Vitrobot MK4 (FEI Company, The Netherlands). 
Frozen grids were transferred to a Philips CM200-FEG electron microscope, which 
was operated at an acceleration voltage of 200 kV. Digital electron micrographs 
were recorded with a 4k x 4k TemCam-F416 CMOS camera (TVIPS Company, 
Germany). 
Zeta Potential. Zeta potential measurements were performed using a Zetasizer 
Nano ZSP (Malvern Instruments Ltd., UK) at 20 °C. Nanomimics or control 
polymersomes (about 3 mg/mL polymer concentration) prepared and purified in 
PBS were 40-fold diluted in 300 mM glucose (75 µg/mL polymer and less than 5 
mM salt).  
Fluorescence Correlation Spectroscopy. FCS measurements were performed 
on a commercial Confocor2 (Carl Zeiss, Jena, Germany) using an Ar+ laser for the 
488 nm wavelength and two HeNe lasers for 543 nm and 633 nm, respectively. 
The laser beam was focused onto the sample through a 40x C-Apochromat water 
immersion objective with a numeric aperture of 1.2 and the appropriate filter sets. 
Finally, the fluorescence intensity was recorded with an avalanche photodiode 
(APD). All measurements were performed at 20 °C. Typically, 5 µL samples were 
used.  Measurement series of 30 x 5 s (fast diffusing species) or 30 x 10 s (slow 
diffusing species) were taken for each sample. Raw data were processed with the 
ConfoCor3 software. R Statistics was used for normalization and graphs. The 
following fit function was used to fit samples with one component and including a 
triplet state:  
! ! !"# = 1 + (1 + !1 − ! !! !!trip) 1! 11 + !!D 11 + !! !!D                 Equation 7 
 
τD is the diffusion time. T represents the fraction of fluorophores in triplet state 
with the corresponding triplet time τtrip. N is the number of particles and R the 
structural parameter. R was set to 5 if fit results yielded R smaller than 3 or bigger 
than 8.  The relation between the x–y dimension of the confocal volume (ωxy) and 
τD was used to calculate diffusion coefficients (D). !D = !xy!4!                                                          Equation 8 
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The Einstein-Stokes equation was utilized to calculate hydrodynamic radii (RH). kB 
is the Boltzmann’s constant, T the absolute temperature, and η the viscosity of the 
surrounding medium. D= kBT
6πηRH
                                                        Equation 9 
RH was calculated for each of the 30 curves, and data are presented as mean ± 
standard deviation. To obtain nanomimic concentrations, calibration of the 
confocal volume was needed. This was obtained by measuring a series of dye 
solutions with known concentrations from 1 to 100 nM. A linear fit of dye 
concentration versus N – obtained from amplitudes of FCS curves – yielded the 
size of the confocal volume (approximately 0.5 fL). This calibrated value was 
subsequently used to determine nanomimic concentrations.  
For binding studies, PfMSP142-OG488 was mixed with controls or nanomimics, 
incubated under shaking at 37 °C for 2 h, cooled to RT (20 °C), put on the cover 
slide, and incubated 5 min, and FCS curves were recorded. Autocorrelation curves 
that could not be fitted due to big diffusing aggregates were excluded from the 
mean (max. 3 of 30 curves, 10%). Brightness (counts per molecule, CPM) of free 
PfMSP142-OG488 was compared to CPM obtained from the mixtures with 
nanostructures in order to calculate the number of PfMSP142-OG488 per 
nanostructure. 
Reduction-Triggered Release and Medium Stability of Dye-loaded 
Nanoparticles Formed from PMOXA-g(SS)-PCL and PMOXA-b-PCL. 
Bodipy630-loaded PMOXA-g(SS)-PCL and PMOXA-b-PCL nanoparticles were 
prepared as described above using theoretical final dye concentrations in the 
nanoparticle stock solutions of 1 µM for FCS release studies, 25 µM and 140 µM for 
FCS studies in cell media.  
For release measurements, aliquots of 20 µL nanoparticle solution (containing 1 
µM Bodipy630) were added to 200 µL pre-warmed (37 °C) PBS, or 11 mM DTT in 
PBS and subsequently incubated under shaking (500 RPM) at 37 °C in an 
Eppendorf Thermomixer Comfort. 5 µL of these mixtures were transferred for 
subsequent FCS measurements at each time point. 20 x 5 s FCS curves were 
recorded for each sample at each time point. Resulting FCS curves were fitted with 
a two-component system, whereas one diffusion parameter was fixed to free dye 
diffusion (typically about 50 – 60 µs). FCS curves that could not be fitted correctly 
by the program were excluded from the average (less than 1% of all curves). The 
following formula for autocorrelation curve fitting was used for one-component 
fits (for e.g. calibration measurements with free dye): 
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! ! !!"#$!!"# = 1 + 1! 11 + !!D 11 + !! !!D                                 Equation 10 
Two-component fits were used for nanoparticle stability and release 
measurements, with one diffusion component being fixed to free dye diffusion 
(typically about 50 – 60 µs) for release and stability measurements in PBS, or 
protein-dye complex diffusion (typically about 300 µs) for stability measurements 
in cell media, respectively: 
! ! !!"#$!!"# = 1 + 1! !!1 + !!D1 11 + !! !!D1 +
1! !!1 + !!D2 11 + !! !!D2  
Equation 11 
With diffusion times (τD1 and τD2), number of particles N, the fraction f of 
molecules with the corresponding diffusion time, and R, the structural parameter, 
which was always fixed to 5. Number of dye molecules per nanoparticle was 
calculated based on the molecular brightness (counts per molecule, CPM in kHz) 
when only one component was found (medium stability measurements):  #dyenanoparticle = !"#!"!#$"%&'()*!"#!"#                              Equation 12 
Percentage of free dye is presented as average ± SEM from three independent 
measurements using two independent samples for each copolymer. Hydrodynamic 
diameters (DH) were calculated using Einstein-Stokes equation; diffusion 
constants obtained for the nanoparticles and free Atto655 in PBS as a calibration 
for the confocal volume.  
For FCS measurements in cell medium, the following four representative dye-
loaded nanoparticle stock solutions were used: PMOXA-g(SS)-PCL 2 (2.5 µM 
Bodipy630), PMOXA-g(SS)-PCL 3 (56 µM Bodipy630) and PMOXA-b-PCL (2.5 
µM, and 133 µM Bodipy630), with the following dilutions in the corresponding 
pre-warmed (37 °C) cell culture medium: 1 to 10 (2.5 µM stocks), and 1 to 50 (56 
µM, 133 µM stocks). Samples were kept under constant shaking (500 RPM) at 37 
°C in an Eppendorf Thermomixer Comfort for four days. At each time point, 5 µL 
of these mixtures were transferred for subsequent FCS measurements of 30 x 5 s. 
Each curve was fitted using a two-component model with one component being 
fixed to protein-dye complex (typically about 300 µs) obtained from 
measurements of a Bodipy630 solution in cell culture media. Few curves with 
bright and slow diffusing aggregates were excluded from the average (< 1% of all 
124 Adrian Najer  
curves), due to their disproportional effect on the average.114 Average values for 30 
curves at each time point and corresponding standard deviation (SD) are 
presented. R Statistics and Excel were used for preparing graphs. 
Fluorescence Cross-Correlation Spectroscopy. FCCS measurements were 
also performed on a commercial Confocor2 (Carl Zeiss, Jena, Germany) – 
equipped with an Ar+ laser for the 488 nm wavelength and a HeNe laser for 633 
nm – according to previous protocols.97,98,259,302 The lasers were simultaneously 
focused onto the sample through a 40x C-Apochromat water immersion objective 
with a numeric aperture of 1.2 and the appropriate filter sets (Green: BP 505-550 
nm, red: LP 650 nm) to separate the two colors (green/red). All measurements 
were performed at 20 °C. FCCS calibration data to test the relative minimal cross-
correlation amplitude, which is given by the cross-talk from one channel to the 
other, was estimated using a mixture of the two used dyes (OG488 and 
Bodipy630) and the relative maximum cross-correlation amplitude using a 
standard sample (IBA standard, double labeled DNA). Different concentrations of 
PfMSP142–OG488 were mixed with diluted control polymersomes (PMOXA-b-
PDMS-b-PMOXA) or nanomimics-25% that were both stained with Bodipy630, 
immediately added onto the sample plate, and incubated at 20 °C on the glass 
plate for 5 min before recording fluorescence intensity fluctuations in both 
detection channels (green/red) 30x for 10 seconds each. This procedure was 
repeated in three independent experiments for each concentration. Intensity 
fluctuations recorded in both channels were auto- (FCS) and cross-correlated 
(FCCS) on the ConfoCor3 software to yield auto-correlation and cross-correlation 
curves. R Statistics was used for preparing graphs. FCCS data was analyzed using 
the following procedure. All auto- and cross-correlation curves were fitted using 
the one-component model without triplet state. R was fixed to 5. 
Relative cross-correlation amplitudes (RCA) were calculated to obtain the 
fractional occupancy of the binding sites on nanomimics:98  RCA =  !! 0 − 1!!,! 0 − 1                                               Equation 13 
Where Gc(0) is the cross-correlation amplitude and Gr,g(0) the auto-correlation 
amplitudes of the respective red or green auto-correlation curves. The average data 
of normalized RCA (n = 3 for each concentration) and corresponding standard 
errors were plotted against the total ligand concentration (PfMSP142-OG488) and 
fit using the following formula in QtiPlot 
(http://soft.proindependent.com/qtiplot.html) to obtain Kd for the 
interaction.97,303 
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RCA =  [!"][!!] =  !! + !! + !! − !! + !! + !! ! − 4 !! !!2 !!      Equation 14 
Where [AB] is the complex concentration, [A0] the accessible heparin 
concentration (2.8 nM fixed), [B0] the PfMSP142-OG488 concentration, and Kd the 
dissociation constant. Quantitative fluorescence correlation spectroscopy (FCS) 
measurements were used to calculate concentrations of nanomimics in solution by 
first measuring a series of known dye concentrations to calibrate the confocal 
volume.   
Static and Dynamic Light Scattering. DLS was performed on a Zetasizer 
Nano ZSP (Malvern Instruments Ltd, UK) at 20 °C. SLS/DLS was carried out to 
determine the hydrodynamic radius (RH), the radius of gyration (Rg) and the value  
ρ = Rg/RH of nanomimics in solution. SLS and DLS experiments were performed 
on an ALV goniometer (ALV GmbH, Germany), equipped with an ALV He-Ne laser 
(λ = 632.8 nm). Measurements were performed in 10 mm cylindrical quartz cells at 
angles of 30 – 140° at 20 °C. Data processing was performed using ALV static and 
dynamic fit and plot software (version 4.31 10/01). SLS data were processed using 
the Berry model. 
Stopped-Flow Measurements. The effect of osmotic pressure on nanomimic 
size was determined using a stopped-flow apparatus (Bio-Logic SAS, France). 
Changes in light scattering were monitored at an emission wavelength of 600 nm. 
As a control, nanomimics in 1 x PBS were mixed equally with 1 x PBS. Osmotic 
pressure was generated using 2 x PBS as the mixing medium with nanomimics in 1 
x PBS. At least four measurements were conducted for each mixture at 20°C. 
Experimental curves were fitted using exponential fits in QtiPlot 
(http://soft.proindependent.com/qtiplot.html). 
Viability MTS Assay. HeLa cells (2000 cells per well) were seeded in a 96-well 
plate, and incubated at 37 °C, 5 % CO2 for 24 h in DMEM containing 10 % fetal calf 
serum and 1% penicillin/streptomycin. After 24 h, nanomimics were added to 
triplicate wells at concentrations ranging from about 50 - 300 µg/mL in a total 
volume of 100 µL per well (90 µL media mixed with 10 µL nanomimic solution in 
PBS). Cells were incubated in the presence of nanomimics for an additional 24 h. 
Cell viability was determined using the MTS assay. Briefly, 20 µL MTS assay 
solution was added to each well and incubated at 37 °C for 3 h. Cell viability was 
determined by measuring absorbance at 490 nm using a microplate reader 
SpectraMax Plus M5e (Molecular Devices) and comparing to a PBS control (100 % 
cell viability) to obtain the percentage of living cells. All samples were corrected 
against controls containing only media and PBS or an SRB solution in PBS. 
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Suspension Culture Assay. Plasmodium falciparum 3D7 strain was 
maintained in culture as described elsewhere.304 Malaria culture medium (MCM) 
was RPMI medium supplemented with 0.5 % Albumax (Chapter 3, 7)305 or 0.5% 
CellMaxx bovine albumin (Chapter 4). Synchronization was performed using 5 % 
sorbitol.306 Invasion inhibition experiments were carried out in standard 24-well 
flat-bottom culture plates (Falcon 353047, Becton Dickinson, NJ, USA). Starting 
parasitemia was about 0.1 % (Chapter 3, 7) or 0.2 % (Chapter 4) ring/trophozoite 
stages at 5 % hematocrit in MCM and parasitemia reached ~ 2 – 4 % after 96 
hours. Total volume added to each well was 500 µL of parasite culture plus 55 µL 
PBS or test samples. Plates were placed in a plastic box with wet paper (for 
humidification) and cultured under continuous and simultaneous rocking (140 
RPM, ProBlot 25 Rocker, Labnet International Inc., NJ, USA) and shaking (105 
RPM, Lab-Therm LT-W, Kühner, Switzerland) at 37 °C for 96 hours by fixing the 
ProBlot 25 Rocker onto the shaking plate of the Lab-Therm shaking incubator. The 
maximum tilt angle was increased to 15° by putting one side of the plastic box on a 
3 cm thick spacer. This setup ensures continuous suspension of RBCs and iRBCs 
over the 96-hour incubation period. Each sample was tested in at least 3 
independent assays in duplicates. After 96 hours, parasitemia was determined by 
flow cytometry (FACSCalibur, BD Biosciences) using dihydroethidium to stain 
parasite DNA. In total, 100’000 cells were counted for each well. Data are 
presented as mean growth ± standard error with respect to PBS controls. 
Statistical comparison of free heparin versus nanostructured heparin was 
performed using Student’s t-test (two-tailed, type 2) in Microsoft Excel. Graphs 
were drawn using QtiPlot (http://soft.proindependent.com/qtiplot.html). To 
obtain IC50 values, experimental growth inhibition curves were fitted using logistic 
or exponential curves in QtiPlot.  
Malaria Parasite Growth Inhibition Assays with Drugs. 10 mM SHMT 
inhibitor (±)-1 stock in DMSO and SHMT inhibitor (±)-1-loaded nanoparticle 
samples in PBS were diluted in PBS immediately before use in the assays. Briefly, 
four-day suspension assays were conducted in 24-well plates under continuous 
agitation at 37 °C. Hematocrit was 5 % and starting parasitemia (% of iRBCs, 3D7 
strain) was about 0.1 %. After 96 hours, control wells (PBS added) reached about 2 
- 4 % iRBCs as measured by flow cytometry (FACSCalibur, BD Biosciences). For 
each well, 100’000 cells were counted and parasitemia was compared to PBS 
control wells to obtain mean growth ± standard error (SEM). Each sample was 
tested in at least three independent assays in duplicates. Statistical comparison 
was performed using Student’s t-test (two-tailed, type 2). Graphs were prepared 
using QtiPlot (http://soft.proindependent.com/qtiplot.html). To obtain IC50 
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values, experimental growth inhibition curves were fitted using logistic fits in 
QtiPlot with fixed maximum value A1 = 100. 
Three-day static assays were performed in 96-well plates using 1.25 % hematocrit 
and 0.3 % parasitemia (NF54 strain) at the beginning. After 48 h, 0.25 µCi 
[3H]hypoxanthine was added to each well, and the assay was continued for an 
additional 24 h. After a total of three days incubation, parasites were harvested 
onto glass-fiber filters, and radioactivity was counted using a Betaplate liquid 
scintillation counter (Wallac, Zurich). The results were recorded and expressed as 
a percentage of the untreated controls. Fifty percent inhibitory concentrations 
(IC50) were estimated by linear interpolation.307 
One-day suspension inhibition assay was performed and evaluated similarly to the 
four-day suspension assay but using 10 % hematocrit and 1 % starting parasitemia 
with late stage parasites (3D7 strain). IC50 values had to be baseline-corrected in 
this case, because dead parasites remained within the culture for this short one-
day incubation periods and therefore still appeared in the flow cytometry 
measurements. Thin blood smears revealed only dead late stages and no ring stage 
parasites at high drug concentration after one-day incubation, which confirms that 
the slightly increased baseline was due to remaining dead parasites (iRBCs) and 
not due to incomplete drug action.  
Preparation of Parasites for Fluorescence Microscopy with 
Nanomimics. Mature 3D7 parasites (trophozoites/schizonts) were purified by 
Percoll density gradient.308 Then, purified late stages were mixed again with RBCs 
to yield a mixture at 20 % parasitemia. Polymersomes or nanomimics (both filled 
with fluorescent dye SRB) were then added to this mixture and incubated at 37 °C 
for 3 hours under static conditions. After incubation, cells were fixed using 2 % 
paraformaldehyde/0.2 % glutaraldehyde in phosphate buffer 0.1 M (pH 7.4) at 4 
°C overnight. Then, fixed samples were centrifuged at high speed (13.5 kRPM) and 
redissolved in a small amount of PBS and finally mounted on a slide using 
Vectashield supplemented with DAPI (Vector Laboratories). 
Preparation of Malaria Parasite Cultures for Imaging with Delivery 
Vehicles. 0.36 mL malaria parasite culture (4% parasitemia, late stages, 5% 
hematocrit) in MCM was transferred to Eppendorf tubes and 40 µL of 25 µM Nile 
Red solution in PBS (freshly prepared from a 10 mM stock in THF and 
immediately added), 25 µM Nile Red in PMOXA-g(SS)-PCL 3 nanoparticles, and 
25 µM Nile Red in PMOXA-b-PCL nanoparticles. The gas in the tubes was 
exchanged by the culturing gas mixture and then incubated under shaking 
conditions at 37 °C for 1.5 h.  Then, 1 µL of 1 mg/mL Hoechst DNA-stain was 
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added and incubation was continued under static condition for 0.5 h. After 
centrifugation, 5 µL of the pellet was mounted on a microscopy slide and images 
were taken using a 60x oil immersion objective. First, the appropriate filters and 
exposure times were adjusted for the free dye sample. Then, parasites were 
searched in DIC mode and automatic overlays were taken for each sample using 
the exact same setting in order to have comparable brightness data. 
Preparation of Parasites for TEM and 3D-SIM. For TEM and 3D-SIM 
imaging, merozoites were mechanically released from mature schizonts using a 
published protocol.249 Briefly, 3D7 mature parasites were purified by Percoll 
density gradient and incubated with 10 µM E-64 inhibitor. After 6 – 8 hours 
incubation, mature schizonts were filtered through 1.2 µm filters to release 
merozoites mechanically, immediately mixed with nanomimics and incubated for 
20 min at 37 °C. Then, merozoites were fixed in 2% paraformaldehyde/0.2 % 
glutaraldehyde in phosphate buffer 0.1 M (pH 7.4) at 4 °C overnight. For TEM, 
samples were prepared according to Tokuyasu.309 Briefly, merozoite-nanomimic 
complexes were washed in PBS, embedded in 12 % gelatin and thin blocks were 
infiltrated with 2.3 M sucrose overnight at 4°C. Each centrifugation step was 
performed at high speed (13.5 kRPM). Ultrathin sections (80 to 100 nm) were 
prepared on a FC7/UC7-ultramicrotome (Leica) at -120 °C. For 3D-SIM fixed 
merozoites were collected by fast centrifugation (13.4 kRPM) and then mounted on 
a slide using Vectashield with DAPI as mounting medium. 
Fluorescence Microscopy and Super–Resolution 3D Structured 
Illumination Microscopy (3D-SIM). Fluorescence micrographs were taken on 
a Leica DM 5000B fluorescence microscope. Image processing was performed on 
GIMP software. In case of dye delivery, images were cropped using GIMP 
software; no other adjustments of original images were performed. 
3D-SIM was performed on a microscope system (DeltaVision OMX-Blaze version 
4; Applied Precision, Issaquah, WA) equipped with 405, 445, 488, 514, 568 and 
642 nm solid-state lasers. Images were acquired using a Plan Apo N 60× 1.42 NA 
oil immersion objective lens (Olympus) and 4 liquid-cooled sCMOs cameras (pco 
Edge, full frame 2560 x 2160; Photometrics). Exciting light was directed through a 
movable optical grating to generate a fine-striped interference pattern on the 
sample plane. The pattern was shifted laterally through five phases and three 
angular rotations of 60° for each z section. Optical z-sections were separated by 
0.125 µm. The laser lines 405 and 568 nm were used for 3D-SIM acquisition. 
Exposure times were typically between 3 and 50 ms, and the power of each laser 
was adjusted to achieve optimal intensities of between 7,000 and 10,000 counts in 
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a raw image of 15-bit dynamic range at the lowest laser power possible to minimize 
photobleaching. Multichannel imaging was achieved through sequential 
acquisition of wavelengths by separate cameras. Raw 3D-SIM images were 
processed and reconstructed using the DeltaVision OMX SoftWoRx software 
package (Applied Precision310,311). The resulting size of the reconstructed images 
was 128 x 128 px from an initial set of 64 x 64 raw images. The channels were 
aligned in the image plane and around the optical axis using predetermined shifts 
as measured using a target lens and the SoftWoRx alignment tool. The channels 
were then carefully aligned using alignment parameter from control 
measurements with 0.5 µm diameter multi-spectral fluorescent beads (Invitrogen, 
Molecular Probes) 
Fluorescence Microscopy of Giant Polymersomes. Fluorescence imaging of 
protein interaction with giant polymersomes was performed on a confocal laser 
scanning microscope (Zeiss CLSM 510-META/Confocor2, Carl Zeiss, Jena, 
Germany). A freshly plasma-cleaned 8-well microscopy chamber (Nunc Lab-Tek 
Chamber Slide System, Thermo Fisher Scientific) was filled with PBS (200 µl, pH 
7.2), GUVs (20 µl in 300 mM sucrose), Bodipy630 (10 µl, 72 mM) in PBS, and 
PfMSP142-OG488 in PBS (5 µl, 2.5 µM). For the CLSM measurements a water 
immersion objective (C-Apochromat, 40 x magnification, NA of 1.2) was used. The 
OG488 signal was obtained by excitation with an Ar laser (λ= 488 nm) with 
dichroic mirrors HFT (main beam splitter) 488 and NFT (secondary beam splitter) 
490 with the band-pass BP 500-550 filter. HFT 488/543/633, NFT 545 and the 
long-pass LP 650 filters were used to collect the fluorescence signal of Bodipy630. 
The pinhole size was set to 70 µm for the green channel, and 90 µm for the red 
channel, respectively. All settings (including laser power, detector gains) were kept 
constant for imaging of positive and negative samples. 
Fluorescence imaging of heparin GUVs with merozoites was performed on a Leica 
DM 5000B fluorescence microscope using the appropriate filters.  
Study Interaction of Giants and Merozoites. A 30 mL petri dish filled with 
human RBCs at 5 % haematocrit and 5 – 6 % parasitemia (iRBC late stages) was 
used for merozoite isolation. First, late stage iRBCs were separated from RBCs and 
young iRBCs by Percoll density gradient. After maturation to schizont stage 
parasites, they were concentrated to 1 mL in malaria culture medium, and viable 
merozoites were mechanically released using 1.2 µm syringe filters. They were 
immediately mixed with 300 µL of a heparin GUV solution in 300 mM sucrose, 
gently shaken, and incubated under static conditions at 37 °C for 15 min. 
Subsequently, 2 µL of 1 mg/mL Hoechst (DNA stain) was added and 
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merozoite/giant mixture was fixed in 2% paraformaldehyde/0.2% glutaraldehyde 
in 150 mM phosphate buffer (pH 7.4) overnight. After gentle centrifugation (3500 
RCF) for 5 min, 10 µL of the pellet was mounted on a microscopy slide. 
Anticoagulation Property of Nanomimics. Anticoagulation property of 
heparin-containing samples was measured using a chromogenic anti-Xa assay 
(Biophen Heparin (LRT) kit and manual) at the University Hospital Basel (Prof. D. 
Tsakiris). The detection limit is 0.1 UI/mL. 
Estimation of Endotoxin Contamination. Commercial Limulus Amebocyte 
Lysate (LAL) Kinetic QCL assay (Lonza) was performed using established 
protocols.266,267 Briefly, 100 µL of known endotoxin concentrations (5 – 0.005 
EU/mL) in LAL water, undiluted nanostructure samples in PBS, endotoxin spiked 
(0.05 EU/mL) nanomimics, and nanomimics in 10 mM MgCl2 in PBS were 
pipetted into sterile 96-well plates. After incubation at 37 °C for at least 10 min, 
100 µL of the Kinetic-QCL reagent was pipetted to each well and absorbance (405 
nm) was immediately measured at 37 °C for about 1.5 h. Onset time was defined as 
time for absorbance to increase by 0.2 A.U. and was compared to the calibration 
performed with known endotoxin concentrations. 
Experiment on “Vaccine-Like” Action of Nanomimics with Surface-
Bound Immunogen. 3x2 BALB/c mice (12 weeks old) were immunized on day 0 
with either a) 150 µL of 0.1 mg/mL PfMSP142 (3D7) in PBS intravenously (i.v.), b) 
150 µL of 0.1 mg/mL PfMSP142 (3D7) in PBS containing 50% Sigma-Adjuvant 
subcutaneously (s.c.), or c) 150 µL of nanomimics-25% that were first incubated 
with 0.1 mg/mL PfMSP142 (3D7) in PBS and then injected i.v. On day 24 a second 
shot was given via the same routes for a)-c) but with slightly lower protein 
concentrations (150 µL, 0.065 mg/mL each). All mice were terminally bled on day 
31. The collected blood was centrifuged, the sera was separated and stored at -
20°C. Induced IgG antibody titers were quantified using ELISA. Briefly, Nuc-
Maxisorb ELISA plates were coated with 3 µg/mL PfMSP142 (3D7) in PBS (50 
µL/well) at 4° for 48 h. Plates were washed and blocked with 3% BSA in PBS (100 
µL/well) at RT for 1 h. Test-sera were diluted 1:10 in 1% BSA TNT and serially 
diluted on the plate up to 1:20’048. Serum dilutions were incubated at RT for 2 h. 
Plates were washed and incubated with anti-mouse IgG alkaline phosphate labeled 
antibodies (1:5000) 1% BSA TNT at RT for 1h.  Plates were developed with 
1mg/mL pNPP in carbonate buffer pH 8.6 for 20 minutes and absorbance was 
measured at 405nm. Antibody endpoint titers are given for the last dilution where 
the absorbance was two times the absorbance of the negative control. All in vivo 
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studies conducted at the Swiss TPH were adhering to local and national 
regulations of laboratory animal welfare in Switzerland. 
Activity Tests in Plasmodium Berghei Mouse Model. Heparinized blood 
(containing 50 µL of 200 UI/mL heparin) was taken from a donor mouse with 
approximately 30% parasitemia, and it was diluted down to 108 parasitized 
erythrocytes per mL using physiological saline. 0.2 mL of this suspension was 
injected intravenously (i.v.) into experimental groups of 3 mice, and a control 
group of 5 mice. 6, 24, 48 and 72 hours post-infection, the experimental groups 
were treated with a single daily dose (i.v.) of 0.2 mL SHMT inhibitor (±)-1-loaded 
nanoparticles in case of drug-loaded nanostructures. For nanomimics, 0.2 mL i.v. 
injection was performed twice daily for four days. 24 hours after the last drug 
treatment, 1 µL tail blood was taken and the parasitemia was determined by flow 
cytometry. Parasitemia on day 4 (in case of three or four day treatment) in % was 
compared to the untreated control group. All in vivo studies conducted at the 
Swiss TPH were adhering to local and national regulations of laboratory animal 
welfare in Switzerland (Permission number for housing: 1018H, and permission 
number 1731 for Plasmodium berghei mouse model). 
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